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iAbstract
Background
Neoadjuvant chemotherapy (NAC) is being used as first line treatment in women with
large and locally advanced breast cancers (LLABCs). However, the response to NAC
is difficult to predict. Growing evidence suggests that these patients are
immunosuppressed and that circulating immunosuppressive regulatory cells and
humoral factors affect the response to NAC. We explored the possible role of the in
situ tumour immune milieu in inducing and affecting the responses to NAC, and the
contribution of concomitant systemic circulating regulatory cells.
Methods
Paraffin-embedded breast cancers and ipsilateral axillary lymph nodes (ALNs) from
pre- and post-NAC samples of a cohort of 33 women with LLABCs, 16 of whom had
their blood regulatory cells previously investigated. Various immune cell infiltrations
and expression of cytokines/ biological molecules in the specimens were studied using
appropriate monoclonal antibodies and immunohistochemistry. Statistical analysis
was carried out using non-parametric tests with SPSS version 21.
Results
High levels of pre-NAC tumour-infiltrating lymphocytes (TILs) (p<0.001) and subsets
of CD4⁺T cells (intratumoural, p=0.023; peritumoural, p=0.001), CD8+T cells
(intratumoural, p=0.008; peritumoural, p=0.002) and CD56⁺NK cells (intratumoural,
p=0.001; peritumoural, p<0.001) were significantly associated with a pathological
complete response (pCR). High levels of CD163⁺macrophages were also significantly
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associated with a good pathological response (p=0.004) and pCR (p=0.008). There
was a positive correlation between the CD8:FOXP3 ratio and grade of pathological
response. In multivariate analyses, TILs and peritumoural CD56+NK cells were found
to be independent predictive factors for pCR. There was a significantly high
expression of IL-10 in post-NAC breast specimens with poor responses to NAC
(p<0.001). NAC significantly reduced infiltrating T regulatory cells (Tregs) (p=0.001)
and PD1⁺T cells (p=0.005), as well as expression of IL-4 (p=0.016). There was no
significant difference between the percentages (%) of immune cells present in ALNs
with or without metastases but there was a T helper-2 cytokine polarisation in
metastatic ALNs. Metastatic ALNs with a high % of CD8+T cells (p=0.048) and low
% of FOXP3+Tregs (p=0.019) were significantly associated with an ALN pCR. There
was a significantly positive correlation between circulating and intratumoural
infiltrating Tregs following NAC (p=0.003).
Conclusions
The tumour immune microenvironment is a key factor in achieving a good
pathological response with NAC. Tumour and blood immune parameters may be
clinically useful in identifying women with LLABCs likely to respond to NAC. Our
findings also suggest that the beneficial effects of NAC are mediated via modulation
of anticancer immunity, in particular by reduction of T regulatory cells and
immunosuppressive humoral factors.
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1CHAPTER 1: INTRODUCTION AND BACKGROUND
1.1 Overview
Despite the rapid improvement in the treatment of cancer and the advancement in the
molecular biology of malignant disease, cancer continues to be a major cause of death.
There are a number of systemic treatments (adjuvant and palliative), such as
chemotherapy, endocrine therapy and targeted therapy, available that improve patient
outcomes. Their efficacy and effectiveness, however, are variable and in many cases
suboptimal. Some of these therapies have serious side effects, preventing their use in
many cancer patients, because of old age and frailty and/or severe co-morbidities. In
addition, resistance may occur during the period of treatment and this may result in
disease progression [1]. As a consequence, the number of deaths per annum from
cancer continues to be high. To date, active research is on-going to find new, less toxic
and more effective treatments.
In the last two decades, the advancement in cancer biology and understanding of
cancer immune surveillance have highlighted the possibility of harnessing and
modulating the host immune system directed against cancer cells [2]. From
observations and experimental findings in a variety of animal tumour models and
clinical trials in man, various immunological processes (innate and adaptive) have
been shown to destroy abnormal or malignant cells [3]. Modulating the immune
2system shows promise as an effective therapeutic modality in cancer treatment, with
the possibility to cure or control disseminated cancer disease.
Regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) in both the
blood and tumour microenvironment are important cellular mechanisms in modulating
and enhancing tumour growth through their ability to suppress the activation and
proliferation of key anticancer CD4⁺ and CD8⁺ effector T cells [4-8]. This results in
immune tolerance to cancer cells and progressive tumour growth [9]. Tumour-
infiltrating macrophages (TIMs) are another group of immune cells which plays a
crucial role in inhibiting anticancer immune defences via its polarised M2 subset [10].
Similarly, various biological molecules and cytokines produced in the tumour
microenvironment are also important loco-regional factors modulating tumour growth
[11]. CD8⁺ cytotoxic T cells (CTLs), in contrast to suppressor cells, are known to
promote anticancer immune defences, and their cytotoxic properties can destroy
cancer cells; they have a positive correlation with a good prognosis in patients with
malignant disease [12].
To better understand and subsequently overcome these immunosuppressive factors,
many studies have focused on identifying and characterising these various cellular
subsets and their functions in different cancers. In breast cancer, there is evidence that
these immune cells play a crucial role as both prognostic and predictive indicators of
responses to treatment, particularly in locally advanced but non metastatic disease [13-
15]. The recognition of density and distribution of these immune cells has been
achieved by exploiting surface and intracellular markers using specific antibodies
3labelled with reporter dyes or fluorophores [13-15]. A number of experimental
techniques are available to study these cells and cytokines/biological molecules in the
blood, lymphoid compartments and in situ in the cancer tissue.
In cancer tissue, the presence of tumour-infiltrating lymphocytes (TILs) within or
around tumour cell nests has been documented in many solid cancers. Their
composition and function are important for tumourigenesis, progression and metastatic
dissemination [16]. The clinical significance of TILs in breast cancer, in particular the
different lymphocyte subsets, is still controversial and a matter of debate [14]. High
scores of TILs, which can be found on histopathological examination of cancer tissue,
is associated with higher rates of both a good pathological response and pathological
complete response (pCR) after neoadjuvant chemotherapy (NAC), particularly in
breast cancer [17-20]. Many studies suggest a survival benefit in the presence of high
levels of TILs in tumours [12, 21, 22].
It is important to study the different subsets of lymphocytes in TILs because they have
different functions in the tumour microenvironment. A high level of tumour-
infiltrating CD8⁺ T lymphocytes and the high ratio of CD8⁺ T cells: FOXP3⁺
(forkhead box protein 3) Tregs have been shown to be associated with a favourable
prognosis [12, 23]. FOXP3⁺ Tregs is one of the most interesting subset of TILs as they
substantially inhibit the function and generation of effector T cells. Their level in
tumours and tumour-draining lymph nodes is significantly higher than that
documented in peripheral blood [24]. Also, they are positively correlated with disease
stage [24]. Most studies suggest that the presence of FOXP3⁺ Tregs in TILs has a
4negative effect on anticancer immunity, responses to NAC and prognosis [13, 20, 21,
25]. However, there is paradoxical evidence that the presence of high levels of
FOXP3⁺ Tregs in TILs is associated with a more favourable prognosis [26, 27]. Some
studies have shown that tumour-infiltrating FOXP3+ Tregs have no prognostic
significance [28]. All of these factors need to be further carefully investigated.
Possible improvements in outcome from cancer treatment in the future may rely on the
depletion or inhibition of immunosuppressor/regulatory cells and their functions.
Chemotherapeutic agents, apart from having adverse effects due to inhibition of
haematopoietic stem cell proliferation in the bone marrow, have been recognised to
enhance specific anticancer immune responses. Anthracycline and taxane-based
chemotherapy have been shown to have such immune modulating effects [29-31].
Furthermore, low dose metronomic cyclophosphamide, which is currently being used
in many clinical trials of cancer vaccine immunotherapy, has been demonstrated to
inhibit the number and activity of Tregs [32-37].
The effects of NAC, however, in women with large and locally advanced breast
cancers (LLABCs), on different immune cell infiltrates in the tumour
microenvironment are unclear. Also, the production of cytokines/biological molecules
in tumours and tumour-draining axillary lymph nodes (ALNs), has been poorly
documented [13]. In particular, the assessment and comparison of these cellular
profiles prior to and following NAC may provide relevant information regarding
anticancer immune mechanisms.
5From a previous study done in our laboratory in the same cohort of patients, Verma et
al. (2013) had clearly demonstrated the presence of significantly higher levels of
absolute numbers (AbNs) and percentages (%) of circulating (blood) Tregs and a T
helper-1 (Th1) to Th2 polarisation of T lymphocyte production of cytokines in women
with LLABCs, compared with healthy female donors (HFDs). There was a significant
reduction of circulating FOXP3⁺ Tregs after NAC in those women whose breast
tumours demonstrated good pathological responses [15]. These findings suggest
women with LLABCs are immunosuppressed and that NAC is able to modulate
systemic anticancer defences in breast cancer patients in the locally advanced setting.
To complement and better understand the immune-modulating effects of NAC, as well
as the influence of immune cell infiltrates on outcomes of NAC, it is important to
study critically the tumour microenvironment which may provide a better
understanding of the interaction between tumour cells and the host immune responses.
Immune parameters in blood may not necessarily represent the tumour in situ immune
status and activity [38].
Such a study may help to establish the roles played by the in situ tumour immune
milieu in the damage and removal of malignant cells during NAC and the possible
relevance of NAC in reducing Tregs in the tumour microenvironment and tumour-
draining ALNs after treatment. A better understanding of the factors preventing the
generation of immune-mediated tumour cell damage associated with NAC, would help
to devise more beneficial therapeutic strategies with chemotherapy.
61.2 Breast Cancer: Background
1.2.1 Incidence
Approximately 331,000 new cancer cases were diagnosed in the UK in 2011 (524
cases per 100,000 people, 910 cases per day) and breast cancer was the most common
cancer in women (49,936 new cases in 2011) accounting for 30% of the cancers [39].
Breast cancer is estimated to be diagnosed globally in more than a million women
each year. The rates vary worldwide ranging from 19.3 to 89.9 per 100,000 women.
The incidence of breast cancer is also high in Europe (Belgium, France, Switzerland,
and Italy), North America and in Australia, whilst India, Thailand, China and Africa
have the lowest incidences. The mortality rate from breast cancer has decreased in the
last 20 years but it is still the leading cause of cancer-related death among women. It
was estimated to be between 6 and 29 per 100,000 women. Thus, breast cancer ranks
as the second most common cause of cancer-related death in women and the fifth most
common cause of death overall [40, 41]. The latest age-standardised 5-year and 10-
year survival following diagnosis and treatment for women with breast cancer in
England were 87% and 78%, respectively [39].
7Table 1.1 Cancer Incidences in the United Kingdom (UK) in 2011
All cancers excluding non-melanoma skin cancer
(From Cancer Research UK (2014) [39], reproduced with permission)
Figure 1.1 The 10 most common cancers in females in the UK in 2011
(From Cancer Research UK (2014) [39], reproduced with permission)
81.2.2 Classification
It is now well recognised that breast cancer is a heterogeneous disease, consisting of
multiple entities associated with distinct histological and biological features, clinical
presentations, responses to therapy and prognosis [42, 43]. The classification of breast
cancer is commonly based on the histological type, the grade of the tumour, the stage
of the tumour and the expression of proteins or genes. Management of patients with
breast cancers depends on a variety of factors including those defining specific
subtypes, as well as clinical staging.
1.2.2.1 Histological grade and tumour types
Histological grading of breast cancer is performed, based on the criteria established by
Elston and Ellis, by a combined evaluation of morphological tubule formation
(glandular differentiation), nuclear pleomorphism and proliferative activity (mitotic
count) [44]. The gene expression profiles and transcriptomic features of breast
tumours have been shown to correlate with histological grade [45]. Currently,
histological grade has been incorporated in validated prognostic algorithms to
determine breast cancer therapy, for example the ‘Nottingham Prognostic Index’ [46-
48] and ‘Adjuvant! Online’ [49]. Low grade (grade 1) breast tumours (well-
differentiated tumours with low mitotic index) are associated with low metastatic
potential and a good prognosis and survival [50]. However, high grade (grade 3)
tumours have been shown to have higher pCR rates in response to NAC [19, 51].
Tumour types of breast adenocarcinomas comprise a diversity of different
morphological and cytological patterns which possess a different prognosis and
9response to treatment. The majority of breast cancers arise from the mammary
parenchymal epithelium, particularly cells of the terminal duct-lobular unit (TDLU). It
was originally believed that distinct histological types of breast cancer arose from distinct
micro-anatomical structures of the normal breast tissue (e.g. ductal carcinoma arose from
ductal epithelium and lobular carcinoma arose from terminal lobules). However, it has
been subsequently demonstrated that the vast majority of invasive breast cancers, and their
in situ precursors, originate from the TDLU regardless of the histological type. The terms
ductal and lobular carcinomas do not imply histogenesis or site of origin within the
mammary ductal system. Instead, these entities are defined based on their discrete
architectural patterns and cytological features [43, 52, 53].
Invasive ductal carcinoma (IDC) not otherwise specified (NOS) /or no special type
(NST) is the most common type accounting for 75% of invasive breast cancers. This
tumour type is a diagnosis of exclusion and consists of adenocarcinomas that fail to
exhibit sufficient characteristics to warrant their classification in one of the special
types. The special types account for up to 25% of all breast cancers. The latest
classification recognises the existence of at least 17 distinct histological special types
(Table 1.2) [43, 54]. Invasive lobular carcinoma (ILC) is one of the special types with
a differing prognosis. The classical lobular, tubulo-lobular and lobular mixed, but not
the solid, subtypes of ILCs are associated with a better prognosis than IDC-NOS.
Tubulo-lobular carcinoma, in particular, has an extremely good prognosis. Tubular,
invasive cribriform and mucinous types possess a very favourable prognosis while
medullary carcinoma/or atypical medullary carcinoma do not have a survival
advantage over IDC-NOS [55].
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Table 1.2 Histological Classification of Malignant Epithelial Tumours of the Breast
Histological Classification of Invasive Epithelial Tumours of the Breast
Invasive ductal carcinoma, not otherwise specified
Mixed type carcinoma
Pleomorphic carcinoma
Carcinoma with osteoclastic giant cells
Carcinoma with choriocarcinomatous features
Carcinoma with melanotic features
Invasive lobular carcinoma
Classical carcinoma
Alveolar carcinoma
Solid carcinoma
Tubulo-lobular carcinoma
Tubular carcinoma
Invasive cribriform carcinoma
Medullary carcinoma
Mucinous carcinoma and other tumours with abundant mucin
Mucinous carcinoma
Cystadenocarcinoma and columnar cell mucinous carcinoma
Signet ring cell carcinoma
Neuroendocrine tumours
Solid neuroendocrine carcinoma
Atypical carcinoid tumour
Small cell / oat cell carcinoma
Large cell neuroendocrine carcinoma
Invasive papillary carcinoma
Invasive micropapillary carcinoma
Apocrine carcinoma
Metaplastic carcinomas
Pure epithelial metaplastic carcinomas
Squamous cell carcinoma
Adenocarcinoma with spindle cell metaplasia
Adenosquamous carcinoma
Mucoepidermoid carcinoma
Mixed epithelial/mesenchymal metaplastic carcinomas
Oncocytic carcinoma
Adenoid cystic carcinoma
Miscellaneous
Data from World Health Organization Classification of Tumours, 2003 [56]
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1.2.2.2 TNM staging
Tumour size has a prognostic significance. Larger tumours have a poorer
outcome/prognosis than smaller lesions [47, 57, 58]. Radiological assessment for
tumour size is stated to be more reliable and precise than clinical evaluation.
Ultrasonography is commonly used for preoperative determination of tumour size
[59]. The presence of loco-regional lymph node metastases is one of the most
important factors affecting the prediction of survival [58]. Axillary nodal metastases
are less frequent in small tumours. It has been estimated that ALN metastases are
found in less than 20% of patients with breast tumours < 10 millimetres (mm) [60].
The TNM staging system was initially proposed in 1954 and subsequently modified
several times [61]. It comprises a clinical determination of tumour size (T), lymph
node stage (N) and the presence of distance metastasis (M). The classification was
developed on the basis of the anatomical extent of the tumour which is closely related
to the treatment outcome [62]. According to TNM staging, breast cancers can be
categorised as early stage breast cancers (stage I and II), locally advanced breast
cancers (stage III) and metastatic breast cancers (stage IV) [57]. A modified TNM
system was formulated by the Union International Cancer Centre (UICC) and the
American Joint Committee on Cancer (AJCC). The seventh edition (latest) was
published in 2010 (Appendix 4). The main purpose of TNM staging is to clinically
characterise patients with a view of determining the treatment algorithm and likely
prognosis. Accurate staging is necessary when comparing the results of different
treatment arms in clinical studies.
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1.2.2.3 Molecular (intrinsic) subtypes
The advance in DNA and RNA analyses and proteomic profiling in breast cancer has
significantly enhanced our knowledge and understanding of the complex molecular
and genetic structures and interactions in breast cancer, leading to new strategies in
diagnosis and treatment in clinical practice.
Currently, at least five major molecular subtypes of breast cancer have been defined,
namely luminal A, luminal B, HER2+ve (human epidermal growth factor receptor 2),
basal-like and normal breast-like subtypes [63]. These subtypes have been associated
with differences in clinical features, response to treatment and prognostic outcome
[64]. The diversity in molecular expression patterns is accompanied by a
corresponding phenotypic diversity in breast tumours. The common biological
markers, such as oestrogen receptor (ER), progesterone receptor, (PR), HER2
amplification and the proliferative activity of the tumour (Ki-67) are being used as
surrogate markers for gene expression analyses. Recently, cytokeratin 5 (CK5) and
epidermal growth factor receptor [EGFR (HER1)] were included to identify basal-like
breast cancer [65, 66]. These markers can be identified by immunohistochemistry
(IHC) and/or in situ hybridisation (ISH) making it possible to study large numbers of
archived breast cancer specimens [67]. However, consensus on molecular subtyping
with IHC or ISH markers as surrogates for gene expression analyses has yet to be
established [68].
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Luminal A and B subtypes
The expression of gene characteristics of luminal epithelial cells (lining the mammary
ducts), including ER cluster, is an important distinction between luminal subtypes and
others (non-luminal subtypes). luminal A breast cancer is the commonest subtype
characterised by the highest expression of ER, oestrogen-regulated protein LIV-1,
hepatocyte nuclear factor 3 alpha (HNF3A), X-box binding protein 1 (XBP1) and
GATA-binding protein 3 (GATA3) [63, 69]. The phenotypic characteristics are the
expression of ER and PR (ER+ve, PR+ve), absence of HER2 over amplification
(HER2-ve), low proliferative Ki-67 index and low histological grade. Luminal
epithelial tumours are relatively chemoresistant having a lower response rate to
chemotherapy. However, patients with luminal A breast cancers have a significantly
better prognosis than other subtypes [70].
The luminal B subtype is distinguished from the luminal A by having a low to
moderate expression of the luminal-specific genes (the ER cluster mentioned above)
and high expression of a novel set of genes such as GGH, LAPTMB4, NSEP1 and
CCNE1. Also, the expression of proliferation genes, such as MKI67 and cyclinB1 has
been found to be increased. Luminal B breast cancers often express EGFR and HER2
[63]. This subtype is phenotypically characterised as being ER+ve, HER2+ve and with
a high level of expression of Ki-67 [71]. The Ki-67 cut off point to distinguish luminal
A and luminal B has not been standardised. There is variability in the assessment of
this marker [72]. Luminal B tumours have a higher histological grade and metastatic
rate, and a worse prognosis than luminal A tumours.
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HER2+ve subtype
HER2+ve breast cancers comprise 15-20% of all breast cancers. They are
characterised by high levels of expression of several genes in the ERBB2 cluster
including ERBB2 (HER2), GRB7 and TRAP100 and absence of genes of the basal-like
cluster [63]. They can show low level of expression of luminal-characteristic genes.
These tumours are highly proliferative, usually high histological grade and related to
p53 mutations [73]. Patients with this subtype have a poor prognosis and short
survival. However, HER2+ve breast cancers are sensitive to chemotherapy [74]. They
demonstrate a higher response rate and pCR, compared with luminal A and B tumours,
in NAC studies. Moreover, the anti-HER2 targeted adjuvant treatment has
substantially improved survival in patients with this subtype [75].
Basal-like and normal breast-like subtypes
The basal-like molecular subtype is characterised by a high level of expression of
KRT5 and KRT17, annexin-8, CX3CL1 and TRIM29 (basal-like cluster) and has a
complete absence of the luminal/ER cluster of genes [63]. High molecular weight
cytokeratin 5 (CK5), CK17, P-cadherin, CD44 and EGFR are present in this subtype
(CK5 and EGFR as basal markers). It accounts for 15% of all breast cancers and
mainly affects younger women [76]. Patients with basal-like breast cancers tend to
have large tumours and lymph node involvement on presentation [77]. The basal-like
tumours have a high rate of p53 mutations, which offers an explanation for their
aggressiveness and poor prognosis. They have a high recurrent rate after treatment
despite having a high response rate to chemotherapy [78]. In addition, breast cancers
with germ-line BRCA1 mutations are found in basal-like subtype [63]. The alterations
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that involve a decrease in the function of the BRCA1, either by mutations or epigenetic
mechanisms, predispose to develop basal-like tumours [77]. BRCA1 is a tumour
suppressor gene responsible for repairing damaged DNA. Its inactivation leads to
genetic instability favouring tumourigenesis. Thousands of DNA molecules are
damaged during cell replication. Inadequate repair leads to the accumulation of errors
and results in cell death (apoptosis). Breast cancers with BRCA1 mutations lack the
ability to appropriately repair damaged DNA. Therapeutic agents inducing DNA
damage such as platinum-based cytotoxic compounds (eg. cisplatin, carboplatin,
oxaliplatin) and inhibitors of poly-ADP-ribose-polymerase (PARP), an enzyme
involved in DNA repair, are optimal for this subgroup of breast cancers (more
dependent on PARP than regular cells) [79]. Basal-like tumours usually lack the
phenotypic expression of ER, PR and HER2, and are referred to as triple negative
breast cancers (TNBCs). It has been reported that basal-like breast cancers account for
56–85% of TNBCs [76].
The remainder of TNBCs, which lack the gene expression profile of the basal-like
tumours, are the normal breast-like subtype (similar to normal mammary stromal cells)
[76]. The normal breast-like subtype of breast cancer has a very similar prognosis to
that of a hormone receptor positive breast cancer [80, 81].
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Table 1.3 Summary of Phenotypic Characteristics of Molecular (Intrinsic) Subtypes
Subtypes Phenotypic Characteristics
Luminal A ER+ve and/or PR+ve, HER2-ve, low Ki-67
Luminal B ER+ ve and/or PR+ve, HER2+ve (or HER2 -ve), high Ki-67
HER2 +ve ER-ve, PR-ve, HER2+ve
Basal-like ER-ve, PR-ve, HER2-ve, CK5+ve, EGFR+ve
Normal breast-like ER-ve, PR-ve, HER2-ve, CK5-ve, EGFR-ve
1.2.3 Breast cancer therapies
A multidisciplinary approach ensures that the breast cancer patient receives the
optimal treatment for that particular cancer. There are a number of treatment
modalities available for breast cancer and the treatment options tend to be
individualised. Curative treatment of breast cancer varies and depends on the types of
tumours and progression of disease (staging) at the time of diagnosis. Treatment of
early breast cancers and operable stage III breast cancers usually starts with surgical
removal of the tumour (lumpectomy or mastectomy) and axillary nodal assessment
followed by additional (adjuvant) treatment. For inoperable and/or LLABCs, primary
treatment may be radiotherapy or NAC prior to surgery. The aim of neoadjuvant
therapy is to downstage the tumour in breast and axilla in order to increase the
likelihood of subsequent effective surgery and, if feasible, carry out breast conserving
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surgery in patients with LLABCs. Loco-regional treatment with surgery ±
radiotherapy is required following NAC. Palliative treatments are reserved for breast
cancers with distant metastases (stage IV) [82, 83].
1.2.3.1 Loco-regional treatment
Breast surgery
Either breast conserving surgery (removal of primary breast tumour with surrounding
normal breast tissue) or total mastectomy (removal of the whole breast) is carried out
in patients with operable/ early breast cancer [84]. Histological assessment of the
resection specimen is necessary to ensure the margins are free of tumour [R0 resection:
a minimal of surgical margin of 1 mm for invasive disease and ≥2 mm for ductal 
carcinoma in situ (DCIS), according to St. Gallen consensus, 2013]. Mastectomy is
normally required for large tumours, multicentric lesions (multiple tumours in
different quadrants of the breast), extensive DCIS and persistent margin-positive
excision cases. However, based on the latest consensus from St. Gallen panel, these
conditions are considered to be only a relative contraindication for breast conserving
surgery (no absolute contraindication). Patient preference also needs to be considered
in deciding surgical options [85, 86].
Axillary surgery
Sentinel lymph node (SLN) biopsy has become the standard treatment for staging the
axilla, replacing the ALN dissection (ALND) for early breast cancers. SLNs are the
first group of lymph nodes which receive lymphatic drainage from the breast and
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tumour. Identification of SLNs with blue dyes and/or radioisotopes (via gamma probe)
during surgery enables SLN isolation and removal. Histologically negative SLNs
[isolated tumour cells (cluster of metastatic tumour cells <0.2 mm) accepted] represent
a tumour-free axilla. No further ALND is required in such cases. Histologically
positive SLNs [macrometastasis (>2 mm)], axillary nodal clearance is usually required
[82, 87]. SLNs with micrometastasis (0.2-2 mm) may indicate a requirement for
adjuvant systemic treatment but is not an indication for axillary clearance [88].
Adjuvant irradiation of the axilla in case of positive SLNs is not an evidence-based
alternative to ALND [86]. The recent results of the American College of Surgeons
Oncology Group Z0011 trial and American Society of Clinical Oncology clinical
practice guideline for patients with minimal SLN involvement (1-2 positive nodes)
suggest no further treatment for axilla in selected cases. This only applies to patients
with small tumour size (T1 or T2) and having a plan to do breast conserving surgery
with postoperative whole breast irradiation (tangential field irradiation) and receiving
adjuvant systemic treatment. The more restrictive criteria include post-menopausal
status, no extra-nodal extension, hormonal receptor positive tumour and ductal
carcinoma cell type [89, 90].
Radiotherapy
Whole breast irradiation after breast conserving surgery and chest wall irradiation after
mastectomy for advanced tumours (clinical T3 and T4) reduce the risk of local
recurrence [91]. It is recommended that, where there is pathological involvement of 4
or more ALNs, postoperative irradiation is delivered to the chest wall, supraclavicular
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area, infraclavicular region and internal mammary nodes (following the NCCN
guideline 2016) [82].
1.2.3.2 Systemic treatment
Chemotherapy
Chemotherapeutic agents destroy both cancer cells and normal cells that are actively
proliferating (e.g. haematopoietic cells, mucosal/epithelial cells). The mechanism of
cell death and damage occurs as a result of the interference of DNA synthesis and
replication during cell division (Table 1.4). Various regimens of cytotoxic agents have
been used as systemic treatments for breast cancer and have both significantly reduced
recurrence and prolonged survival. Adjuvant chemotherapy is given after surgery with
the purpose of destroying occult micrometastases and reducing the risk of future
recurrence. NAC downstages breast tumours and increases the likelihood of achieving
definitive surgery, including breast conserving surgery, as well as dealing with
micrometastases [83]. The responses of breast cancers to NAC can be studied and
monitored. This is crucial for the study of tumour biology and host defences. Palliative
chemotherapy may prolong survival in patients with distant metastases.
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Table 1.4 Summary of Mechanisms of Action of Common Chemotherapeutic Agents
Used in the Treatment of Breast Cancers
Groups Mechanisms Examples
Antimetabolites
Pyrimidine nucleoside analogues that
inhibit thymidylate synthase in order
to disturb RNA and DNA synthesis
5-fluorouracil,
Capecitabine,
Gemcitabine
Inhibit dihydrofolate reductase,
thereby depleting cells of reduced-
folates, which are required for DNA
synthesis
Methotrexate
Alkylating agents
Interfere with the DNA double strands
by forming methyl cross-bridges to
prevent the two DNA strands coming
apart during mitosis
Cyclophosphamide,
Chlorambucil,
Mitomycin C
Anthracylines
Intercalate between base pairs of the
DNA or RNA strands thereby
inhibiting DNA/RNA synthesis and
progression of topoisomerase II
enzymes which control DNA de-
coiling during replication
Adriamycin
(doxorubicin),
Epirubicin
Taxanes
Affect mitotic spindle formation
during mitosis
Paclitaxel,
Docetaxel
Platinum compounds
Form inter- and intra-strand platinum-
DNA crosslinks, thereby inhibiting
DNA replication/transcription
Cisplatin,
Oxaliplatin,
Carboplatin
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Hormonal (endocrine) therapy
Sex-steroid hormones (oestrogen and progesterone) have significant effects on cell
growth, differentiation and function in the breast and other tissues. Approximately,
two third of all breast cancers expresses receptors for these hormones. These receptors
are structurally-related intra-cellular proteins. Upon binding to steroid hormones they
relay their signals leading to downstream gene expression (signal transduction). Such
cancers grow in response to the exposure of these hormones. The mechanism of
hormonal therapy is based on inhibiting the effect of oestrogen/progesterone on
hormone receptor positive tumours (luminal epithelial subtypes) either by blocking ER
on breast cancer cells or lowering oestrogen levels in the body. This form of treatment
can be used as adjuvant therapy to reduce the risk of cancer recurrence after surgery
and as neoadjuvant therapy to downstage locally advanced tumours [1]. Recent
guidelines including the St. Gallen Expert Group consensus suggest that adjuvant
hormonal therapy should be used in all patients with ER+ve/ PR+ve cancers, even if
only 1% of tumour cells are found to be positively stained for ER or PR on IHC
testing [92, 93].
Tamoxifen [selective ER modulator (SERM)] acts as a receptor binding competitor of
oestrogen and blocks its effects (antagonist). It has an established role in both the
prevention and treatment of breast cancers [94]. Fulvestrant [selective ER down-
regulator (SERD)] is another drug that also acts on ERs. Instead of just blocking, it
also eliminates the receptor temporarily. Fulvestrant is more effective than tamoxifen
with 100-fold higher affinity to ER. It is often effective even if the breast cancer is no
longer responding to tamoxifen [95].
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Aromatase inhibitors (e.g. anastrozole, letrozole, exemestane), block the enzyme
involved in oestrogen biosynthesis from androgens (aromatase cytochrome P450 or
oestrogen synthetase) in peripheral tissues outside the ovaries, which is the main
pathway of oestrogen production in post-menopausal women. As a result, oestrogen
levels in the body decrease. They are unable to inhibit the production of oestrogen
from ovaries in pre-menopausal women. Therefore, they are only effective in women
with no ovarian function (post-menopausal women or after ovarian ablation/ bilateral
oophorectomy) [96].
Luteinizing hormone stimulates the ovaries to produce oestrogen. GnRH
(gonadotropin-releasing hormone) [such as luteinizing hormone releasing hormone
(LHRH)] causes ovarian ablation by downregulating its own production in the
hypothalamus through a reversible reaction. As a result, a GnRH agonist is able to
inhibit oestrogen production from the ovaries and is effective in pre-menopausal
women [1, 96]. Megestrol acetate (Megace) is a progesterone-like drug used as a
hormonal treatment in advanced breast cancer, usually for patients whose cancers do
not respond to the other hormonal treatments. Androgens may rarely be considered
after failure from other hormonal treatments.
Targeted therapy
Molecularly targeted therapy is a form of systemic treatment that uses biological
agents to block or interfere with specific targeted molecules needed for carcinogenesis
and tumour growth (rather than by simply interfering with all rapidly replicating cells
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as with chemotherapy). Immunotherapy with monoclonal antibodies (MAbs), small
molecules tyrosine kinase inhibitors and small molecule-drug conjugates are examples
of targeted therapy.
Trastuzumab is a MAb targeted against HER2, which is overexpressed in
approximately 25% of breast cancers (HER2+ve breast cancers). HER2 is one of the
epidermal growth factor receptors on the cell membrane. Upon binding with epidermal
growth factor (EGF), its intracellular domain sends a signal activating several tyrosine
kinase pathways to promote cell growth and proliferation [97, 98]. Trastuzumab
improves progression-free survival (PFS) and overall survival (OS) in women with
metastatic breast cancers [99]. It has also been used to treat early stage breast cancers
and LLABCs with significantly improved disease-free survival (DFS) and OS [100].
The combination of trastuzumab with chemotherapy has been shown to increase the
response rate and OS, compared with trastuzumab alone [101].
Lapatinib, a small molecule tyrosine kinase inhibitor interrupting downstream signal
processes of HER2 and EGFR pathways, is being used in combination therapy (with
capecitabine) for the treatment of patients with advanced metastatic HER2+ve breast
cancer [102]. PARP inhibitors (iniparib, olaparib) in TNBCs, bevacizumab [MAb
against vascular endothelial growth factor (VEGF)] in metastatic HER2-ve breast
cancers and pertuzumab (MAb binding to a domain of the HER2 separately from
trastuzumab, used in combination with docetaxel and trastuzumab) in HER2+ve breast
cancers are all being studied in clinical trials and various regimens have been
approved for breast cancer treatment [79, 103, 104].
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1.2.4 Large and locally advanced breast cancer (LLABC) and neoadjuvant
chemotherapy (NAC)
In spite of the comprehensive understanding of the epidemiology and pathogenesis of
breast cancer and the availability of effective diagnostic tools and well established
screening programmes for breast cancer, a significant number of breast cancer patients
in the UK continue to be diagnosed in the late stages of the disease. This is even more
pronounced in developing countries [13]. Up to 30% of breast cancer patients in the
UK present with LLABCs and the clinical course of patients with LLABCs can vary.
The 5-year survival rate has been reported to range from 50 to 80% [105].
NAC is being used more frequently as a standard first-line treatment in women with
LLABCs and is an option for primary operable disease [106]. The primary aim of
NAC is to downstage the disease and increase the resectability of large/or inoperable
tumours, as well as increasing the likelihood of breast conserving surgery and possibly
to minimise the risk of residual micrometastases. To date, no survival benefit over
adjuvant chemotherapy has been reported in this high-risk group of patients with the
use of NAC. Nevertheless, the responses to NAC are difficult to predict. The variable
responses are observed even in histologically similar breast cancers. Pathological
complete response (pCR) in the breast and/or ALNs after NAC is considered to be a
good prognostic marker and is associated with prolonged survival in most studies
[107-109]. However, pCR is observed in only 10–50% of patients depending on the
NAC regimens used and the type of breast cancer undergoing NAC (17% of luminal
A, 47% of luminal B, 33% of HER2 overexpressing, and 50% of basal-like tumours)
[13, 110]. The National Surgical Adjuvant Breast and Bowel Project (NSABP)
protocol B-27 reported a doubling of pCR rate (13.7% versus 26.1%, p<0.001) with
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additional sequential docetaxel in the NAC regimen containing doxorubicin and
cyclophosphamide in operable breast cancer patients [111, 112].
The response of NAC can be assessed clinically and/or pathologically. Clinical
assessment of response is generally evaluated by clinical measurement of tumour size
or imaging. Tumour size reduction is used as an indicator of clinical response. A
number of guidelines to define tumour response have been proposed. Among these,
the traditionally standard World Health Organization (WHO) criteria [113] and the
criteria validated by the Response Evaluation Criteria in Solid Tumours (RECIST)
Group [revised in 2009 (RECIST version 1.1)] are widely accepted [114, 115].
According to these guidelines, clinical responses of measurable disease can be
classified as a complete response, partial response, stable disease and progressive
disease depending on changes of target lesions following treatment. On the other hand,
pathological assessment of response can be evaluated in the excised surgical
specimens. The grading criteria used to define histopathological responses in breast
cancers have been established [116]. Most criteria define a pCR as the complete
disappearance of invasive tumour, with residual in situ components accepted. The
presence of residual DCIS following NAC has not demonstrated any adverse effects,
in terms of long-term survival [110]. Some guidelines, however, recommend that to be
designated a pCR there must be no invasive or non-invasive (in situ) tumours in both
breast and axillary tissues removed at the time of the surgery [106]. Although the
majority of responses to NAC are similar in all sites of tumour involvement (breast,
axilla), mixed responses (response in the primary breast tumour but no response in the
ALNs and vice versa) are well documented. The achievement of a pCR in both the
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breast and axilla appears to be the most significant predictor of long-term outcome
[110, 117].
Up to 75% of patients with LLABCs do not undergo a pCR with NAC and are thus
subjected to drug toxicities/side effects for apparent little benefit [118]. This may lead
to disease progression and/or failure to obtain a durable loco-regional control of
disease with surgery. Identification of reliable predictive markers associated with a
pCR/good pathological response may enable clinicians to identify patients with
LLABCs with a high or low probability of attaining a good response to treatment.
Unfortunately, currently there are few accurate or reliable predictive markers available
in clinical practice. The identification of factors predicting a pCR is an area of current
interest and active research and a focus for targeting NAC to those patients most likely
to benefit.
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Table 1.5 Previously Reported and Established Clinical and Pathological
Characteristics Related to Pathological Complete Response Following NAC in Breast
Cancer
Predictive Factors Reported Evidence
Age and menopausal
status
A pCR was achieved in 18% of pre-menopausal (aged
<50 years) compared with 37% of post-menopausal
women (aged >50 years) (p=0.007) [119].
Tumour size A pCR was achieved in 50% of tumours < 2 cm, 38% of
tumours 2-4 cm and in 18% of tumours > 5 cm in size
[120].
TNM stage Early stage was more likely to be associated with a pCR
compared with later stage of disease [121, 122]
Histological type Invasive lobular carcinoma (ILC) was less likely to
achieve a pCR compared with invasive ductal carcinoma
(IDC) (3% versus 15%, p < 0.001). However, most ILCs
were ER+ve and had low histological grade [123].
Histological grade High grade (grade III) tumours are more sensitive to
NAC and more likely to achieve a pCR compared with
low grade tumours (grade I) [118, 119, 124]
Hormone receptor status pCR rates were 24% in ER-ve tumours and 8% in
ER+ve tumours, regardless of the NAC regimens used
(p<0.001) [125].
HER2 status There was a higher pCR rate in tumours with HER2
overexpression [74]. The pCR rates increased from 25%
to 67% in combinations of trastuzumab with NAC in
HER2+ve tumours, (p<0.02) [126].
Proliferation index Ki-67 Tumours with high cell proliferation expressed high Ki-
67 and responded well to NAC [127]. However, there is
no consensus view on association with pCR [118].
Molecular subtype The pCR rate was 45% in basal-like and HER2+ve
subtypes and 6% in the luminal epithelial subtypes
[128].
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1.2.5 Chemotherapy resistance
Despite the significant improvement in systemic treatments for breast cancer,
resistance to chemotherapeutic agents continues to pose an obstacle to beneficial
treatment outcomes. The emergence of resistant phenotypes of breast cancer, the
frequent occurrence of multi-drug resistance (MDR), renders many chemotherapeutic
agents ineffective in controlling and/or destroying the cancer cells. Chemotherapy
resistance can be intrinsic (present before treatment) or acquired, occurring during
treatment by various therapy-induced adaptive responses. Breast cancer is
heterogeneous. Drug resistance, therefore, can also arise by positive selection of a
drug-resistant tumour subpopulation. Data, largely from in vitro laboratory-based
studies in breast cancer cell lines, have identified several mechanisms responsible for
clinical drug resistance. The best known mechanism of cellular resistance (classical
MDR: drug efflux mechanism) is the adenosine tri-phosphate (ATP)-binding cassette
(ABC) family of proteins including P-glycoprotein (P-gp), the multidrug resistance-
associated protein (MRP1) and breast cancer resistance protein (BCRP). These
proteins are responsible for translocating a variety of compounds across cell
membranes by using energy from ATP hydrolysis. The energy released by hydrolysis
results in a conformational change in the configuration of the transmembrane protein
and subsequently a decrease in the intracellular retention of drugs. Overexpression of
these transport proteins, particularly P-gp, has been linked to clinical drug resistance
[129-131].
Contrary to the classical MDR, atypical MDR phenotypes do not overexpress P-gp or
other transport proteins, and are unaltered in their ability to accumulate drugs. The
reduction of catalytic activity or nuclear localization efficiency of topoisomerase IIα 
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(an essential nuclear enzyme for cell division, which catalyses the breakage and re-
joining of double-stranded DNA including relaxing DNA supercoils, actively
participates in the lethal action of cytotoxic drugs) has been documented to be one of
the mechanisms of MDR phenotypes [132, 133].
Resistance to microtubule disrupting agents (taxanes, vinca families), through
alteration of β-tubulin isotypes, overexpression of β-III tubulin (TUBB3), changes in 
microtubule-associated proteins and post-translational modifications of tubulin, has
been identified [134]. Breast cancer stem cells (CSCs) with the capability of limitless
proliferation, characterised by cellular surface expressions of CD44 and lack of CD24,
are recognised to have low rates of cell division and exhibit chemotherapy and
radiation resistance. This is possibly mediated by expressing anti-apoptotic proteins,
MDR proteins and possessing efficient DNA repair mechanisms [135]. The over-
activation of the phosphoinositol 3-kinase (PI3K)/ protein kinase B (Akt)/ mammalian
target of rapamycin (mTOR) pathway (regulating cell proliferation, cell growth and
survival) has been identified in breast cancer and associated with resistance to
chemotherapeutic and hormonal agents [136].
Furthermore, resistance to trastuzumab (targeted therapy) by heightened signalling
through other EGFR family members, alternative splicing of the extracellular domain,
activation of the PI3K pathway with subsequent constitutive activation, and loss of
expression or function of the tumour suppressor gene phosphatase and tensin
homologue (PTEN) has been proposed [137].
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Combination of low dose chemotherapeutic agents, as well as combining
chemotherapy with other therapeutic modalities, may not only decrease the toxicity of
conventional chemotherapy, but also up-regulate the efficacy of anticancer therapies.
Giving chemotherapy in this manner has several potential advantages, including
inhibiting the onset of mutation-dependent mechanisms of acquired drug resistance
and increasing the efficacy and durability of combinatorial therapeutic modalities
[138]. As the understanding of the mechanisms of drug resistance increases, the ability
to specifically select appropriate drugs or drug combinations to the specified
phenotype of the breast cancer will become more realistic and therapeutically more
beneficial.
1.3 Immune System: Background
1.3.1 Human immune system
The human immune system consists of cellular and humoral components, which are
essential for the host in providing protection against invading pathogens, as well as the
recognition and elimination of damaged/malignant transformed cells. The cellular
component comprises various leukocyte subsets. Antibodies, cytokines and the
complement system make up key elements of the humoral component.
The leukocytes (white blood cells including lymphocytes), erythrocytes (red blood
cells) and thrombocytes (platelets), are derived from the same progenitor cells
(haematopoietic stem cells) in the bone marrow. Haematopoiesis is a continuous
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process which replenishes all the different blood cells from senescent loss. Two
common specific progenitors, which are the common myeloid and the common
lymphoid progenitor cells, arise from pluripotent stem cells. The myeloid lineage
develops and fully differentiates in the bone marrow to become erythrocytes,
thrombocytes, mast cells, granulocytes (neutrophils, eosinophils and basophils),
monocytes, macrophages and dendritic cells (DCs). The lymphoid lineage gives rise to
lymphocytes, which are distinguished by their sites of maturation and differentiation.
B lymphocytes develop and mature in the bone marrow while T lymphocytes and
natural killer (NK) cells do so in the thymus.
The immune system can be functionally classified into the innate and adaptive
immune components. Innate immunity is made up of structural cellular-epithelial
barriers (skin, mucosa), soluble components (complement system proteins, cytokines,
chemokines, acute-phase proteins) and specific innate cell subsets (monocytes,
macrophages, neutrophils, DCs, NK cells, platelets). The innate immune subsets
possess germ line-encoded surface receptors called pattern recognition receptors
(PRRs). Toll-like receptors (TLRs), nucleotide-biding domain (NOD)-like receptors
(NLRs) and retinoic-acid-inducible gene 1 receptors (RLRs) are examples of PRRs.
These receptors recognise broad classes of pathogen molecular structures [pathogen-
associated molecular patterns (PAMPs)] to trigger an immediate response. PRRs also
recognise products (danger signals) of damaged, injured or stressed host cells [danger
(or damage)-associated molecular patterns (DAMPs)]. Heat shock protein (HSPs),
S100 proteins, DNA, high mobility group box protein 1 (HMGB1) are examples of
DAMPs. Innate immunity, therefore, is rapidly initiated to eliminate the pathogen. On
the other hand, the adaptive immune system uses a large repertoire of receptors
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encoded by rearranging genes to recognise a variety of specific pathogen molecular
structures. Unlike innate immunity, adaptive immunity exhibits the property of
immunological memory for previously encountered pathogens which confers a long-
lasting immunity. However, the small number of specific B and T lymphocytes for the
particular pathogen/antigen must undergo a period of clonal expansion and become
effector cells [B cells (plasma cells) producing antibodies, cytotoxic T cells (CTLs), T
helper (Th) cells] to specifically remove the targeted pathogens. This results in a delay
in the generation of an adaptive immune response. Thus, the immediate and early
immune responses are mediated by innate immunity, whereas the late and specific
responses are induced and mediated by adaptive immunity. Innate and adaptive
immunity interact in a synergistic manner resulting in the removal of pathogens. Cells
and cytokines of the activated innate immunity make an important contribution (via
signals) to optimal activation of adaptive immunity. DCs, as antigen presenting cells
(APCs), play a key bridging role and in facilitating the immune response to pathogens.
The key functions of cellular and soluble components have been summarised in Tables
1.6 and 1.7.
The lymphoid organs consist of lymphoid structures organised into specific anatomical
and functional compartments with lymphocytes and other immune cell subsets. They
are classified as primary/central lymphoid organs (where lymphocytes develop from
common lymphoid progenitor cells), and secondary/peripheral lymphoid organs
(where the naïve T and B lymphocytes induce the adaptive immune response). The
bone marrow and the thymus are considered to be primary/central lymphoid organs.
Within the secondary/peripheral lymphoid organs, a series of distinct compartments
can be distinguished. The peripheral lymph nodes and spleen respond to antigens that
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have entered the tissues and travelled via the lymphatics or entered into the blood
stream. The mucosal immune system [mucosal-associated lymphoid tissues
(MALTs)], including the gut-associated lymphoid tissues (GALTs) and specialized
structures called Peyer’s patches, responds to pathogens entering the mucosal barriers
in the intestines. In each of these compartments, specially adapted responses to
pathogens are generated by a particular set of lymphoid tissues with discrete functions.
Thus, naïve lymphocytes are constantly circulating between the blood and secondary
lymphoid organs until they encounter their specific antigens and become activated
[139-141].
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Table 1.6 Components and Functions of the Innate Immune System
Cellular Components Main Functions
Epithelial integrity Physical barrier
Neutrophil Phagocytosis, killing of bacteria
Basophil Killing of parasites, release of histamine
Eosinophil Killing of antibody-coated parasites
Mast cell Release of histamine
Natural killer (NK) cell Killing of virus-infected cells and malignant-
transformed/damaged cells
Macrophage Phagocytosis, killing of bacteria, antigen
presentation
Dendritic cell (DC) Phagocytosis, killing of bacteria, antigen
presentation
Soluble (Humoral) Components Main Functions
Complement system Opsonisation, killing of antibody-coated
pathogens (classical pathway), chemotaxis
Cytokines Induce, enhance or inhibit cellular responses
Chemokines Act as a chemoattractant to direct the migration
of cells, recruit monocytes, neutrophils and
other immune effector cells from the blood to
sites of infection or tissue damage
Acute-phase proteins Destroy or inhibit growth of microbes, affect
coagulation, recruit immune cells to
inflammatory sites, downregulate inflammation
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Table 1.7 Components and Functions of the Adaptive Immune System
Cellular Components Main Functions
Dendritic cell (DC) Potent antigen presenting cell (APC)
T helper (Th) cells Modify immune responses:
 Th1 cells activate macrophages, CTLs
and NK cells
 Th2 cells activate B cells, provide
immunological memory
 Th17 cells mediate inflammation and
autoimmunity through the CTL
responses in cancer and autoimmune
diseases
Cytotoxic T lymphocyte (CTL) Specific killing of virus-infected cells and
malignant-transformed cells (induce apoptosis),
provide immunological memory
T regulatory cells (Tregs) Inhibit the generation of CTL responses and
downgrade activated T lymphocytes, prevent
autoimmunity by inhibiting self-reactive CTLs
B lymphocyte/plasma cell Production and release of antibodies, induction
of immunological memory
Soluble (Humoral) Components Main Functions
Antibodies Opsonisation, neutralization and complement
activation
Cytokines Induce, enhance or inhibit cellular responses
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1.3.2 Carcinogenesis and cancer immune surveillance
Carcinogenesis is a multi-stage process and has been traditionally divided into
initiation, promotion and progression. Initiation (induction) begins with DNA damage
in a normal cell which is exposed to chemical, physical or microbial (mostly viral)
carcinogens. If the damage is not properly repaired, the alteration of DNA may cause
genetic mutations. The majority of DNA alterations are irrelevant and totally innocent
in terms of cancer risk. On the other hand, damage of critical genes can be lethal
causing immediate cell death. Infrequently, the mutations occur on proto-oncogenes
(activating; e.g. EGFR, Ras and c-Myc) and tumour suppressor genes (inactivating;
e.g. p53, BRCA1, BRCA2 and PTEN). These mutations result in increased cellular
proliferation and reduced cell death, and subsequently initiating an immortal cell.
Promotion is a process of clonal expansion of an initiated cell. This results in the
formation of pre-neoplastic lesions such as nodules, polyps or papillomas. The
progression stage is characterised by the transformation of a pre-neoplastic lesion into
a malignant tumour (invades surrounding tissues and metastasises) [142-144].
A series of mutations and/or epigenetic changes are required to transform a normal
cell into a malignant cell and a subsequent tumour. The limitless proliferation is
accomplished by a mechanism of preserving/lengthening telomeres which
progressively shorten with cell divisions. Telomeres form a molecular cap (DNA
repeats) protecting the ends of chromosomes against degradation and preventing their
end-to-end fusion [145]. Telomerase reverse transcriptase (TERT) is the catalytic
subunit of human telomerase which synthesises telomeric DNA repeats [146]. More
than 90% of malignant tumours express telomerase. Malignant tumours also possess
the ability to survive due to autonomous sufficiency of growth promoting signals,
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insensitivity to anti-growth inhibitory molecules and resistance to apoptosis [147].
Tumours are unable to develop beyond the size of 1-2 mm in diameter without
angiogenesis. Growing tumours need new blood vessels that can support their
metabolic demands [144]. In order to invade the surrounding tissues, malignant cells
need to lose their adhesion molecules that keep them attached to each other and
adjacent epithelial cells (e.g. loss of E-cadherin) and to produce enzymes that enable
dissolving the elements of the basement membrane and extracellular matrix [plasmin,
matrix metalloproteinases (MMPs)] [148]. The acquisition of new blood vessels also
provides a route for escape of malignant cells from the primary site. The alteration of
adhesion molecules enables interaction between circulating malignant cells and
endothelial cells facilitating extravasation (blood, lymphatic), dissemination and
metastasis formation. However, only a very small subset of tumour cells can proceed
through each step of this process. It is estimated that less than 0.01% of circulating
tumour cells will ultimately form metastatic colonies [149].
A crucial protective mechanism against cancer is the activity of the immune system.
Both innate and adaptive immunity participate in antitumour mechanisms. The
immune system plays a key role in preventing, detecting and eliminating malignant/
transformed cells. There is growing evidence to suggest that this happens via many
mechanisms. Firstly, the immune system can protect against virus-induced cancers by
eliminating viral infections. Secondly, the immune system can eliminate pathogens
and resolve the pathogen-induced inflammation which may predispose to
carcinogenesis. Lastly, the immune system can specifically identify, recognise and
destroy malignantly transformed cells. The last mechanism is defined as ‘cancer
immune surveillance’ [150].
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The stressed/damaged cancer cells release specific molecules/danger signals leading to
activation of innate immunity. The cancer cells usually express various tumour-
associated antigens (TAAs) (non-self antigens) which can be detected by immune cells
leading to the generation of specific adaptive anticancer immune responses and
elimination of these cells. The specific adaptive anticancer immunity needs to be
effectively monitored and controlled in order to prevent untoward normal tissue
damage and the development of acquired autoimmunity. To develop specific effector
T cells (Th, CTLs), tumours with their unique TAAs are sampled, internalised and
processed by APCs (DCs, macrophages; activated via PRRs). APCs, then, present the
antigenic peptides of TAAs in linkage with major histocompatibility complex (MHC)
molecules (MHC class I or class II) to naïve CD8+ or CD4+ T cells, respectively via T
cell receptors (TCRs). This process is referred as signal 1. The subsequent activation
of effector T cells requires a second signal called ‘costimulatory’. It is the interaction
between the B7 family ligands on APCs and the CD28 family receptors on T cells
(e.g. CD80/86 on DCs interacts with CD28 on T cells). In order to progress into an
effective anticancer response, costimulatory interactions need to be reinforced by the
crucial signals from APCs (third signal/signal 3). Danger signals are released by
stressed cancer cells and interact with PRRs on APCs. Signal 3 released from activated
APCs can influence the type(s) of T cell response(s) (Th1, Th2, Th17, Tregs or CTLs)
elicited. Interleukin-12 (IL-12)/ interferon gamma (IFN-γ) produced by activated 
APCs can drive naïve T cells towards a Th1 phenotype and favour CD8+ CTL
induction. On the other hand, IL-4 can induce naïve T cells to a Th2 phenotype
(Figures 1.2a and 1.2b) [141, 150-152].
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Figure 1.2a Signals for priming and proliferating of the effector T cells
Figure 1.2b The host’s innate and adaptive immunity interacting with tumour-associated antigen (TAA)
leading to multiple pathways targeting of tumour cells
(Adapted from Aloysius et al. (2011) [150], reproduced with permission)
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Examples from mice and man include the increased incidence of certain malignancies
in athymic nude mice (genetically immunosuppressed rodents with a greatly reduced
number of T cells) and in immunosuppressed human recipients of organ
transplantation. Furthermore, this can also be found frequently in patients with inborn
or acquired defects in the immune system [144]. Specific immune defects
subsequently being associated with certain malignancies (both solid cancers and
lymphomas) have been widely demonstrated in animal models with transgenic
(knockout) mice, including carcinogen-induced tumours. To date, a number of specific
defined immunodeficiency mice have been investigated for their susceptibilities to
carcinogens. For example, Trail-/-mice [mice strain with defect in tumour necrosis
factor (TNF) -related apoptosis-inducing ligand-(TRAIL) gene] and SCID mice (severe
combined immune deficiency strain with defects in both T and B cells) are very
susceptible to developing tumours with the chemical carcinogen methylcholanthrene
(MCA) [153, 154]. In addition, several cytokine-deficient mice also develop
spontaneous malignancies. The study in mice with granulocyte-macrophage colony
stimulating factor (GM-CSF) and IFN-γ deficiencies showed susceptibility to 
developing cancer [155]. In human tumours, a variable degree of tumour-infiltrating
inflammatory cells can be found and this has been correlated with prognosis. This is
discussed in more detail in the next section (Tumour Microenvironment).
Despite the activity of anticancer defences involved in cancer immune surveillance,
some malignant transformed cells can escape and proliferate (immunoediting). There
are several possible mechanisms to promote cancer survival and growth: reduced
immunogenicity by either modulation of the binding of tumour peptides to MHC
molecules or binding of TCRs to MHC-peptide complexes [156]; inactivated or
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suppressed immune system via secretion of immunosuppressive mediators/ molecules
including nitric oxide (NO), transforming growth factor beta (TGF-β) and interleukin-
10 (IL-10) [157]; as well as generation/ recruitment of immune-inhibitory cells such as
Tregs [8], MDSCs and macrophages (M2s) into the tumour microenvironment [158].
1.3.3 Immune editing
Immunoediting consists of three phases occurring either independently or sequentially.
Firstly, ‘elimination’, the immune system functions as an extrinsic tumour suppressor.
Secondly, ‘equilibrium’, tumour cells survive but are held in check by the immune
system. Thirdly, ‘escape’, tumour cell variants with either reduced immunogenicity or
the capacity to attenuate immune responses grow into clinically apparent cancers
[159].
The elimination phase of cancer immunoediting is described as cancer immune
surveillance. In this phase, the immune system detects and eliminates tumour cells.
The elimination phase can be incomplete, where only a portion of tumour cells are
eliminated. In this case, a temporary state of equilibrium can then develop between the
immune system and the developing tumour. During this period, tumour cells can either
remain dormant or continue to grow very slowly. The accumulating changes (such as
DNA mutations or changes in gene expression) can modulate the expression of TAAs
and release of stress-induced signals. As this process continues, the immune system
exerts a selective pressure by eliminating susceptible tumour clones, where possible.
The pressure exerted by the immune system during this phase is sufficient to control
tumour progression, but eventually, if the immune response still fails to completely
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eliminate the tumour, the process results in the selection of tumour cell variants that
are able to resist, avoid, or suppress the anticancer immune response, leading to the
escape phase. During the escape phase, the immune system is no longer able to control
or contain the tumour growth. This results in the emergence of progressively growing
tumours which are resistant to host defences and therapy (Figure 1.3). These phases
have been termed the 3 Es of cancer immunoediting [150, 160, 161].
Figure 1.3 Cancer immunoediting is considered a process composed of 3 phases: elimination, or cancer
immune surveillance; equilibrium, a phase of tumour dormancy where tumour cells and host defences
enter into a dynamic equilibrium that keeps tumour expansion in check; and escape, where tumour cells
emerge that display either reduced immunogenicitiy, resistance to chemotherapy or engage a large
number of possible immunosuppressive mechanisms to attenuate the anticancer immune response.
(Adapted from Aloysius et al. (2011) [150], reproduced with permission)
43
1.3.4 Immune-mediated tumour cell death enhanced by chemotherapy
During normal cellular turnover, cell injury or infection, damaged or dead cells are
exposed to the immune system. The immune system discriminates between different
forms of cell death to correctly eliminate pathogens and promote healing while
avoiding responses to self-antigens, which can result in autoimmunity (defined as
tolerogenic or silent or non-immunogenic cell death). On the other hand, cell death
(cancer cells) induced by treatment with certain chemotherapeutic agents (including
radiotherapy) is required to generate an effective anticancer immune response. This
later form of cell death is referred as immunogenic cell death (triggers immune
response) [162].
Depending on the initiating stimulus, cancer cell death can be immunogenic or non-
immunogenic. Immunogenic cancer cell death involves changes in the composition
and architecture of the cell surface, as well as the release of soluble mediators and
signals. Such signals operate on a series of receptors expressed by DCs to stimulate
the presentation of TAAs to naïve T cells. Immunogenic cancer cell death can be
induced by some chemotherapeutic agents and constitutes a prominent pathway for the
activation of the anticancer immunity. This in turn modifies the responses of
chemotherapy in inducing damage and removal of tumour cells through enhancing
‘immune-mediated tumour cell death’ (through activated CD8⁺ CTLs). Moreover, this
type of cancer cell death also helps to establish the long-term beneficial outcome of
anticancer therapies [163].
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Most chemotherapeutic agents act through direct induction of tumour cell death by
either apoptosis or necrosis and have temporary suppressive effects on the innate and
adaptive immune systems, as well as inhibition of haematopoiesis [31]. However,
some drugs and regimens may enhance specific aspects of anticancer immunity.
Chemotherapy can induce cancer cell stress and/or damage resulting in the release of
immunogenic TAAs, as well as ‘danger’ signals. These can activate antigen presenting
DCs and other innate cells to release pro-inflammatory cytokines and eventually
inducing specific anticancer cell-mediated immune responses [164].
Certain chemotherapeutic drugs by damaging cancer cells can produce a variety of
tumour antigens (e.g. fragmented cellular proteins or peptides). Several prominent
features of immunogenic cell death after cytotoxic chemotherapy, such as
translocation of calreticulin (CRT), secretion of HMGB1 protein, and release of ATP
by dying tumour cells have been identified. Doxorubicin induces rapid translocation of
the endoplasmic reticulum resident protein CRT to tumour cell surfaces facilitating
phagocytosis by DCs. HMGB1 protein released from the nucleus into the surroundings
of dying tumour cells acts on TLR4 on DCs to initiate efficient antigen processing and
presentation (TLR4-Myd88-signalling pathway). The release of ATP by dying tumour
cells acts on purinergic P2RX7 receptors on DCs and triggers the NOD-like receptor
family pyrin domain containing- protein 3 [NLRP3 (also called NALP3 or
cryopyrin)]-dependent caspase-1 activation complex (inflammasome) allowing for the
secretion of IL-1β. Caspase-1 activated by the NLRP3 inflammasome is required for 
the proteolytic maturation of pro IL-1β and, hence, IL-1β secretion in response to 
purinergic P2RX7 receptor agonists. This ultimately leads to IL-1β-dependent adaptive 
immunity. Cyclophosphamide has been also reported to cause CRT translocation and
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HMGB1 protein release in some types of tumours [165-167]. The following
chemotherapeutic compounds, which were used as NAC in the primary treatment of
LLABCs in this study, have been documented to have immuno-modulatory effects.
1.3.4.1 Cyclophosphamide
Cyclophosphamide is a nitrogen mustard alkylating agent which displays cytotoxicity
against actively DNA-replicating cells. Cyclophosphamide is an inactive pro-drug that
requires activation by the hepatic cytochrome P-450 enzyme system to form the active
metabolite 4-hydroxycyclophosphamide, which is in equilibrium with its tautomer
aldophosphamide. These two intermediate metabolites rapidly diffuse out of hepatic
cells into the circulation and are subsequently taken up by other cells, including cancer
cells. Within cells, aldophosphamide degrades to form the cytotoxic phosphoramide
mustard, which produces the interstrand DNA methyl cross-bridges preventing the two
DNA strands coming apart in mitosis. The selective toxicity on tumour cells occurs
because the concentration of the enzymes converting aldophosphamide into the
cytotoxic metabolite is higher in tumour cells than in normal cells. Differential cellular
expression of aldehyde dehydrogenase has an effect on the anticancer therapeutic
index and immunosuppressive properties of cyclophosphamide [35, 168].
Cyclophosphamide is one of the most successful and widely used drugs for the
treatment of haematological and solid malignancies, as well as for the treatment of
different autoimmune disorders and, therefore, is commonly considered an
immunosuppressive drug. However, evidence exists that cyclophosphamide may have
immune-stimulatory effects. Recent studies have linked the immune-stimulating effect
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of cyclophosphamide to the selective inhibition and depletion of CD4⁺CD25⁺ Tregs in
humans with malignant tumours [169]. Moreover, these effects are also documented
with CD8⁺ Tregs [35]. Recently, oral administration of low dose metronomic
cyclophosphamide has been used in many clinical trials of cancer vaccine
immunotherapy and has been demonstrated to inhibit both the number and activity of
Tregs [32-37]. A recent study, however, from Sevko et al. (2013) revealed that low-
dose cyclophosphamide enhanced accumulation of CD11b⁺Gr1⁺ MDSCs, which
exhibited elevated suppressive activity and NO production, as well as inhibition of T
cell proliferation in the ret transgenic murine melanoma model [170, 171]. Examples
of other chemotherapeutic agents with immuno-modulatory effects, which were used
in this study, are described below.
1.3.4.2 Anthracyclines
Anthracyclines can kill tumour cells by mechanisms involving DNA intercalation and
inhibition of DNA replication. From experiments in mice models, Maccubbin et al.
(1990) were the first to demonstrate that doxorubicin was an effective immune
modulator capable of boosting CD8⁺ CTL responses [172]. A number of following
studies, particularly in mice mammary tumour models, demonstrated that treatment
with doxorubicin (alone or in combination with other chemotherapeutic agents)
enhanced tumour antigen–specific proliferation of CD8⁺ T cells and promoted tumour
infiltration of activated, IFN-γ producing CD8⁺ T cells [173]. Furthermore, a recent in
vitro study by Park et al. (2009) showed the effects of doxorubicin on increased
antigen-specific CD4⁺ Th1 immune responses by inducing expression of CD40 ligand
and 4-1BB (co-stimulator molecules) on the surface of CD4⁺ T cells [31].
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1.3.4.3 Taxanes
Taxanes can induce tumour cell death by disrupting intracellular microtubule networks
during cell division. Members of the taxane family, including docetaxel and paclitaxel,
have been used in a variety of malignancies including breast cancer. In a murine study
with 4T1-Neu mammary tumour-bearing mice, docetaxel has been demonstrated to
suppress MDSCs and selectively enhance CTL response in vivo [174]. In advanced
breast cancer patients, single-agent paclitaxel or docetaxel showed an increase in
serum levels of IFN-γ, IL-2, IL-6 and GM-CSF and enhancement of circulating NK 
and lymphokine-activated killer (LAK) cell activity. Moreover, these immune
stimulatory effects of docetaxel are more pronounced than those of paclitaxel [29, 30].
Primary (neoadjuvant) treatment with trastuzumab plus docetaxel in patients with
HER2+ve breast cancer has been documented to be associated with significantly
increased numbers of tumour-infiltrating NK cells and increased expression of
Granzyme B [175]. However, therapeutic concentration of paclitaxel and docetaxel
have been shown to effectively inhibit NK cell-mediated killing of different NK cell
lines in vitro [176].
1.3.4.4 Capecitabine
Capecitabine is an orally-administered chemotherapeutic pro-drug that is
enzymatically converted to 5-fluorouracil (5-FU) in the body. It is a pyrimidine
analogue (known as anti-metabolites) which irreversibly inhibits thymidylate synthase.
This enzyme is necessary for nucleoside (thymidine, pyrimidine) synthesis during
DNA replication [177]. Beyond its direct cytotoxic effect on cancer cells, 5-FU is able
to specifically reduce the number of MDSCs in the tumour microenvironment by
triggering apoptosis. Data from an in vivo murine study showed 5-FU (including
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another anti-metabolites: Gemcitabine) was able to mediate MDSC depletion, increase
IFN-γ production by CD8+ CTLs in the tumour bed and promote T cell-dependent
anticancer immunity [178]. These findings have suggested that 5-FU possesses
immuno-modulatory effects that rely on elimination of MDSCs. In man, however, the
combination of capecitabine and gemcitabine in patients with advanced pancreatic
carcinoma showed no consistent reduction of MDSCs [179]. 5-FU has also been
reported to increase the expression of TAAs on the cell surface of cancer cells and
enhance antibody-dependent cell-mediated cytotoxicity (ADCC) [177].
1.3.5 Immune checkpoints
Regulation and activation of T lymphocytes depend on signalling by the TCR and by
co-signalling receptors that deliver stimulatory or inhibitory signals. The amplitude
and quality of the T cell immune response are controlled by the equilibrium between
co-stimulatory and co-inhibitory signals, called ‘immune checkpoint’. The generation
and maintenance of adaptive immune responses are controlled by co-stimulatory (also,
signal 2 in priming effector T cells) and co-inhibitory signalling through T cell co-
receptors. These co-receptors mostly belong to the immunoglobulin (Ig)-like
superfamily or the tumour necrosis factor receptor (TNFR) superfamily [180]. Co-
stimulatory receptors including CD28 and inducible T cell co-stimulator (ICOS) are
members of the immunoglobulin-like superfamily, while OX40, CD27, 4-1BB, CD30,
glucocorticoid-induced TNFR-related protein (GITR) and herpes virus entry mediator
(HVEM) are members of the TNFR superfamily. Cytotoxic T lymphocyte associated
antigen 4 (CTLA-4), programmed death 1 (PD1), lymphocyte activation gene 3
[LAG3 (CD223) interact/bind with MHC class II molecules] and B and T lymphocyte
attenuator (BTLA), on the other hand, are the established co-inhibitory receptors and
49
members of the Ig-like superfamily [181-183]. Upon interaction with their B7 family
ligands, signalling through these receptors regulates T cell responses.
The regulatory mechanisms of immune checkpoints act to limit T cell responses
following T cell activation on exposure to antigen (e.g. up-regulation of CTLA-4 on
activated T cells). Following chronic exposure to antigen and on-going inflammatory
responses in tissues/cancer, PD1 receptors on activated T cells can be induced by
inflamed tissues or tumour cells [e.g. increased expression of programmed death
ligand 1 (PDL1; B7-H1), B7-H3 or B7x (B7-H4) on tumour cells] [184]. These
mechanisms induce tumour tolerance and escape from the anticancer responses of the
immune system.
MAbs have revolutionised the treatment of certain cancers. The mechanisms of action
vary, but can be broadly classified as direct (blockade or stimulation of function,
targeting local delivery of conjugated therapeutic agents such as cytotoxic drugs or
radioisotopes) and indirect mode of action. The indirect mode is mediated by the
immune system [complement-dependent cytotoxicity or antibody-dependent cellular
cytotoxicity (ADCC)] including interfering with the function of co-stimulatory and co-
inhibitory pathways on effector T cells. Currently, stimulating [stimulatory antibodies
to 4-1BB (CD137), OX40 (CD134) and GITR] or blocking [checkpoint blockade:
CTLA-4 (CD152), LAG3, PD1 (CD279) and PDL1 (CD274)] MAbs are being
investigated extensively for their abilities to enhance T cell numbers, function and
maintenance of immunological memory via modulation of co-stimulation or co-
inhibition (Table 1.8) [181, 185, 186].
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Table 1.8 Developments of Monoclonal Antibodies Targeting Immune Checkpoint
Pathways
Target Biological
Function
Monoclonal
Antibody
Development
CTLA-4 Co-inhibitory
receptor
Ipilimumab,
tremelimumab
Approved for advanced metastatic
melanoma, phase II and III trials for
different cancers [187, 188]
PD1 Co-inhibitory
receptor
Nivolumab
(MDX-1106),
pembrolizumab
Approved for advanced metastatic
melanoma and squamous non-small
cell lung cancer, phase II and III
trials for different cancers [188-190]
PDL1 Inhibitory ligand Atezolizumab
(MPDL3280A)
Phase I trial in different cancers
[191]
LAG3 Co-inhibitory
receptor on T cells,
DC activator
(causing increased
antigen presentation)
IMP321
(a recombinant
soluble LAG-3Ig
fusion protein)
Phase I and II trials in different
cancers including breast cancer,
adjuvant for cancer vaccines [192,
193]
B7-H3 Inhibitory ligand, its
receptors have not
been identified
MGA271 Phase I trial in different cancers
(MacroGenics®)
B7-H4 Inhibitory ligand, its
receptors have not
been identified
A recombinant
human B7-H4
Preclinical development [194]
OX40 Co-stimulatory
receptor
MAb agonist Preclinical development [195]
GITR Co-stimulatory
receptor
MAb agonist Preclinical development [196]
51
1.3.6 Immunotherapy in cancer
Accumulating evidence suggests a possible role of the immune system in the treatment
of cancers. A positive correlation between tumour infiltrating lymphocytes (TILs) and
T cells and patients survival has been observed [197, 198]. Spontaneous tumour-
specific T cell responses occur in patients with premalignant lesions [199] and
malignant tumours [200]. However, tumours have also established several different
strategies to escape immune surveillance such as loss of TAA expression, MHC down
regulation, expression of Fas ligand (FasL) (induces apoptosis in activated T cells),
secretion of VEGF and immunosuppressive cytokines (e.g. IL-10 or TGF-β). Other 
mechanisms include the generation of Tregs and MDSCs, as well as alternative
activation of macrophages (M2) [159].
The induction of an effective tumour-specific immunity will disrupt the tumour
tolerance and generate anticancer immunity. To achieve this, a variety of strategies in
both preclinical models and clinical trials are continuingly being investigated. The
identification of TAAs in human cancers has encouraged the development of cancer
vaccines (whole tumour cells, antigenic tumour peptides or DNA vaccination) as well
as adoptive T cell therapy and DC-based therapy. These are anticipated to induce both
therapeutic T cell immunity (tumour-specific effector T cells) and protective T cell
immunity (tumour-specific memory T cells) [201].
MAb therapy is one of the most successful forms of immunotherapy, and is used in
treating a wide range of cancers. Specific cell surface receptors/antigens are common
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targets for MAb therapy. Once bound to the target, MAbs can induce ADCC, activate
the complement system or prevent a receptor from interacting with its ligand.
The examples of immunotherapy which have been used clinically in some types of
advanced cancers, are sipuleucel-T (autologous generated active T cell
immunotherapy) in metastatic castration-refractory prostate cancer [202, 203],
trastuzumab (MAb blocking HER2) in HER2+ve breast cancer [204], bevacizumab
(MAb to inhibit angiogenesis by blocking VEGF) in metastatic colorectal cancer and
metastatic HER2-ve breast cancers [104, 205], cetuximab and panitumumab (MAbs
against EGFR) in KRAS wild type metastatic colorectal cancer [206]. Also, MAbs
directed against the immune checkpoints in co-inhibitor pathways. A variety of
immune-therapeutic agents have emerged from the laboratory setting into clinical
practice. These have been shown to be relatively safe and with acceptable side effects
[207, 208].
1.4 Tumour Microenvironment
Tumours grow within a complex network of epithelial cells, blood vessels, lymphatic
channels, cytokines and chemokines, as well as infiltrating immune cells. Different
types of tumour-infiltrating immune cells have different effects on tumour
progression. These effects can vary amongst different cancer types [209]. The possible
effects of the local immune milieu on clinical outcome have important implications for
the identification of prognostic biomarkers that predict response to chemotherapy. The
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effect of the host immune response on tumour progression, recurrence and metastasis
has come from analyses of the in situ immune components. Immune cell infiltrations
are heterogeneous among cancer types and vary from patient to patient. T lymphocytes
(including various subsets of CD4+ and CD8+ T cells: Th1, Th2 and Th17 cells, naïve
and memory T cells, Tregs and CTLs), macrophages, neutrophils, DCs, NK cells,
MDSCs and B lymphocytes can all be found in the tumour microenvironment. It has
been estimated that T lymphocytes constitute 75% of the lymphocyte infiltrates, B
lymphocytes less than 20% and NK/ NKT cells constitute fewer than 5% [210]. These
immune cells can be located in the core of the tumour (intratumoural), or in the
invasive margin/ surrounding stroma (peritumoural). The analysis of the density,
distribution and functional orientation of the different immune cell populations in
tumours has allowed the identification of components of the local immune milieu that
are beneficial to anticancer immunity and cancer treatments.
1.4.1 Immune cell infiltrations
1.4.1.1 Tumour-infiltrating lymphocytes (TILs)
There is a small number of lymphocytes, resembling mucosa-associated lymphoid
tissue (MALT), observed in normal breast tissue [211]. By contrast, prominent
numbers of lymphocytes are commonly found within the tumour cell nests and in the
peritumoural stroma in breast cancer tissue, and are believed to reflect a defensive
immune response by the host against the cancer [17, 18, 26]. The state of pregnancy
(associated low host immunity) affects the level of TILs. Significantly lower levels of
TILs were found in breast tumours diagnosed during pregnancy [212]. The majority of
TILs in solid tumours are CD3⁺ T cells. CD3⁺ T cells can be classified into CD4⁺ T
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helper cells, including Th1, Th2 and Th17 subtypes based on their cytokine profiles,
CD4⁺ Tregs and CD8⁺ CTLs. These lymphocytes take part in tumourigenesis,
progression and metastatic spread/ or regression of disease as their roles can be both
promotional and suppressive via cellular interactions and various cytokine productions
in the tumour microenvironment. The adoptive cell therapy with cultured autologous
TILs has shown a promising result in metastatic melanoma and is undergoing further
clinical evaluation [213]. The clinical significance of TILs in breast cancer is still
controversial. Some studies have documented that TILs (CD4⁺ and CD8⁺ T cells) were
associated with unfavourable tumour features such as high tumour grade, ER-ve status
and HER2/neu overexpression as well as metastatically involved ALNs [214]. Droeser
et al. (2012) showed, in a survival analysis, that the numbers of TILs did not represent
a major prognostic indicator in ductal and lobular breast cancer [14]. In contrast, most
studies have shown that increased numbers of TILs in breast cancer (ductal
carcinomas) was associated with a better prognosis and better pathological responses
after NAC [17-19]. These contrary findings may be the result of the different types of
lymphocyte subsets present within the TILs, particularly infiltrating Tregs. It is
necessary, therefore, to define more precisely the different subsets of lymphocyte in
TILs in order to evaluate their significance in anticancer immune responses and likely
impact on immune-mediated tumour cell death during NAC.
1.4.1.2 CD8⁺ and CD4⁺ T cells
CD8⁺ T cells (effector, memory) are important subset of T lymphocytes documented
in TILs. They represent CTLs which are crucial components of tumour-specific
cellular adaptive immunity. CD8⁺ CTLs can interact with and destroy tumour cells
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presenting with TAAs in conjunction with MHC class I proteins on their surface [215].
After TAA recognition and adequate co-stimulation from DCs, CD8⁺ CTLs become
activated. They subsequently produce cytotoxins, cytokines and apoptotic signals
lethal to the TAA harbouring cells. Cytotoxins are stored in lytic granules within the
naïve CD8⁺ T cells. Once activated these cells release the contents of the granules by
calcium-mediated exocytosis. Cytotoxic proteins lyse the target cells [perforins
polymerise in target cell membranes to form trans-membrane pores; granzymes (serine
proteases) are released through the pores and lyse intracellular cellular structures].
Activated CD8⁺ CTLs also express FasL, which induces target cell apoptosis by
activating the caspase cascade. Several cytokines are released by activated CD8⁺ CTLs
including IFN-γ [216-218]. 
Many studies have shown that tumour-infiltrating CD8⁺ T lymphocytes (and
CD45RO⁺ memory T cells) have anticancer activity providing a favourable effect on
prognosis in many solid cancers (colorectal, ovarian, oesophageal, renal, lung and
pancreatic tumours) [22, 209, 219, 220]. However, there are relatively few published
studies in this area in breast cancer. One study has shown that the presence of tumour-
infiltrating CD8⁺ T cells correlated with lymph node involvement by tumour and
unfavourable prognosis in early breast cancer [214]. In contrast, Mahmoud et al.
(2011) analysed the impact of the level of tumour-infiltrating CD8⁺ CTLs on
prognosis in a large series (1,334 breast cancers) of patients with long-term follow up.
CD8⁺ T cells were counted in three locations in each specimen (in tumour nests-
intratumoural, in stroma adjacent to tumour cells and in stroma distant to tumour
cells). The total number was determined by the sum of the counts of these three
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locations. Higher total infiltrating CD8⁺ T lymphocyte counts were independently
associated with longer breast cancer-specific survival, using multivariate analysis
[219]. The association between infiltrating CD8+ T cells and favourable prognosis has
been subsequently confirmed in basal-like breast cancer subtype with a large series of
3,403 breast cancer patients including 496 TNBCs by Liu el al. (2012) [221]. A much
larger series of patients involving 12,439 breast cancer patients studied by Ali et al.
(2014) confirmed infiltrating CD8+ T cells (both intratumoural and stromal) were
associated with a significant reduction in the relative risk of death from disease in
HER2+ve (both ER+ve and ER-ve) subtypes [222]. These studies with large cohorts
of patients, however, were investigated using the tissue microarray (TMA) technique
which may not well represent the heterogeneity in tumours.
The significance of CD4⁺ T effector cells within tumours is not well studied and has
produced contradictory results in terms of clinical outcome. Tumour-infiltrating CD4⁺
T cells consist of Th1, Th2, Th17, follicular helper T, naïve and memory T cells, as
well as Tregs [210]. The contribution of tumour-infiltrating CD4⁺ T cells to local
immune milieu depends on their polarisation and cytokine expression. The differential
effects of Th cell populations may be due to their plasticity, dependency on the tumour
microenvironment and on the cancer type. Th1 cells are strongly associated with good
clinical outcome for most solid cancers. On the other hand, Th2 cells, through the
activation of B cells or through the production of the immunosuppressive IL‑10,
appear to be associated with aggressive tumours [209]. The analysis of the Th17
population has also yielded contradictory results amongst cancer types. CXCL13
[chemokine (C-X-C motif) ligand 13; also known as B lymphocyte chemoattractant]-
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producing CD4⁺ follicular helper T cells infiltrates, principally located in tertiary
lymphoid structure (TLS) germinal centres, are an important constituent of TLS in
tumours and may link with favourable prognosis in various cancers including breast
cancer [210]. The chemokine receptor CXCR5 expressed by B cells and follicular
helper T cells is required for migration and responsiveness to CXCL13 to form
follicles. CD4+ T cells that express CXCR5 can migrate in response to CXCL13 and
relocate to follicles [223]. In breast cancer, Droeser et al (2012) found that a high level
of tumour-infiltrating CD4⁺ T cells was significantly associated with high tumour
grade and ER-ve status but was not an important prognostic indicator for survival [14].
Garcia-Martinez et al. (2014) documented that a high level of tumour-infiltrating
CD4⁺ T cells was the main factor responsible for a higher pCR rate with NAC [224].
1.4.1.3 Regulatory T cells (Tregs)
Regulatory T cells are a subset of CD4⁺ T cells, which co-express CD25 (the alpha
chain of the IL-2 receptor) and the forkhead family transcription factor FOXP3. Tregs
play important roles in the control of autoimmunity and maintenance of
transplantation tolerance [225]. Mutation of the FOXP3 gene causes the scurfy
phenotype in mice and the IPEX syndrome (immune dysfunction, polyendocrinopathy,
enteropathy, X-linked syndrome) in humans [226]. Tregs are able to suppress a large
number of distinct target cell types including CD4⁺ and CD8⁺ T cells, NK cells, NKT
cells and DCs [8, 227]. From in vitro studies, a number of suppressive mechanisms of
Tregs have been proposed: the secretion of TGF-β and IL-10, which down-regulate 
anticancer immune responses; the suppression of antigen presentation or decreased co-
stimulation of APCs; cytokine-mediated deprivation of the effector cells by
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competition with effector T cells for IL-2 consumption; suppression of the CD4⁺ Th
cell function and the generation of tumour specific CD8⁺ CTLs [8, 227]. Although
multiple mechanisms for Tregs suppression have been shown in vitro, it is unclear
whether the same or different mechanisms are used by Tregs in vivo [227]. Increased
levels of Tregs have been documented in blood, lymph nodes, and infiltrating the
tumour microenvironment in breast cancer as well as other solid cancers [228]. Their
suppressive functions on anticancer immune responses may influence not only
immune surveillance and tumour escape but also the outcome of conventional breast
cancer treatment such as NAC. In most varieties of human cancers, a high level of
infiltrating FOXP3⁺ T lymphocytes is associated with an unfavourable clinical
prognosis [229-234] (shown in Table 1.9). However, studies in colorectal cancer and
also head and neck cancer have documented the opposite findings, namely that high
levels of infiltrating FOXP3⁺ T lymphocytes can be associated with an improved
prognosis. Ladoire et al. (2011) suggested that this could be linked to their capacities
to suppress tumour-promoting inflammatory immune responses generated by
infectious stimuli from bacterial translocation through the gut mucosal barrier and also
to suppress Th17 cells [27].
Tregs which naturally develop in the thymus are called natural Tregs (nTregs). New
knowledge supports the existence of sub-populations of Tregs which may be generated
peripherally from naïve CD4⁺ T cells. The term induced or adaptive (iTregs) has been
applied to this subgroup of Tregs. Even though the mechanisms to generate iTregs are
still unclear, some evidence suggests that the immunosuppressive cytokines such as
IL-10 and TGF-β present in the microenvironment may be the major contributors to 
59
this inhibitory effect. The majority of tumour-infiltrating Tregs is more likely to be
nTregs and express stable FOXP3. In contrast, FOXP3 expression on iTregs is
somewhat unstable and may be lost. To date, many studies have attempted to explore
the role of iTregs versus nTregs in tumour immunobiology and their phenotypic
characteristics which may provide a useful strategy to deplete them and enhance
anticancer immune defences [235]. Neuropilin-1(Nrp-1), a type-1 transmembrane
protein is one of the molecules which have been studied (in mouse models) as a
potential marker to identify the composition of iTregs (low level of Nrp-1 expression)
in tumour-infiltrating Tregs [236]. Although their differential expression has not been
clearly assigned to either iTregs or nTregs, CCR4 (C-C chemokine receptor type 4),
PD1 and CTLA-4 have been shown to be highly expressed on tumour-infiltrating
Tregs and are potential targets for treatment for cancers enriched in Tregs expressing
such phenotypes [237].
Table 1.9 The Association of High Levels of Tumour-infiltrating FOXP3⁺ Tregs and
Unfavourable Prognosis in Various Cancers
Cancers N Stage P value References
Breast carcinoma 183 +214 Invasive P= 0.0001 (DMFS) Merlo et al. [234]
Breast carcinoma 309
Invasive: 237
Non-invasive (DCIS): 62
Normal breast: 10
P = 0.04 (RFS) Bates et al. [229]
Non-small cell lung
carcinoma 64 Stage I P = 0.05–0.007 (DSS)
Petersen et al.
[230]
Hepatocellular carcinoma 302 Non-metastatic P = 0.006 (OS) Gao et al. [232]
Renal-cell carcinoma 125 Stage I-IV P = 0.017 (OS) Li et al. [233]
Pancreatic carcinoma 198 Stage I-IV P= 0.0001 (OS) Hiraoka et al. [231]
N: Number of patients analysed; RFS: Relapse-free survival; DSS: Disease-specific survival; OS:
Overall survival; DMFS: Distant metastases-free survival
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Cytotoxic T lymphocyte-associated antigen 4
CTLA-4 (cytotoxic T lymphocyte-associated antigen 4; CD28 homologue; CD152) is
a co-inhibitory immune checkpoint molecule that negatively regulates T cell
activation. It is a type 1 transmembrane glycoprotein of the immunoglobulin
superfamily interacting with the B7-1 (CD80)/ B7-2 (CD86) ligand-binding sites via
its extracellular domain and the cytoplasmic tail. Notably, most CTLA-4 molecules
are intracellular residing in vesicles close to the microtubule organizing center
(MTOC). Only a small pool is expressed on the cell surface in a dynamic way. Its
distribution and intracellular trafficking are regulated through the cytoplasmic tail of
CTLA-4. At the molecular/ protein level, it shares some similarities to and competes
with CD28 which up-regulates T cell activation in the context of TCR-dependent
signaling [238, 239]. CTLA-4 which is expressed on the surface of Tregs, has been
documented to play a crucial role in anticancer immune responses by inhibiting the
interaction of the CD28 ligand on T lymphocytes with the CD80/86 receptors on DCs,
IL-2 production, IL-2 receptor expression, and cell cycle progression of activated T
cells [240]. As a result of this, the activation of DCs and the generation of specific
CD8⁺ CTLs are decreased. CTLA-4 is produced and mobilized from the internal side
of the cell membrane, then bound to either one of the co-stimulatory molecules, CD80
and CD86 on DCs. Thus, CTLA-4 expression switches the activated T cell into a
suppressed T cell. Clinically, targeting CTLA-4 with MAb against CTLA-4 (anti-
CTLA-4: ipilimumab and tremelimumab) has been used in the treatment of metastatic
melanoma showing an improvement in overall survival [187, 241]. In a recent study of
the effect of CTLA-4 in breast cancer, the level of CTLA-4 expression in breast cancer
tissue was higher than in normal breast tissue (weakly positive or negative expression
of CTLA-4 in control group of normal breast tissue) [242]. Also, higher mRNA levels
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of CTLA-4 in breast cancer tissue were associated with worse prognostic features
[242, 243]. Moreover, the spontaneous expression of CD3⁺CTLA-4⁺ T lymphocytes in
peripheral blood of breast cancer patients was also significantly higher than that of
healthy donors [15, 242, 243].
FOXP3 expression in breast cancer cells
The expression of FOXP3 is not only found in Tregs, but has also been documented in
some human tumour cells (e.g. lung, colon and breast cancers, and melanoma) with
the possibility of providing immunosuppressive mechanisms, as occurs with Tregs
[244]. The biological function of FOXP3 in tumour cells and its significance currently
remains unclear. Most studies have shown detrimental effects on anticancer immune
responses, resulting in tumour escape from immune surveillance [25, 245]. Ladoire et
al. (2011), by contrast, revealed a positive outcome for high levels of FOXP3
expression in a subgroup of breast cancer patients with HER2 overexpression after
NAC [246]. This effect may be a result of FOXP3 acting as a transcriptional repressor
of SKP2 (S-phase kinase-associated protein 2) and HER2, two breast cancer
oncogenes [246]. Our study is designed to provide more information in this
controversial area.
1.4.1.4 Natural killer cells (NK cells)
NK cells are morphologically defined as large granular lymphocytes, comprising 10-
15% of all circulating lymphocytes; they are also found in peripheral tissues. NK cells
are an important part of innate immunity and responsible for rapidly eliminating
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virally-infected cells, as well as tumour cells, without prior sensitisation and priming.
Their main functions are cytotoxicity and cytokine production [247].
Activation of NK cells is controlled by the balance between the stimulation of their
cell surface activating [KARs: killer activating receptors, including NKG2D (natural-
killer group 2, member D)] and inhibitory receptors (KIRs: killer cell
immunoglobulin-like receptors and LIRs: leukocyte immunoglobulin-like receptors).
KARs recognise and bind to certain molecules only expressed on abnormal or stressed
cells (pathogen or cell stress-induced ligands) to induce ‘killing signals’. On the other
hand, KIRs detect the level of MHC class I molecules on the surface of target cells and
provide inhibitory signals. Upon sufficient binding of KIRs to MHC class I molecules,
the killing signal is overridden by inhibitory signals to prevent the killing of normal
cells (self-tolerance). In contrast, if KIRs are not engaged with a sufficient number of
MHC class I molecules, the activating/killing signals override the inhibitory signals
from KIRs (missing-self), resulting in NK cell activation and killing of target cells
[248-250].
NK cells are able to extravasate and infiltrate into tissues where infected, stressed,
damaged, transformed or malignant cells are located [247, 251]. By their cytotoxic
activities, they can recognise and eliminate target cells without prior sensitisation by
sensing loss of self-MHC class I molecules [252]. When NK cells encounter the target
cells their cytoplasmic granules, which contain granzyme B and perforin, are released.
Perforin causes transmembrane pore formation and endosomal disruption. Granzyme
B enters the target cells via the pores and mediates apoptosis. The expression of FasL
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and TRAIL are also recognised as other mechanisms for NK cells to induce target cell
apoptosis. Low affinity Fc receptors known as CD16 are also found on the surface of
NK cells. Binding to the Fc (fragment, crystallisable) region of IgG antibodies on
opsonized infected cells also activates the NK cell resulting in ADCC [218, 253, 254].
CD56 expression is commonly used to identify human NK cells and to characterise the
NK cell population into two subsets which are different in their functional properties.
A low density-expression of CD56 (CD56dim) subset, which comprises around 90% of
NK cells, possesses potent cytotoxic activity but produces low levels of pro-
inflammatory cytokines (such as IFN-γ, TNF-α, GM-CSF and IL-3). In contrast, a 
minor subset which expresses CD56bright and the IL-2 receptor alpha chain (IL-
2Rα⁄CD25), has poor cytotoxic function but produces high levels of cytokines [251].
The ability to kill cancer cells makes NK cells a promising target of cancer
immunotherapy. Stimulation of endogenous NK cells with cytokines (IL-2 or IFNs) or
adoptive transfer of in vitro-activated autologous NK cells is ongoing in clinical trials
[255].
In the tumour microenvironment, NK cells extravasate from blood and migrate
through the extracellular space, using a number of MMPs. They infiltrate into and
around tumour nests where they can interact with other immune cells and tumour
cells. NK cells may function as potent regulators of T cell responses and interact with
APCs as a bridge between the innate and adaptive immune system [255]. Their
cytotoxic activities which need direct target-cell contact can lysis tumour cells without
MHC recognition. The density and distribution of NK cells within the tumour
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microenvironment have been shown to be significant prognostic factors in various
cancers (colorectal carcinoma, oesophageal squamous cell carcinoma, gastric
carcinoma, squamous cell lung cancer) [256-259]. There is lack of data about
infiltrating NK cells in LLABCs and particularly in the NAC setting.
1.4.1.5 Myeloid-derived suppressor cells (MDSCs)
The majority of solid tumours are infiltrated by diverse leukocyte subsets, including
both myeloid- and lymphoid-lineage cells. Their profile and activation status vary
depending on the tissue/organ milieu, as well as the stage of the malignancy. The
majority of these infiltrations include Tregs, MDSCs and M2 TIMs. These cells may
collectively or alone enable cancer cells to escape anticancer immunity.
MDSCs are immunosuppressive immature myeloid cells which have been found to be
elevated in most patients with cancers and in mice tumour models. They are a
heterogeneous population of myeloid cells with suppressive activities and contain the
precursors of granulocytes, macrophages and DCs. In mouse models, MDSCs are
defined as CD11b⁺ Gr1⁺ cells with immunosuppressive function. Graded
measurements of Gr1 expression allow the differentiation of CD11b⁺Gr1high (CD11b⁺
Ly6G⁺Ly6Clow) granulocytic MDSCs that are CD49d negative, and CD11b⁺ Gr1low
(CD11b⁺Ly6G-Ly6Chigh) monocytic MDSCs that are CD49d positive. Expression of
the IL-4R alpha-chain (CD124), the monocytic marker CD115, low levels of the
macrophage marker F4/80, and the stimulatory receptor CD40 have also been
suggested as markers for MDSCs, though they are not unique and mostly lack
relevance for identifying the suppressive population. In humans, phenotypic
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characterization of MDSCs is even more difficult. A great number of MDSC
phenotypes have been described in many different human diseases. Most of them are
malignancies involving solid tumours. Some of these overlap at least partially, while
others are mutually exclusive [260].
MDSCs can employ a wide range of suppressive mechanisms, which depend on their
granulocytic or monocytic subtype and often appear to involve more than one
mechanism. Besides overexpression of arginase 1 (Arg1) and inducible NO synthase
(iNOS) which can deplete L-arginine in the tumour milieu and generate NO,
respectively, suppressive mechanisms of human MDSCs involve production of
suppressive cytokines, such as IL-10 and TGF-β [260]. The CD49d positive subset of 
MDSCs (monocytic) strongly suppresses arginine-specific T cell proliferation in an
NO-dependent mechanism whereas the CD49d negative subset of MDSCs
(granulocytic) is relatively weaker in this suppressive mechanism, when compared
with the CD49d positive subset of MDSCs (monocytic). Together with tumour-
infiltrating macrophages (TIMs), MDSCs have been found to be involved in the
polarisation of naïve CD4⁺ T cells toward IL-17⁺ T cells (represented by Th17
secretion) [261]. MDSCs are important obstacle for naturally occurring or
therapeutically-induced anticancer immunity; their therapeutic targeting and
elimination is a highly attractive option. However, specific identification in the tumour
microenvironment along with selective depletion of these cells is difficult due to a lack
of unique markers. Therefore, to date, only rather unspecific approaches are available
[178].
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1.4.1.6 Tumour-infiltrating macrophages (TIMs)
In humans, macrophages are differentiated cells of the mononuclear phagocytic
lineage characterised by the expression of CD68, CD163, CD16 (Fc receptor), CD312
and CD115 (colony stimulating factor-1 receptor; CSF-1R) markers. Macrophage
differentiation, growth and chemotaxis are regulated by several growth factors,
including CSF-1, GM-CSF, IL-3, and chemokines such as CCL2 [chemokine (C-C
motif) ligand 2] [262]. All solid tumours recruit macrophages into their
microenvironment [also known as tumour-associated macrophages (TAMs)]. It has
been shown that breast carcinomas contain a substantial number of macrophages
[263]. Originally it was thought that these cells induced the rejection of the
immunologically ‘foreign’ cancer as macrophages can kill tumour cells in vitro.
However, recent clinical and experimental evidence indicates that in most cases, TIMs
play a major role in initiation, progression and metastatic dissemination of malignant
tumours. Some experimental evidence for the causal relationship between
macrophages and poor prognostic features comes from mouse models of breast cancer
in which genetic ablation of macrophages resulted in attenuation of tumour
progression and generation of metastases [158]. Based on their immunological
responses, in the tumour microenvironment TIMs can be classified into two main
polarised phenotypes. The classically activated M1 macrophages are characterised by
the expression of NOS2 as well as many pro-inflammatory cytokines (e.g. IL-1β, IL-6, 
IL-12, IL-23 and TNF-α). This phenotype has been reported to have a high 
tumouricidal capacity and enhanced anticancer immunity. On the other hand, the
alternatively activated M2 macrophages (express the scavenger receptor CD163 as a
cellular marker) have immune regulatory/ inhibitory functions. Many of the factors,
produced by M2 macrophages, result in stimulation of tumour growth and tumour
67
progression [via enhanced activity of EGF, fibroblast growth factor 1 (FGF-1) and
TGF-β], angiogenesis (induced by VEGF) and matrix remodelling (by MMPs) [264].  
CD163 is a haemoglobin scavenger receptor only expressed on the cell surface of
monocytes/macrophages with an alternatively activated (M2) phenotype. It plays a
crucial role in dampening the inflammatory response and in scavenging components of
damaged cells. CD163-mediated endocytosis of haptoglobin-haemoglobin complexes
(from haemolysis of red blood cells) leads to lysosomal degradation of the ligand
protein. CD163 directly induces intracellular signalling leading to secretion of anti-
inflammatory cytokines. Moreover, CD163-mediated delivery of haemoglobin to
macrophages may fuel an anti-inflammatory response because haeme metabolites have
potent anti-inflammatory effects [265].
Classically activated (M1) macrophages, following exposure to IFN-γ, have 
antitumour activity and elicit tissue destructive reactions. In response to IL-4 or IL-13
(involved in Th2-type responses), macrophages undergo alternative (M2) activation
[266]. In most tumours, the majority of TIMs have been documented to have a M2-
like phenotype which is oriented towards promoting tumour growth, remodelling
tissues, promoting angiogenesis and suppressing adaptive immunity [267]. A meta-
analysis, produced by Bingle et al. (2002), showed that the increased TIMs
density/level in the tumour microenvironment was associated with poor prognosis in
more than 80% of solid cancers [268]. This review showed that in breast cancer (335
breast cancer cases from four studies) there was a significant correlation with poor
prognosis for both RFS and OS and also there was an association with angiogenesis,
68
high tumour grade, tumour necrosis and large tumour size [268-271]. Tsutsui et al.
(2005) demonstrated a significant positive correlation between TIMs and VEGF
expression in breast tumours [272]. However, the large study with 1,322 breast
tumours of Mahmoud et al. (2012) was unable to find a relationship between TIMs
and prognosis [273]. TIM Infiltrates in the microenvironment may be important in
mediating responses to chemotherapy. There is a paucity of data regarding TIMs and
response to primary chemotherapy in breast cancer. One study has documented that a
high number of TIMs was significantly associated with a pCR in LLABCs receiving
NAC [274].
Therapeutic approaches focusing on TIMs which include blockade of macrophage
recruitment into tumours, suppression of TIM survival, re-polarisation towards an M1-
like phenotype and MAbs to enhance antitumour activities of TIMs, are on-going
investigations [275].
1.4.1.7 Dendritic cells (DCs)
DCs are special subsets of leukocytes derived from haematopoietic progenitor cells.
They function as potent APCs capable of initiating and directing adaptive immune
responses. Various types of DCs have been recognised and categorised according to
their morphological characteristics, functions and in situ residence. The two main
types are myeloid DCs (mDCs) and plasmacytoid DCs (pDCs). In peripheral tissues,
immature DCs come in contact with, engulf/ phagocytose foreign antigens and
pathogens, and degrade these into small molecules and peptides. DCs migrate to
regional lymph nodes where the peptides/small molecules are presented by DCs
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(linked to MHC molecules) to both memory and naïve T cells. Antigens bound with
MHC class I molecules are recognised via TCRs on CD8⁺ T lymphocytes whereas
CD4⁺ T cells recognise and interact with peptides linked with MHC class II molecules.
Following this process, DCs become activated and mature. Simultaneously, DCs up-
regulate the expression of co-stimulatory molecules such as CD80 (B7-1) and CD86
(B7-2) on their cell surface to enhance the ability of T cell activation (co-stimulator
pathway). Mature DCs also synthesise high levels of IL-12 which enhance both innate
(NK cells) and adaptive (B and T cells) immunity [276].
In breast cancer, evidence suggests that DCs in the tumour microenvironment are
absent or only present in a very low number and are poorly activated [277-279].
Moreover, dysfunctional DCs (switched-off) were also identified in tumour-draining
regional ALNs and in the peripheral circulation in patients with operable breast cancer
[280].
There are a number of specific markers which have been used to identify DCs
according to their subtypes, level of activation and maturation. CD1a molecules,
which are expressed on DCs during the antigen capture and processing phases, have
been widely used as a general marker for putative DCs [281-283]. High levels of DCs
(CD1a⁺ or S100 protein⁺) in the tumour microenvironment have been associated with
a better clinical outcome and survival in gastric, thyroid, lung and colorectal
carcinomas [284-287]. Coventry et al (2003) also demonstrated a higher 5-year
survival rate in a group of patients with breast cancer with high levels of tumour-
infiltrating CD1a⁺ DCs but this did not reach statistical significance (p=0.331) [281].
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To date, there is no data on the significance and effect of tumour-infiltrating DCs on
the responses to NAC and vice versa in women with LLABCs.
1.4.1.8 Programmed death 1 (PD1) and its ligands
Similar to CTLA-4, PD1 (CD279) is a transmembrane immunoglobulin receptor and a
member of the CD28 family. PD1, expressed on activated T cells, follicular helper T
cells (CXCR5+) and Tregs, consists of a single extracellular IgV domain, a
transmembrane region and a cytoplasmic domain (receptor tyrosine-based switch
motif) [223, 288]. When interacting with its ligands [programmed death ligand 1
(PDL1 or B7 homologue1 or CD274) and programmed death ligand 2 (PDL2 or B7-
DC or CD273)] in a co-inhibitory pathway, it dampens down activated T cells and T
cell responses (cytotoxic activity, proliferation, and cytokine production) and depletes
T cells in the tissue/ tumour microenvironments. Contrary to the action of CTLA-4
which inhibits the early stage of T cell activation, the PD/ PDL pathway is necessary
to maintain peripheral T cell tolerance in tissues and is crucial for preventing
autoimmunity and maintaining T cell homeostasis [289]. The PD1 pathway is one of
the immune checkpoints which cancers cells appear to exploit and thereby escape from
anticancer immune defences [290].
In the microenvironment PDL1, which is normally expressed on various types of
lymphoid cells and non-lymphoid tissues (pancreatic islet cells, smooth muscle cells,
endothelial cells in the heart and liver, epithelial cells in the cornea, colon and skin,
and trophoblasts in the placenta), has been documented to have a high expression in
most solid tumours (lung, ovary and colon and melanoma). It has been shown to be
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correlated with poor survival, high tumour grade, large tumour size, metastatic spread,
a high recurrence rate, and fewer tumour-infiltrating CD8⁺ T cells [190, 291, 292]. In
breast cancer, however, high levels of PDL1 expression and in situ PDL1 mRNA
levels have been documented to be associated with increased TILs and improved RFS,
as well as increased pCR rates following NAC [293-295]. PDL1 has been found to be
expressed in 20% of TNBCs, and basal breast cancer cell lines constitutively
expressed the highest levels of PDL1 in response to IFN-γ [296, 297]. High levels of 
tumour-infiltrating PD1⁺ cells in operable breast cancers have been shown to have a
significant correlation with a shorter survival [298]. In univariate survival analyses,
the presence of PD1⁺ cells was associated with a significantly worse OS [Hazard ratio
(HR) = 2.736, p<0.001]. In subgroup analysis, the prognostic significance of tumour-
infiltrating PD1⁺ cells was observed in patients with luminal B and in basal-like
subtypes [299]. Flow cytometric studies demonstrated that, in breast tumours, PD1 is
expressed primarily on CD4⁺ TILs [300].
The strategy of blocking the interaction between PD1 and its ligand by using MAbs
targeting PD1 (MDX-1106) or PDL1 have been studied in early phase clinical trials. It
has been shown to have a promising efficacy in advanced metastatic melanoma and
NSCLC, with low rates of drug-related adverse events [189, 190].
1.4.1.9 Tumour-associated neutrophils (TANs)
Polymorphonuclear leukocytes (PMNs or neutrophils) are the most common white
blood cells found in blood. Their primary roles are to defend the host from invading
pathogens and also to assist in wound healing. These cells possess a number of toxic
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substances such as reactive oxygen species (ROS) and proteinases [serine proteinases
including neutrophil elastase (NE), cathepsin G (CG) and proteinase-3 (PR3); MMPs
including neutrophil collagenase (MMP-8) and gelatinase B (MMP-9)] to combat
invading foreign microorganisms [301, 302]. These substances, in addition, are
capable of modifying tumour growth and invasiveness [303].
In the tumour microenvironment, PMNs are recruited, in response to chemotactic
stimuli from macrophages or tumour cells, to sites of tumourigenesis where they
attempt to kill foreign tumour cells using the same toxic substances as those which kill
bacteria. Unlike the alternative phenotype M1/ M2 macrophages, neutrophil activation
states are likely to follow a linear progression. Naive circulating PMNs do not release
large amounts of oxygen radicals and proteinases when they enter the tumour
microenvironment. Mildly or moderately activated PMNs (recently described as N2
TANs) do release moderate concentrations of these toxic substances with detrimental
effects on the host’s defences and resultant promotion of tumour growth. Nevertheless,
PMNs can be induced to a highly activated state (recently described as N1) releasing
high levels of these substances with tumouricidal or cytotoxic activities [303, 304].
TANs, therefore, possess a potentially valuable anticancer role provided their
activation can be manipulated and properly controlled. The therapeutic potential of
highly activated PMNs (N1), however, may come with major consequence to
neighbouring host tissues. Sepsis, acute lung injuries (ALI) and acute respiratory
distress syndrome (ARDS) are conditions associated with the presence of highly
activated PMNs (N1) [305].
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The presence of tumour-infiltrating PMNs, which are defined as CD66b⁺ cells, has
been documented to be an independent predictor of mortality in renal cell carcinoma.
This latter study showed that the 5-year RFS rate decreased from 87%, in the absence
of tumour-infiltrating PMNs, to 53% in the presence of infiltrating PMNs [306]. The
significant association of increased numbers of infiltrating PMNs with a poorer
outcome was also documented in bronchoalveolar cell carcinoma [307]. In
hepatocellular carcinoma, increased intratumoural PMNs (but not peritumoural PMNs)
were significantly associated with decreased DFS and OS [308].
In breast cancer, an increased pre-treatment circulating neutrophil to lymphocyte ratio
(NLR), which may be a marker of systemic cancer-related inflammation, has been
shown to be associated with poor DFS [309, 310]. The level of neutrophil elastase
(NE) in breast cancer tissue has been correlated with poor clinical outcomes in many
studies [311-313]. There is a dearth of data on the significance of tumour-infiltrating
PMNs in LLABCs and the effects NAC on these infiltrating cells.
1.4.2 Cytokines and biological molecules
Cytokines are small proteins [about 5-25 kilo-dalton (kDa)] which are produced and
released by a broad range of cells (including innate and adaptive immune cells, as well
as endothelial cells, fibroblasts, and various stromal cells) and are involved in cell
signalling and responses to various stimuli. Cytokines induce responses through
binding to specific receptors. The nomenclature of cytokines is based on their cellular
sources. Cytokines can be classified as monokines (e.g. IL-1, TNF-α) which are 
produced primarily by monocytes and macrophages, and lymphokines produced by
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lymphocytes. The term interleukin (IL) is preferred for the cytokines which are
secreted by a number of different leukocytes and act on other leukocytes. The vast
majority of ILs is produced by Th cells. Another common classification is on the basis
of their biological functions/responses which are pro- and anti-inflammatory cytokines
depending on their effects on immune cells (Table 1.10), as well as type 1 (enhance
cellular immune responses; e.g. IL-2, IFN-γ, TNF-α) and type 2 (anti-inflammatory, 
favour antibody/humoral responses; e.g. TGF-β, IL-4, IL-10) cytokines. The majority 
of cytokines include ILs, growth hormone, IFNs (α, β, γ) and TNFs (α, β). Cytokine 
synthesis may be initiated by a gene transcription as a result of cellular activation and
controlled by RNA processing and by post-translational mechanisms. Cytokine
secretion is a brief, self-limited event and the actions are often pleiotropic and
redundant. Some cytokines may have the same functional effects [314, 315].
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Table 1.10 Lists of the Common Cytokines and their Functions
Cytokines Major Sources Main Targets Functions
IL-1β Macrophages, 
DCs
APCs, T cells, B
cells
Pro-inflammatory; promotes activation,
co-stimulation, secretion of other
cytokines, secretion of acute-phase
proteins; pyrogenic
IL-2 Th1 cells T cells, B cells,
NK cells,
macrophages
Proliferation; enhancement of
cytotoxicity, IFN-γ secretion and 
antibody production
IL-4 Th2 cells, mast
cells
T cells, B cells,
monocytes,
macrophages
Proliferation and differentiation of Th2;
promotes IgG and IgE production;
inhibits cell-mediated immunity
IL-5 Th2 cells, mast
cells
Eosinophils, B
cells
Proliferation and activation of Th2;
maturation of eosinophils
IL-6 Macrophages,
monocytes,
Th2 cells,
fibroblasts
B cells, T cells,
thymocytes,
myeloid cells,
osteoclasts
A multi-functional cytokine regulator of
immune responses; involved in B cell
differentiation; induction of acute phase
proteins; induction of IL-2 and IL-2
receptor expression; proliferation and
differentiation of T cells
IL-10 Th2 cells,
Tregs, DCs,
macrophages
Macrophages, T
cells, DCs, B
cells
Immune suppression; decreases antigen
presentation and MHC class II
expression of DCs; down- regulates
Th1, Th2, and Th17 responses
IL-12 Macrophages,
DCs, B cells
T cells, NK cells Differentiation and proliferation;
promotes Th1 and cytotoxicity
IL-17 Th17 cells Epithelial cell,
endothelial cells,
fibroblasts
Induces stromal cells to produce pro-
inflammatory and haematopoietic
cytokines, enhances the surface
expression of intracellular adhesion
molecule 1 (ICAM1) in fibroblasts
TNF-α Macrophages, 
monocytes, NK
cells, mast cells
Neutrophils,
macrophages,
monocytes,
endothelial cells
Pro-inflammatory; promotes activation
and production of acute-phase proteins
IFN-γ Th1 cells, NK 
cells, CD8⁺ T
cells
Macrophages, NK
cells, T cells
Promotes activation of APCs and cell-
mediated immunity; increased MHC
class I and II expression on APCs;
antiviral and anticancer activity
TGF-β Tregs, DCs, 
macrophages,
All leukocyte
populations
Regulatory; inhibits growth and
activation; Treg maintenance
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1.4.2.1 T helper-1 (Th1) and T helper-2 (Th2) cytokines
Cytotoxic lymphocytes, including NK cells and tumour-specific CTLs, eliminate
tumour cells in a MHC-dependent manner. NK cells kill tumour cells that are missing
“self” markers of MHC class I molecules whereas tumour-specific CTLs destroy
tumour cells presenting with TAAs in conjunction with MHC class I molecules [316].
Furthermore, Th1 cells and their secreted cytokines such as IL-2 and IFN-γ, play a 
crucial role in the generation of CTL-mediated anticancer immune responses and
subsequent regression of tumours [164, 316]. NK cells also serve as a source of IFN-γ 
at an early stage in tumour development, further enhancing anticancer immunity by
assisting effective priming of Th1 cells and CTLs [316]. Tumour and immune
suppressor cells, however, implement diverse strategies against the generation and
action of CTLs and Th1 cells. Tregs, as well as tumour cells, produce cytokines to
modulate cytotoxic lymphocytes. In this case, IL-4, IL-10 and TGF-β have been well 
documented to play a major role as immunosuppressive cytokines [8]. IL-4 and IL-10
(Th2 cytokines) function as down-modulators of Th1 generation. IL-10 is also known
to decrease the expression of MHC molecules on tumour cells and to reduce the
capacity of DCs to generate antigen-specific Th1 cells. Tumour microenvironments
enriched with IL-10 can effectively recruit Tregs into the tumour sites. Lastly, excess
TGF-β derived from tumour cells vigorously down-regulates the proliferation of 
tumouricidal lymphocytes, especially Th1 cells and induces the generation of
peripheral FOXP3⁺ Tregs from naïve T cells [8, 164, 316].
In cancer tissues, the expression of IL-4, IL-10 and TGF-β can be identified on the cell 
membrane and in the cytoplasm of tumour cells by IHC. Cancer cells produce and
secret IL-4, IL-10, TGF-β and VEGF and have been documented as one of the tumour 
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escape mechanisms [144, 317]. Llanes-Fernandez et al. (2006) studied IL-10
expression in the tumour microenvironment in 27 breast cancer patients and found that
23 out of 27 breast cancer samples exhibited a strong expression of IL-10. They also
proposed the association between IL-10, Bcl-2 and Bax, and the inverse association of
IL-10 with p53 [318]. In addition, from the recent study of Liu et al. (2013), strong
expression of IL-10 in ductal and lobular breast cancer tissues was seen in 80.34%
(94/117) of cases. They also suggested that IL-10 expression was correlated with the
high B7-H3 (a member of the B7-family) expression in human breast cancer tissues
and contributed to tumour immune evasion and tumour progression. This expression
appeared to be correlated with the ability of B7-H3 to promote IL-10 secretion [319].
However, there is evidence that pro-inflammatory cytokines such as IL-1, IL-2 and
IFN-γ are also found expressed by cancer cells [320-326]. 
1.4.2.2 Interleukin-17 (IL-17)
IL-17 was originally found to be produced from a subset of CD4⁺ effector T
lymphocytes and was IL-23 dependent, thus, differing from the Th1 and Th2 lineages.
Although it plays a crucial role in inflammation and autoimmune disease, there is
relatively little data regarding its role in anticancer immunity [327]. Moreover, the
data available is somewhat conflicting. Some murine studies reported that IL-17
supported tumour growth and promoted angiogenesis [328, 329]. Other studies have
suggested it may enhance anticancer defences by increased generation of specific
CTLs [330]. In vitro invasion assays have shown that IL-17 promoted invasiveness of
breast cancer cell lines [331].
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In females with breast cancer, the expression of IL-17 can be found in TILs (Th-17),
cancer cells and CD68⁺ TIMs [14, 331, 332]. The number of Th17 cells (IL-17⁺ TILs)
in breast cancer tissue is higher than that documented in normal breast tissue. In
addition, high levels of this expression have been shown to be associated with
improved prognosis and reduction of metastases [332]. It has been reported also to
predict better survival in oesophageal and gastric cancers [333, 334]. Conversely, its
association with poor prognosis have been reported in colorectal, lung and
hepatocellular carcinoma [335-337].
1.4.2.3 Interferon gamma (IFN-γ) 
IFN-γ is a type II interferon and is defined as a primary cytokine of Th1 lymphocytes 
(secretion of large amounts of IFN-γ is the defining feature of Th1 lymphocytes). Its 
molecular structure and binding receptor are unrelated and different from Type I
interferons (IFN-α, IFN-β and IFN-ω). Mostly, IFN-γ is produced by NK cells, CD4⁺
Th1 cells and CD8⁺ CTLs. However, recent data have suggested that B cells, NK T
cells, and APCs can also secrete IFN-γ [338, 339]. The IFN-γ production is positively 
controlled by IL-12 and IL-18 while IL-4, IL-10, TGF-β and glucocorticoids are 
negative regulators. Apart from antiviral function, IFN-γ has immunoregulatory and 
immunomodulatory properties and promotes the anticancer immune response. IFN-γ is 
capable of activating macrophages and APCs, promotes NK cell activities, assists in
the development of a Th1-type response and suppresses Th2 cell differentiation.
Moreover, IFN-γ up-regulates the expression of MHC molecules (both class I and II) 
on APCs which increase the potential for T cell recognition of presented foreign/
tumour peptides, thus promoting the induction of adaptive cell-mediated immunity
[339-341].
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1.4.2.4 Transforming growth factor beta (TGF-β) 
TGF-β is able to suppress tumours at the early stages of carcinogenesis. However, at 
the later stages, during tumour development, TGF-β exerts an oncogenic activity by 
promoting growth, invasiveness and metastases. TGF-β ligands and their receptors are 
expressed in normal cells, lymphocytes, and also in tumour cells. In both normal and
malignant cells, with the exception of fibroblasts, TGF-β is a potent inhibitor of cell 
proliferation including CTLs [342]. It can also promote cell differentiation and induce
apoptosis. These activities are responsible for its immunosuppression. Unfortunately,
during the later stages of tumour development, tumour cells escape from TGF-β-
mediated growth arrest due to inducing mutations of genes encoding TGF-β receptors 
or signalling pathway proteins. At this later stage, tumour cells become refractory to
TGF-β, but it still exerts immunosuppressive activity interfering with 
immunosurveillance. Thus, it can facilitate tumour progression and dissemination
[144].
1.4.2.5 Vascular endothelial growth factor (VEGF)
VEGF is a primary stimulant for tumour angiogenesis, which is important for tumour
growth and formation of metastases. When tumours reach a size of about 0.2–2.0 mm
in diameter, they become hypoxic and limited in size in the absence of an appropriate
vascular bed. In order to increase further in size, the tumour needs to develop a blood
supply that can support its metabolic requirements. In addition, the new blood vessels
can also provide an escape route by which cells can leave the primary tumour to
disseminate and form metastases [144]. The major mechanism for driving
angiogenesis results from the increased production of VEGF following up-regulation
of the hypoxia-inducible transcription factor. VEGF binds and activates via VEGF
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receptor 1 (VEGFR1) and VEGF receptor 2 (VEGFR2) [343]. Elevated levels of
VEGF in tumour cells correlate with increased lymph node metastases, HER2
overexpression and a worse prognosis in breast cancer [344]. To date, anti-VEGF
therapy has been widely used and approved for the treatment of metastatic HER2
negative breast cancer. Serum levels of VEGF and soluble VEGF receptors appear to
be potential biomarkers of responses in advanced breast cancer patients treated with
metronomic cyclophosphamide [345]. Furthermore, cyclophosphamide and
capecitabine have been shown to be able to significantly reduce serum VEGF in
patients with metastatic breast cancer [346]. However, to date, there is no data on
VEGF expression in the tumour microenvironment of breast cancer with NAC,
particularly in relationship to pCR and cellular immune parameters.
1.4.2.6 Indoleamine 2, 3-dioxygenase (IDO)
One of the important mechanisms that enables tumour cells to escape from anticancer
immune defences and induces immune tolerance is that involving IDO. The expression
of this molecule has been found in several human cells, including activated DCs,
macrophages, endothelial cells, fibroblasts and MDSCs [347]. IDO is the rate-limiting
catalytic enzyme of tryptophan degradation through the kynurenine pathway. This
enzyme causes both the depletion of the essential amino acid L-tryptophan which is
necessary for the function of T cells and the increased production of tryptophan
metabolites which are immunosuppressive. These downstream tryptophan metabolites
can suppress T cell proliferation and cause T cell apoptosis in vitro.[348]. In addition,
IDO can affect NK cell functions [349]. Data from in vitro studies has indicated that
IDO expression by DCs can promote the differentiation of naïve CD4⁺ T cells into
Tregs [350].
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IDO⁺ cells have been observed by IHC in tumour and tumour-draining lymph nodes in
melanoma and breast cancer, as well as other cancers [351]. The expression of IDO by
tumour cells has been shown to correlate with a poor clinical prognosis in ovarian,
endometrial and colon carcinomas [352-354]. Studies in patients with malignant
melanoma, IDO expression in sentinel lymph nodes was associated with a markedly
worse clinical prognosis [355, 356].
In studies with breast cancer, serum IDO metabolism determined by tryptophan/
kynurenine ratio has been proposed as a prognostic indicator in patients with recurrent
breast cancer [357]. The overexpression of IDO in the tumour microenvironment has
been shown to have a significant positive correlation with extensive nodal metastases
and levels of infiltrating Tregs [358]. However, the DFS rate in patients with IDO
overexpression was not significantly lower than that in patients with negative or low
expression of IDO [359].
Up-regulated expression of IDO (IDO hyperactivity) leads to tumour progression by
suppressing T cell immunity and inducing anticancer immune tolerance, hence
targeting IDO may be a potential novel anticancer therapy. To date, IDO inhibition
with 1-methyl-D-tryptophan (1-MDT) has been studied in early clinical trials [360].
Moreover, cyclooxygenase (COX)-2 inhibitors have been shown to down-regulate
IDO expression at tumour sites in animal tumour models [361].
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1.4.2.7 Prostaglandins (PGs)
PGs are a catalysed product of arachidonic acid. The activity of COX enzymes is
coupled to several terminal synthases which produce the different PGs. The major PGs
produced are the PGE2, PGD2, PGF2α and PGI2 by their respective synthases and are 
present in normal tissues/organs [362]. Two COX isoforms are identified including the
COX-1 and COX-2. COX-1 is constitutively expressed in several tissues and is
essential in maintaining various homeostatic conditions whilst COX-2 is an inducible
enzyme which is up-regulated in association with inflammation [363].
In a range of solid cancers (e.g. lung, prostate, bladder and colon) with a prominent
immune cell infiltration, there is often associated with enhanced expression of COX-2
and increased production of PGE2. COX-2 expression and PGE2 production are
detected in both the tumour cells and immune cells (MDSCs and TIMs), and are
increased in the tumour microenvironment [364, 365]. PGE2 is involved in various
biological processes which result in anticancer immune dysfunction, in particular by
inducing the generation of MDSCs. It inhibits the differentiation and activation of
bone marrow-derived APCs, reduces NK cell cytotoxicity and suppresses T cell
function (inhibiting CD4+ T cell survival and generation of CD8+ CTLs) [366, 367].
Moreover, inhibition of the Th1 cytokine production and stimulation of the Th2 and
Th17 cytokine productions have been demonstrated [368, 369]. PGE2 up-regulates
FOXP3 expression in Tregs and enhances in vitro Treg activity [370]. It also up-
regulates Arg1 in MDSCs and TIMs. Arg1 is important in inducing MDSC-mediated
immune suppression. PGE2 promotes the entry and accumulation of MDSCs into the
tumour microenvironment [371]. The overexpression of the COX-2 enzyme in breast
cancer is associated with a poor prognosis [372]. COX-2 inhibitors have been used to
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reduce PGE2 production and inhibit the expansion of MDSCs in vivo [367, 373]. As
PGE2 is a lipid rather than a protein, PGE2 present in the tissues (paraffin-embedded)
is difficult to be measured using IHC technique and may lose during tissue process and
washing with detergent-contained solutions. The thesis, therefore, did not document
the level of PGE2 in the microenvironment of LLABCs.
1.4.3 Cancer stem cells (CSCs) in breast tumours
It has been shown that breast cancer, as well as other malignant tumours, contains a
small distinct subset of cells called cancer stem cells (CSCs). This subset is
responsible for tumour initiation and possesses the ability of self-renewal, a high
proliferative rate and production of multiple differentiated progenies. CSCs are
resistant to both chemotherapy and radiotherapy and may be responsible for poor
outcome and recurrence after treatment [374-376]. In the tumour microenvironment of
breast cancer, CSCs can be identified as they strongly express the adhesion molecule
CD44 and very low levels of the adhesion molecule CD24 [377, 378]. However, in the
study using immunohistochemical double staining to detect CD44⁺ CD24-/low breast
cancer cells, no significant correlation was demonstrated between the high percentage
of CD44⁺ CD24-/low cells and tumour progression or OS [378].
CD24 is a small, heavily glycosylated cell surface protein which is considered to play
a crucial role in tumour metastasis through P-selectin. It has been shown to have a
higher expression in DCIS and invasive breast cancer than in normal breast tissue, and
positively correlated with tumour grade [379].
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CD44 is a transmembrane glycoprotein receptor for the extracellular matrix
hyaluronan. The interaction between extracellular matrix hyaluronic acid and CD44
influences adhesion, migration and invasion of many cancers. Increased CD44
expression has been demonstrated to have an association with a poor prognosis in
breast cancer, as well as other cancers [380, 381].
1.4.4 Tumour-infiltrating lymphocytes (TILs) and pathological responses to
neoadjuvant chemotherapy (NAC) in breast cancer
Neoadjuvant administration of primary chemotherapy provides an opportunity for a
relatively rapid assessment of the therapeutic efficacy of a given drug regimen. This
clinical setting allows the evaluation of the predictive role of biomarkers including
TILs and also enables an assessment of the dynamic changes of biomarkers before and
after therapy [300]. The administration of NAC to patients with breast cancer results in
the activation of systemic immunity as characterised by increased numbers of
circulating CD4⁺ and CD8⁺ T lymphocytes [382] and decreased numbers of circulating
Tregs [15].
There is little data on the significance of TILs and their subsets to the contributions to
the pathological responses elicited with NAC in breast cancer. Demaria et al. (2001)
evaluated the extent/ degree of lymphocytic infiltration in the primary tumour and the
presence of TILs (defined as lymphocytes present within tumour cell nests) using
H&E (haematoxylin and eosin)-stained histological sections from pre-treatment
biopsies and post-treatment surgical specimens of 25 breast cancer patients who had
received neoadjuvant paclitaxel. They found that an increased level of TILs in post-
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treatment specimens correlated with clinical responses (partial and complete clinical
response) [383]. This was the first study to demonstrate the relevance of TILs in the
neoadjuvant setting. Tumours which showed a response to NAC had increased levels
of TILs, when compared with pre-treatment TIL estimations. Unfortunately, only 1 out
of the 25 patients achieved a pCR and the level of TILs in the pCR specimen was
difficult to evaluate. Within the scar tissue at the primary tumour site of a pCR, the
levels of TILs and other immune cells need to be carefully evaluated.
In the larger study of Denkert et al. (2010), the core biopsies of 1,058 breast cancer
patients from two cohort studies (the GeparDuo and GeparTrio) were examined. The
study showed a significant and independent prediction of pCR rates from the high
levels of TILs presenting in the pre-treatment biopsies. High levels of TILs were
associated with pCR rates of 41.7 and 40.0%, compared with 2.8 and 7.2%,
respectively, in the absence of TILs [19]. These results provide strong evidence for the
relevance of TILs from a large set of more than 1,000 breast cancer patients.
Yamaguchi et al. (2012) studied histomorphology and biomarkers to predict pCR after
NAC in various stages of breast cancer (TNM stage I-IV). They found that high levels
of TILs, high histological grade, negative hormone receptor status and HER2
overexpression in tumours were significantly associated with a pCR. Among these
predictors, high level of TILs was the best independent predictor for a pCR (p<0.0001)
[17]. Ono et al. (2012) was the first to document the association between high levels of
TILs and high pCR rates in TNBCs [18]. Furthermore, this association was
subsequently validated in HER2-ve breast cancer by Issa-Nummer et al. (2013) [384].
In an analysis of breast cancer subgroups from the study of Loi et al. (2013), increased
levels of TILs were associated with a better prognosis in ALN positive, ER-ve and
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HER2-ve subgroups of breast cancers regardless of NAC drugs and regimens used
[385]. High levels of TILs, particularly in the stroma, have been documented to be an
independent prognostic factor for improved DFS and OS in TNBCs by Adams et al.
(2014). Their study involved 481 patients with TNBCs [386]. The relevance of TILs
present after NAC has been further demonstrated by Dieci et al. (2014) [387]. In this
study, high levels of TILs present in both the stroma and intratumourally in the
residual tumour tissue after NAC in TNBCs were significantly associated with a better
DFS and OS. However, these studies did not define the subsets of TILs, in particular
the interaction of FOXP3⁺ Tregs and CD8⁺ T lymphocytes.
Hornychova et al. (2008) characterised the TIL subsets using IHC in pre-NAC
biopsies and post-NAC resection specimens from 73 patients (10 patients with a pCR;
63 patients with no pCR) undergoing NAC containing doxorubicin and paclitaxel.
They found that higher levels of CD3⁺ TILs and CD83⁺ DCs were significantly
associated with a pCR. In tumours with no pCR, an increase in the mean and maximal
numbers of CD3⁺ TILs, CD56⁺ TILs and DCs (characterised as CD83⁺, CD1a⁺ or
S100⁺ cells) and a decrease in the number of CD68⁺ monocytes, and lower VEGF
expression were observed in the residual tumours after NAC [388]. West et al. (2011)
showed that high levels of CD3+ TILs in breast cancer correlated with prolonged DFS
and better pCR rates following anthracycline-based chemotherapy in ER-ve breast
cancers [389]. Ladoire et al. (2008; 2011) studied FOXP3⁺ Tregs and CD8⁺ T cells.
He and his colleagues established a correlation between the rates of pCR and the levels
of FOXP3⁺ Tregs and CD8⁺ T cells in different stages of breast cancer using various
regimens of NAC. A pCR was associated with the disappearance of FOXP3⁺ Tregs in
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post-NAC surgical specimens whilst the level of CD8⁺ T lymphocytes remained
unchanged. High levels of CD8⁺ and low levels of FOXP3⁺ TILs post-NAC were
associated with improved long-term clinical outcomes. The CD8⁺ TIL: FOXP3⁺ TIL
ratio was the significant prognostic parameter in multivariate analysis [390, 391]. A
high level of infiltrating CD8+ T cells was significantly predictive of a pCR, was also
documented in another study by Nabholtz et al. (2014) with a cohort of 47 patients
with TNBCs [392]. Seo et al. (2013) demonstrated a positive correlation between the
levels of infiltrating CD4+ T cells and pCR rates. In addition, the levels of infiltrating
CD8+ T cells and FOXP3+ T cells were also positively correlated with pCR rates in
this study [393]. These findings were consistent with the findings documented by Lee
et al. (2013) [394].
Aruga et al. (2009) compared the levels of FOXP3⁺ TILs between pre- and post-NAC
samples. The median value of FOXP3⁺ Treg counts was 16.3 cells/high-power field
(HPF) for pre-NAC tumour biopsies, but only 6.6 cells/ HPF for post-NAC surgical
specimens. Failure of breast cancers to respond to NAC was found to be significant in
patients with high FOXP3⁺ Treg counts. The patients with low FOXP3⁺ Treg counts in
both specimens (pre- and post-NAC) had a better prognosis [395]. Oda et al. (2012)
found that the presence of infiltrating FOXP3⁺ Tregs and CD8⁺ T cells but not IL-17⁺
T cells in breast cancers before NAC was significantly associated with higher pCR
rates than breast cancers lacking these infiltrating cells [396]. Liu et al. (2012) studied
the relevance of peritumoural and intratumoural FOXP3⁺ TILs before and after NAC.
They reported that the peritumoural FOXP3⁺ Tregs were sensitive to NAC and
decreased peritumoural FOXP3⁺ Tregs after NAC was associated with a pCR.
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Moreover, intratumoral FOXP3⁺ Tregs after NAC was an independent prognostic
predictor (both OS and PFS) [397]. Cimino-Mathews et al. (2013) compared TILs in
primary breast tumours and distant metastatic tumours in 15 breast cancer patients.
The levels of CD4⁺, CD8⁺ and FOXP3⁺ TILs were significantly lower in metastatic
lesions, in particular brain metastases, compared with primary breast lesions. These
TIL subsets were higher in TNBCs, compared with luminal tumours. Remarkably, a
CD8⁺ TIL: FOXP3⁺ TIL ratio of ≥3 in primary breast tumours but not in metastases 
was associated with a better prognosis [398]. Demir et al. (2013) showed a significant
correlation between low levels of infiltrating FOXP3⁺ Tregs after NAC and high pCR
rates. This significant correlation was found in both the breast and ALNs [13] (Table
1.11).
Recently, Garcia-Martinez et al. (2014) analysed pre- and post-NAC TIL subsets
(CD3⁺, CD4⁺, CD8⁺, CD20⁺ and FOXP3⁺) and CD68⁺ monocytes in tumour
specimens using TMAs in a series of 121 breast cancer patients (TNM stage II and III)
treated with NAC containing taxanes and anthracyclines plus concomitant trastuzumab
(if tumours overexpressed HER2). They found that a group of tumours (labelled as
cluster B in their study) characterised by low CD8⁺, high CD4⁺ and high CD20⁺ TILs
and high CD68⁺ monocyte infiltrations was significantly associated with a pCR (pCR
rate 58% in cluster B versus 7% in non-cluster B). Moreover, they proposed that a
higher infiltration by CD4⁺ TILs was the main factor for the occurrence of a pCR and
that NAC induced an inversion of the CD4⁺ TILs: CD8⁺ TILs ratio. NAC produced a
significant decrease of CD4⁺ and CD20⁺ TILs and CD68⁺ monocytes. CD8⁺ TILs, in
contrast, were significantly increased after NAC while FOXP3⁺ TILs remained
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unchanged [224]. The TMA technique used in this study, however, may produce
different results from a standard whole tissue section. TMAs focus on a much smaller
area of a specimen and appear to be less reliable for documenting immune cell
infiltrates in cancer tissue (the disadvantages of TMAs are discussed in the next
chapter).
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Table 1.11 Previous Studies on Tumour-infiltrating Lymphocytes and Subsets in
Patients with Breast Cancers Undergoing Neoadjuvant Chemotherapy
Studies N Stages Overall PCR NAC Regimen Biomarkers Results
Demaria et al.
(2001) 25 T2 or greater 1 out of 25
Paclitaxel (200 mg/m2) every 2
weeks x 4 cycles
TILs
Persistence of TILs after
NAC correlated with
cl inical response
Hornychova et
al. (2008) 73 AJCC stage II, III 10 out of 73 Doxorubicin and paclitaxel
CD3, CD56,
CD83, CD1a,
S100, CD68
CD3⁺ TILs and CD83⁺ DCs 
significantly associated
with a pCR
Ladoire et al .
(2008)
56 T1-4, N0-3, M0 21.4%
Anthracycline-based: n=25
Anthracycline and taxane: n=11
Trastuzumab and taxane: n=20
CD3, CD8,
FOXP3
Poor prognostic factors
correlated with higher
FOXP3+ Tregs before NAC,
higher pCR after NAC
correlated with absence
of FOXP3⁺ Tregs and high 
levels of CD8⁺ T cells
Aruga et al.
(2009)
93 T1-4, N0-3, M0 No data Anthracycline and
cyclophosphamide
FOXP3
Clinically non-responders
and poor OS significantly
associated with patients
with high FOXP3⁺ cells 
counts in tumours
Denkert et al.
(2010)
Total: 1,058
GeparDuo: 218
GeparTrio:840
GeparDuo: T2-3, N0-2,
M0 GeparTrio: T2-4,
N0-3, M0
GeparDuo: 12.8%
GeparTrio 17%
Doxorubicin/cyclophosphamide
fol lowed by docetaxel or
docetaxel plus doxorubicin
TILs
High TILs: pCR rates 42%
and 40% versus 3% and
7% for low TILs
Ladoire et al .
(2011)
111 HER2+ve
51 HER2-ve
AJCC stage I-IIIa 30% in HER2+ve
17% in HER2-ve
Trastuzumab–docetaxel: n=63
Anthracycline-based: n=99
CD8, FOXP3
High CD8/FOXP3 ratio
associated with improved
RFS,OS and pCR
West et al.
(2011)
255 ER-ve AJCC stage I-III 43.2% Anthracycl ine-based and non
anthracycl ine-based (CMF)
TILs, CD3
(TMAs)
TILs associated with a
pCR, High CD3⁺ inﬁltrates 
correlated with DFS in
anthracycline group
Oda et al.
(2012) 180 AJCC stage II, III
31.3% in presence of
FOXP3⁺infiltrates
12 cycles of
Weekly paclitaxel followed by 4
cycles of FEC (fluorouracil,
epirubicin, and
cyclophosphamide)
CD8, FOXP3,
IL17
The presence of FOXP3⁺ 
and CD8⁺ infiltrates but 
not IL17⁺ infiltrates 
before NAC associated
with high pCR rate
Liu et al.
(2012) 132 AJCC stage I-III 15.9%
Anthracycline- and/or
taxane-based chemotherapy FOXP3
Decreased peritumoural
Tregs after NAC
associated with pCR,
while intratumoural Tregs
after NAC was an
independent prognostic
predictor for OS
Yamaguchi et
al. (2012)
16 (pCR)
52 (non-pCR) AJCC stage I-IV 16 out of 68
Anthracycline- and/or
taxane-based chemotherapy TILs
The best predictor for
pCR: high TILs (p<0.0001)
Ono et al.
(2012)
474 total
102 TNBCs
AJCC stage II, III 32% in TNBCs Anthracycline- and/or
taxane-based chemotherapy
TILs
TNBCs associated with
high level of TILs, TILs
correlated with a pCR in
TNBCs
Loi et al.
(2013)
2,009 node-
positive from
BIG 2-98 trial
Node-positive (N1-3) No data
Anthracycline- and/or
taxane-based chemotherapy TILs
Increasing TILs
associated with better
prognosis in node-
positive, ER-ve, HER2-ve
subtypes
Demir et al.
(2013)
101 Locally advanced stage
12.9% for breast
tumours, 14.8% for
axillary metastatic
tumours, 4.9% for
both breast and
axillary tumours
Various regimens FOXP3
Lower FOXP3⁺ Tregs after 
NAC correlated with
higher pCR rates for
breast (p=0.001), breast
and axi lla (p=0.05)
Seo et al.
(2013) 153 AJCC stage II-III 13.1%
Anthracycline- and/or
taxane-based chemotherapy
CD4, CD8,
FOXP3
Levels of CD4⁺, CD8⁺ and 
&K yWϯЀd/>ƐƉŽƐŝƟǀ ĞůǇ
correlated with a pCR
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N: Number of patients; pCR: Pathological complete response; RFS: Relapse-free survival; OS: Overall
survival; AJCC: American Joint Committee on Cancer; TMAs; Tissue microarrays
Lee et al .
(2013)
175 AJCC stage I-III 11% Anthracycline- and/or
taxane-based chemotherapy
TILs, CD3,
CD8, FOXP3
Levels of TILs, CD3⁺, CD8⁺ 
and FOXP3⁺ cells 
positively correlated with
a pCR
Issa-Nummer
et al. (2013)
313 HER-ve AJCC stage I-III 20.1% Anthracycline- and/or
taxane-based chemotherapy
TILs
High TILs (LPBC)
associated with a PCR
(P<0.001), Stromal TILs
and LPBC were
independent predictors
for pCR
Dieci et al.
(2014)
278 TNBCs with
non-pCR AJCC stage I-III None
Anthracycline- and/or
taxane-based chemotherapy TILs
High TILs in residual
disease after NAC: better
5 years OS (p=0.0017)
Adams et al.
(2014) 481 TNBCs AJCC stage I-III No data
Anthracycline- and/or
taxane-based chemotherapy TILs
Stromal TILs correlated
with improved DFS and
OS in TNBCs
Nabholtz et al.
(2014)
47 TNBCs AJCC stage II-III 46.8%
Anthracycline-taxane-based
chemotherapy plus anti-EGFR
antibody (panitumumab)
CD8
High level of CD8+ TILs
was predictive of pCR in
TNBCs
Garcia-
Martinez et al.
(2014)
121 AJCC stage II, III
58% in cluster B,
7% in cluster A, C
Taxanes and anthracyclines plus
concomitant trastuzumab
(if HER2+ve)
CD3, CD4,
CD8, CD20,
CD68, FOXP3
(TMAs)
Low CD8⁺, high CD4⁺, high 
CD20⁺ and high CD68⁺ 
infiltrations (cluster B)
significantly associated
with a pCR
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1.5 Hypothesis and Objectives
1.5.1 Hypothesis
The microenvironment in tumours and tumour-draining ALNs in women with
LLABCs contains various innate and adaptive immune cell infiltrates and expression
of specific cytokines/ biological molecules, and from these the response to NAC can
be predicted.
1.5.2 Objectives
(i) To critically analyse the immune microenvironment in breast tumours and tumour-
draining ALNs and its association with the response to NAC.
(ii) To ascertain the immunosuppressive status in situ in the breast tumours and
tumour-involved ALNs and its effect on preventing a good pathological response to
NAC.
(iii) To document the immune-modulatory effects (cellular, humoral) and related
immune-mediated tumour cell death of an NAC regimen (doxorubicin,
cyclophosphamide, docetaxel and capecitabine) in the breast tumour and ALN
microenvironment following NAC.
(iv) To determine whether the systemic immunosuppressed state (high levels of
circulating Tregs) and response to NAC in patients with LLABCs, is mirror-imaged in
the immune microenvironment in the breast tumours.
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CHAPTER 2: MATERIALS AND METHODS
2.1 Patients and Specimens
Paraffin-embedded breast cancer and lymph node specimens from 33 women with
LLABCs (>3 cm, T3-4, N0-2, M0) were used in the study. Twenty of the 33 women
with LLABCs had additional pre-NAC biopsy specimens of metastatic tumours from
ipsilateral ALNs. Sixteen of the 33 women with LLABCs had blood levels of FOXP3⁺
Tregs and CTLA4⁺ Tregs (pre- and post-NAC) on file from a previous study (Verma
et al, 2013). The specimens were from patients enrolled in a study of NAC (between
2008 and 2011) [110]. Diagnosis of breast cancer was established by histological
assessment of image-guided core needle biopsies of breast tumours and, where
appropriate, tumour-involved ipsilateral ALNs. Patients were clinically evaluated in a
multidisciplinary setting and tumours were staged according to the TNM classification.
Mammography and ultrasonography were used to determine the presence, nature, and
size of the primary breast tumours, as well as to determine the presence of metastases
in loco-regional lymph nodes. The NAC trial evaluated the effect of the addition of
capecitabine (X) to docetaxel (T) preceded by adriamycin (doxorubicin: A) and
cyclophosphamide (C). After two cycles of AC patients were assessed by magnetic
resonance mammography (MRM), compared against pre-NAC MRM, and classified
as clinical responders or non-responders. All patients received either 4 courses of AC
followed by 4 courses of T ± X or 2 courses of AC followed by 6 courses of T ± X, as
per the trial protocol. All patients underwent surgery (wide local excision or
mastectomy and axillary surgery) 4 weeks after the last course of NAC.
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Pathological responses in the breast and ALNs were assessed in the excised surgical
specimens after NAC. Pre-NAC assessment was done on core biopsies (breast and
ALNs), obtained prior to commencement of NAC. Established and previously
published grading criteria (Table 2.1a Miller/Payne grading system) were used to
define histopathological responses in the breast (grades 5 to 1). Good pathological
responses were graded 5 [pathological complete response (pCR), no residual invasive
disease] and 4 (90% loss of invasive disease). Poor pathological responses were
graded 3 (30-90% loss of invasive disease), 2 (<30% loss of invasive disease) and 1
(no loss of tumour cells) [116, 399, 400]. Pathological responses in metastatic tumours
in ALNs were defined as pCR (grade 3) and non pCR (grade 2 and grade 1) (Table
2.1b). Histopathological sections of post-treatment breast tumours and ALNs were
graded blindly by an experienced breast pathologist. The histopathological findings
were discussed at a multidisciplinary meeting. If there was uncertainty a review was
carried out by a second breast pathologist and a consensus decision reached.
117 patients were enrolled into the NAC trial, 112 were randomised of which 110
patients were evaluated. It was not possible to analyse the immune parameters in the
microenvironment of tumours and tumour-draining ALNs for all of the patients due to
the large number of patients enrolled in the study, the amount of time required to carry
out the assays and the substantial costings involved. However, the number of patients
used (33 patients) was considered to be appropriate and also significant following a
sample size calculation with a probability of p≤0.05, with a power of 80%. These 33 
patient cases included a cohort of 16 patients with previously studied blood Treg
levels. An additional 17 cases were randomly selected to ensure a comparable
distribution of pathological responses (pCR versus non pCR) in the groups compared.
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The study was given approval by the Leicestershire, Northamptonshire & Rutland
Research Ethics Committee 1: Reference Number 07/H0406/260; Favourable Opinion
24/01/2008. All patients enrolled in the study gave informed consent to participate in
and to publish the results of the study. The study Registration is ISRCTN00407556.
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Table 2.1a Miller and Payne Grading System to Assess Response of Breast Cancers to
Primary Chemotherapy [400]
Grades Description
Grade 1 No change or some alteration to individual malignant cells but no
reduction in overall cellularity.
Grade 2 A minor loss of tumour cells but overall cellularity still high; up
to 30% loss.
Grade 3 Between an estimated 30% and 90% reduction in tumour cells.
Grade 4 A marked disappearance of tumour cells such that only small
clusters or widely dispersed individual cells remain; more than
90% loss of tumour cells.
Grade 5 No malignant cells identifiable in sections from the site of the
tumour (pCR); only vascular fibroelastotic stroma remains.
However, ductal carcinoma in situ (DCIS) may be present.
Table 2.1b Grading System to Assess Response of Metastatic Tumours in Axillary
Lymph Nodes to Primary Chemotherapy [110]
Grades Description
Grade 1 No pathological response (NR): metastatic tumour deposits
remain with no evidence of fibrosis
Grade 2 Partial pathological response (PR): residual metastatic tumour
deposits remain with evidence of fibrosis
Grade 3 Complete disappearance (pCR) of metastatic tumour deposits
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2.1.1 Inclusion and exclusion criteria for patients with large and locally advanced
breast cancers (LLABCs)
Women over 18 and under 75 years, able to sign an informed consent and with
histologically proven LLABCs (≥3 cm or T3-4, N0-2, M0) were invited to participate 
in the NAC trial. Patients who had a poor WHO performance status [Eastern
Cooperative Oncology Group (ECOG) score >2] [401], prior chemotherapy or
radiotherapy (except for basal cell carcinoma), significant cardiac dysfunction, insulin
dependent diabetes, pregnancy or lactation, inadequate organ function (laboratory
tests) and/or inability to complete the quality of life (QoL) questionnaires, were
excluded.
2.1.2 Trial design and chemotherapy regimen
After the diagnosis was established, patients underwent a chest radiograph and liver
ultrasonography or computerised tomography of thorax and abdomen, bone
scintigraphy, electrocardiography, echocardiography and a MRM prior to commencing
treatment. The QoL was assessed using validated questionnaires. Prior to each cycle,
and after NAC, the Hospital Anxiety and Depression Scale, Mood Rating Scale and
Treatment Side-Effects Questionnaires were completed. Before cycles 1, 5 and after
completion of NAC, a Patient Satisfaction Questionnaire and the Functional
Assessment of Cancer Therapy with Taxane modules were completed. Patient
enrolment, randomisation, treatment and assessment are outlined in the CONSORT
diagram (Figure 2.1). Randomisation was carried out according to the MRM findings
after 2 courses of NAC, using permuted blocks. Treatment allocation was determined
using sealed sequential envelopes from Responder and Non-responder containers.
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Patients received 3 weekly intravenous A (60mg/m2) and C (600mg/m2) for two
cycles. Responders were randomised into Group A or B. Both groups received 2
further 3 weekly intravenous AC followed by 4 cycles of intravenous T (100mg/m2)
every 3 weeks (Group A) or 4 cycles of intravenous T (75mg/m2) and oral X
(2,000mg/m2/day) for 14 days every 3 weeks (Group B). Non-responders were
randomised into Group C and D. Group C received 6 cycles of intravenous T
(100mg/m2) every 3 weeks. Group D received 6 cycles of intravenous T (75mg/m2)
and oral X (2000mg/m2/day) for 14 days every 3 weeks. Ondansetron and
dexamethasone were prescribed during and after each cycle. All patients received
lenograstim (263μg/day) subcutaneously, days 2-6 after each cycle from cycle 3 
onwards. If febrile neutropenia occurred with cycle one, lenograstim was given from
cycle 2 onwards.
Breast conserving surgery or mastectomy, according to surgical advice or patient
preference, and either ALN sampling (at least 4 nodes) or axillary clearance (pre-NAC
involved ALNs) was performed approximately 4 weeks following NAC. After
definitive surgery adjuvant hormonal therapy was administered in all patients with
ER/PR+ve tumours and trastuzumab was given to patients with tumours
overexpressing HER2. Adjuvant radiotherapy was administered to the breast following
breast conservation. Chest wall irradiation following mastectomy was given if the
patient was deemed at risk of local recurrence. If lymph node sampling established
metastatic involvement, the axilla and supraclavicular region were irradiated.
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Figure 2.1 CONSORT diagram: Of the 112 patients randomised, 77 (69%) were responders [assessed
by magnetic resonance mammography (MRM) after 2 cycles of AC] and were randomised to group A
(38) or B (39); 35 (31%) were non-responders and were randomised to group C (19) or D (16). A:
doxorubicin; C: cyclophosphamide; T: docetaxel; X: capecitabine; MMG: mammogram; USS:
ultrasound scan
Data from the NAC trial [110]
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2.1.3 Patient data and clinico-pathological characteristics
All the patients’ clinical and pathological data were anonymised. The patients’ age,
weight, height and menopausal status were documented. The patients were classified
as <50 or ≥50 years of age. Body mass index (BMI), derived from body weight 
(kilograms) divided by the square of the body height (metres), was used to delineate
obesity (≤30: non-obese, >30: obese). Pre-menopausal state was defined as being <55 
years of age with normal menstrual cycles. Patients aged >50 years with no
spontaneous menses for at least one year/ or age ≤50 years with no spontaneous 
menses within the past 2 years/ or women who had bilateral oophorectomy prior to the
diagnosis of breast cancer was defined as post-menopausal. Clinical nodal status,
tumour size, tumour type and histological grade were obtained. Tumours were
phenotypically characterised for hormonal receptor status using Allred scoring system
(score ≥ 3 for positive, < 3 for negative) [402]. HER2 overexpression was determined 
by an IHC score of 3+ and/or a FISH (fluorescence in situ hybridisation) ratio ≥2. 
The level of circulating blood CD4⁺ CD25⁺ FOXP3⁺ Tregs and CD4⁺ CD25⁺ CTLA-
4⁺ Tregs [absolute number (AbN) and percentage (%)] before commencing the NAC
and following 8 cycles of NAC in 16 corresponding patients were obtained from a
previous study [15]. The blood data were obtained using whole blood for AbNs and
peripheral blood mononuclear cells (PBMCs) for % using fluorescence-labelled MAbs
and flow cytometry (Beckmann Coulter FC 500 and MoFlow XDP) analyses.
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2.2 Immunohistochemistry (IHC)
IHC is a powerful tool for obtaining more information than the routine morphological
assessment of tissue specimens. The IHC technique is used to study specific cellular
markers defining cellular/tissue phenotypes as well as the presence of interesting
proteins/molecules in the tissue specimens. This information can provide important
diagnostic, prognostic and predictive values related to disease status and normal
biology. The application of enzyme-labelled antibodies to study formalin-fixed tissue
specimens provides a ready and important dimension to the assessment of tumour
biology.
2.2.1 Antibody structure and class
Antibodies are a group of proteins called immunoglobulins (Igs) which are produced
by B lymphocytes in response to stimulation by antigens and which react specifically
with those antigens. They are formed in the blood and tissues of normal individuals. Ig
consists of five major classes (IgG, IgA, IgM, IgD and IgE). Each antibody has two
identical heavy chains and light chains. The heavy chains vary in antigenic and
structural properties and define the classes of Ig. IgG is the most frequently used in
IHC. IgG structure comprises of two monovalent antigen-binding fragment (Fab) and
one crystalline fragment (Fc). IgG molecules can be further divided into variable
domains and constant domains. Variable domains of heavy and light chains form the
antigen-binding site (paratope) which specifically recognises the antigenic
determinant (epitope) of an antigen [403].
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MAbs generated by a single B cell clone (usually by an in vitro culture of a hybridoma
cell line) or by molecular engineering, are a homogeneous population of Ig which is
directed against a single epitope. Every MAb molecule is identical, with a unique
specificity and affinity. Unlike MAbs, polyclonal antibodies (antiserum) are
heterogeneous consisting of a mixture of antibodies directed against several epitopes
of the same antigen. Polyclonal antibodies are harvested from the blood of animals
immunised with a known antigen. Due to their ability to detect multiple epitopes on an
antigen, polyclonal antibodies are more robust than MAbs, when used on routinely
processed specimens, and independent from an effect of epitope retrieval [404].
Recognising multiple epitopes, however, increases the likelihood for cross reactivity
with other antigens/proteins. A lot to lot inconsistency is also a disadvantage of
polyclonal antibodies.
2.2.2 Antibody affinity and titre (dilution)
The functional affinity (measure of the binding strength between an antibody-binding
site and antigenic determinant) of antibodies can be defined by the total time required
to saturate all available antibody binding sites with antigens (reach equilibrium).
Antibodies with a low affinity will need a longer time to reach a plateau of maximal
staining intensity. While the time required defines the functional affinity, the
concentration of antigen needed to saturate the antibody delineates intrinsic affinity.
An antibody with a higher intrinsic affinity needs a lower concentration of antigen to
reach equilibrium. Affinity also refers to the strength of the antigen-antibody binding
(immune complex). In IHC, antigen-antibody reactions are reversible and may
dissociate during the process of washing. A lower temperature reduces the
dissociation of an immune complex.
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The optimal antibody titre is the highest antibody dilution which provides a maximum
of specific staining intensity with the least non-specific background staining under
each assay condition. An optimal dilution is also determined by antibody affinity. In
case of constant (fixed) dilution and incubation period, a high-affinity antibody
provides more staining intensity than an antibody with a low affinity.
2.2.3 Incubation period: Time and temperature
The incubation time, temperature, antibody titre and antibody affinity are inter-
dependent factors. An adjustment in one affects the others. Generally, antibodies with
a higher titre require less incubation time. Incubation time varies from 10 minutes to
24 hours. The incubation period of 10-30 minutes is usually sufficient for antibodies
with a high affinity and concentration to be saturated with their respective antigens,
and is widely used in a majority of staining protocols. A 24-hour incubation period
offers economic benefits because a lower amount of antibody is needed. Antibodies
with low affinity need to be incubated for a long period of time.
The equilibrium of antigen-antibody reactions can be reached rapidly at 37˚C [faster 
than room temperature (RT)]. Increasing temperature allows incubation time to be
shortened but may give rise to increased background staining. A temperature of 4˚C is 
commonly used with a 24-hour or overnight incubation. A humidity chamber is
required for preventing drying/evaporation of tissue sections [405].
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2.2.4 De-masking of antigens
During formalin fixation, the 3-dimentional structure of proteins is altered. This can
mask or destroy the antigenic epitopes and electrostatic charges and result in inability
to react with antibodies. De-masking of antigens or epitope retrieval can reverse this
process and restore the epitopes by breaking the protein cross-links (formed during
fixation) to uncover the hidden antigenic sites. Epitope retrieval can be done by either
heating for a certain length of time [heat-induced epitope retrieval (HIER)] or using
enzymatic digestion. The regular use of HIER minimises the inconsistency of IHC
staining caused by variable fixation processes. Although many retrieval protocols have
been proposed, heating in a microwave oven with citrate buffer pH 6.0 (used in this
study) is widely used and applicable to many antibodies. The optimal protocol for
each antigen/antibody interaction, however, needs to be determined [404, 406].
2.2.5 Immunoenzymatic staining with enzyme substrate reactions
In immunoenzymatic staining methods, enzymes convert colourless chromogens
(substrates) into coloured end-products. The catalytic activity of enzymes depends on
several factors e.g. concentration, pH, buffer milieu, temperature and light.
Horseradish peroxidase (HRP) and calf intestine alkaline phosphatase (AP) are
commonly used in conjugation (binding) to antibody. Substrates being oxidised by
HRP become coloured. The visualised colour of the end-product depends on the type
of chromogen used. Diaminobenzidine (DAB), which is used in this study, produces a
brown end-product and is highly stable in alcohol/organic solvents. Amino-
ethylcarbazole (AEC) forms a red end product while chloro-naphthol (CN) provides a
blue colour. Unlike DAB, AEC and CN are alcohol soluble. An aqueous counterstain
and aqueous mounting medium must be used instead of haematoxylin and non-
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aqueous DPX (dibutyl phthalate and xylene) mounting medium. Naphthol phosphate
esters, which are substrates for AP, upon being hydrolysed by AP provide bright red
or blue end-products [405].
2.2.6 Secondary antibody: Labelling reagents and amplifications
Various amplification methods have made a significant improvement in demonstrating
antigens. Small amounts of antigenic intact protein can be detected by a high
sensitivity test using amplification methods. The signal/colour intensity can be
increased by employing a conjugated/labelled secondary antibody or biotinyl
conjugate which is used in the peroxidase anti-peroxidase (PAP) complex method,
avidin-biotin complex (ABC) method, polymer-based method or tyramine
amplification technique [407]. This enables amplification of a faint, but specific,
initial signal without compromising the specificity. Streptavidin and avidin molecules
have four binding sites with strong affinities for the vitamin biotin. HRP is easily
conjugated to biotin. ABC or labelled streptavidine-biotin methods use a biotinylated
secondary antibody that links primary antibodies to a HRP conjugate. This enables a
single antibody to be associated with multiple peroxidase molecules [408]. A larger
enzyme-to-primary antibody ratio increases sensitivity in antigen detection compared
with a direct peroxidase-conjugate method. The presence of endogenous biotin in the
tissue, however, can lead to background staining with these amplification methods.
Blocking endogenous biotin methods are partially effective. The polymer-based IHC
method, which was used in this study, does not rely on endogenous biotin. This
method utilises a polymer dextran backbone in which multiple secondary antibodies
and peroxidase enzymes are conjugated. The secondary antibody attached to this
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polymer contains both anti-mouse and anti-rabbit Ig. Therefore, this reagent can be
used to detect tissue-bound primary antibodies of mouse or rabbit origin [409].
2.2.7 Immunohistochemistry (IHC) standardisation
Standardisation of the IHC technique used is a critical issue. While IHC has been
proven to be a successful technique for demonstrating related biomarkers in diagnosis
and classification of tumours, concerns have been raised for the validation of reagents,
overall reproducibility of the staining methods and the interpretation of results. There
have been many attempts to standardise IHC techniques. Nevertheless, standardisation
remains a great challenge. This is due, in large part, to the presence of uncontrollable
intrinsic factors such as variable conditions of fixation and tissue processing, which
affect antigen preservation [410]. Fixation, however, prevents proteins in the tissue
specimens from elution, degradation or modification and preserves the cellular
location of antigens, whether nuclear, cytoplasmic or membrane-bound. The adverse
influences of formalin on tissue antigenicity, as well as the great variation in fixation,
tissue handling and processing procedures, on the other hand, are some of the most
difficult factors to control. Because necrotic degradation of tissue begins immediately
after removal from the body, the time to fixation and processing is critical. Moreover,
there is also a potential to obtain inequivalent IHC staining among formalin-fixed,
paraffin-embedded (FFPE) tissue sections with different periods of time between
tissue fixation and staining [411]. The use of validated reagents, optimised staining
conditions and protocols, properly and simultaneously utilised positive and negative
controls are necessary to acquire a high test sensitivity and specificity, as well as
reproducibility. These considerations and validated protocols ensure that results
emanating from different laboratories are comparable.
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2.2.7.1 Primary antibody validation and optimisation
The selection of primary antibodies with the desired specificities in detecting target
antigens relies on the relevant data provided by the manufacturers (except when
prepared de novo in-house). Even if these antibodies have been tested for specificity
by reliable suppliers, it is necessary to confirm functional specificity of each antibody
using appropriate positive and negative control materials. The concentration [except
pre-diluted or ready-to-use (RTU) reagent] of the primary antibody must be adjusted
for each staining condition with a selected secondary labelling system in order to have
the optimal intensity and reproducibility of specific reaction with the lowest level of
non-specific background staining (maximal signal to noise ratio). The optimal
working concentration can be determined experimentally within each laboratory by
serial titration experiments. The concentration of primary antibody can be accurately
determined as µg/ml for MAbs, but can only be estimated for polyclonal antibodies
(due to the presence of different molecules). A simple dilution fraction e.g. 1:50,
1:100 etc. is often given instead of an accurate concentration (by weight).
2.2.7.2 Positive and negative controls
The positive control is a tissue section fixed and processed in a similar manner to the
test section and known to contain the target antigen. Ideally, positive controls should
have a range of intensity of reaction (from strong to weak). Positive controls which
contain very high amounts of target antigen may lead to selecting optimal working
dilutions of primary antibody that fail to detect lower levels of target antigen in the
test sections. The negative controls, identified by lack of staining, encompass two
concepts. The first is a negative reagent control typically performed by omitting the
primary antibody on a parallel control tissue section. The second is a negative
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tissue/cell control identified by lack of staining of the cells in the test sections that do
not contain the target antigen. The positive and negative control sections should be
included in every IHC run [412, 413].
2.2.7.3 False positive and false negative errors
Endogenous peroxidase activity is commonly found in haemoglobin (in red blood
cells), myoglobin (in muscle), cytochrome (in granulocytes, monocytes) and catalases
(in liver, kidney) and can cause false positive staining with HRP-based detection
methods. Suppressing endogenous peroxidase activity is routinely required prior to the
addition of primary antibody in the staining protocol and can be achieved by
incubation of tissue sections in 3% H2O2 for 5-10 minutes. In case of AP-based
detection methods, the endogenous AP activity (frequently encountered in the
intestine, kidney, lymphoid tissue or placenta) also needs to be blocked. Endogenous
biotin needs to be blocked when the ABC method is used [414].
Primary antibodies and detection systems are protein-based reagents which can react
with non-specific binding sites in tissue specimens. This can result in false positive
staining, as well as increased background staining. A protein blocking reagent is used
to reduce various non-specific protein-protein interactions between reagents and
tissues by competing for tissue binding sites.
Inappropriate tissue handling, fixation, processing or antigen retrieval may cause the
loss of antigenicity in tissue specimens and result in false negative findings. In
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addition, false negative staining can occur when any steps of the staining procedure in
a protocol are left out inadvertently.
2.2.8 Tissue microarray (TMA): Advantages and disadvantages
The advent of high throughput techniques such as microarray assays has led to
numerous studies and a large dataset of results. In a tissue-based study, performing
whole section IHC on hundreds to thousands of tissue blocks (specimens) requires
substantial resources and time. Moreover, each tissue block yields a limited number of
sections. A number of potential biomarkers therefore have not been studied as a result.
The TMA technique can overcome these problems. TMAs use a 16-gauge needle to
manually bore cores from tissue blocks and array them in a multi-tissue straw with a
recognisable pattern. This technique provides a high throughput analysis with arraying
of up to 1000 cores in one section [415].
The major advantage of TMAs is the ability to investigate a large number of patient
samples cost-effectively. Many studies have demonstrated the consistent and
comparable results between TMA-based and whole section approaches [416]. Each
core, however, is a fraction of the lesion and may not represent a whole section
particularly in tumours with marked heterogeneity. In addition, TMAs are not useful
in the study of rare or focal events such as in documenting the level of certain types
(particularly, less prominent) of immune cell infiltrates in tumours. The interactions
between tumour and stroma are also difficult to study with TMAs as stromal
components may not be adequately represented in the cores. This is considered to be a
major weakness of TMAs. Increasing the number of cores form each sample and the
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core size (vary from 0.6 to 2 mm) has been advocated to compensate for this
inadequacy [417]. Because our study encompassed various subsets of immune cell
infiltrates including less prominent subsets and stromal infiltrates, whole tissue
sections were used to avoid inadequate examination of tissue specimens and to
provide an accurate profile of cellular infiltrates and humoral expressions in both
tumour cell nests and stroma.
2.2.9 Computer-assisted scoring (image analysis): Advantages and disadvantages
The interpretation of IHC has been primarily through human visual scoring. The
scoring criteria are usually predetermined by qualitative or semi-quantitative cut-off
values, resulting in categorical values for statistical analyses. The quantitative
continuous values are more time-consuming when conducted by human assessment.
Pathological analysis of tissue specimens remains a subjective process in which the
intensity of staining and scoring may be directly influenced by visual bias. Computer-
assisted pathological scoring with automated scanning devices and image analysis
software provides a solution for overcoming the limitations of manual IHC scoring.
This can enhance reproducibility and reliability of the scoring results. The computer-
aided measurements are not subject to external confounding factors such as human
fatigue, ambient lighting or noise and may minimise the problem of inter-observer
variations [418]. It has been shown to be more time-effective when scoring a larger
number of slides (for high-throughput studies). At least, two commercially automated
image analysers (the Ariol SL-50 system and the Nuance system) are currently
available. Both systems use bright-field microscopy for automated and standardised
quantification of IHC, while the Nuance system has spectral deconvolution
capabilities. The software associated with the multispectral imager allows accurately
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automated classification of tissue type into epithelial and stromal structures [419].
Many studies have documented digital image analysis to be an alternative and reliable
tool to manual visual scoring in IHC quantification. It does not, however, provide an
analytical advantage [420, 421].
The common drawbacks of automated imaging systems include an inability to classify
tissue type and an inability to clearly segregate membrane, cytoplasmic and nuclear
staining, as well as an inability to distinguish reliably between tumour and non-tumour
tissues. In addition, more time is required for analysis using these systems [419]. To
avoid these problems, manual IHC quantification was used in this study. Also, in the
early phase of the study, slides were read and assessed by both myself and an
experienced breast pathologist to ensure concordance in delineating the different
components of the stained sections and to ensure good quality of the IHC used.
2.3 Methods
Specimens from 33 women with LLABCs that had taken part in a NAC trial were
investigated and evaluated in the study. The presence of various immune cell
infiltrates including CD4⁺ and CD8⁺ T cells, FOXP3⁺ and CTLA-4⁺ Tregs, CD56⁺
NK cells, PD1⁺ lymphocytes, CD1a⁺ DCs, CD66b⁺ neutrophils, CD68⁺ and CD163⁺
macrophages and in situ expression of various cytokines (IL-1, IL-2, IL-4, IL-10, IL-
17, TGF-β, IFN-γ) and biological molecules (VEGF, IDO and PDL1), together with a 
subset of CD44⁺CD24-/low CSCs, were studied using IHC of paraffin-embedded breast
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tumours (pre- and post-NAC) and tumour-draining ALNs (pre-NAC metastatic
tumours in ALNs and post-surgery ALNs following NAC).
All specimens were sectioned with the LEICA® RM2125 Microtome (Figure 2.2) and
mounted on SurgipathTM X-traTM Adhesive Leica® slides and then immune-stained
following an established protocol (Appendix 2) using 12 antibodies to characterise
immune cells (Table 2.2) and 10 antibodies to determine cytokines and biological
molecules (Table 2.3). The results were analysed and compared amongst groups
showing good versus poor pathological responses, pCR versus non pCR, in primary
breast tumours versus metastatic tumours in ALNs, prior to versus after NAC for
tumour specimens and metastatic (tumour excluded) versus non-metastatic ALNs. In
the group of metastatic ALNs, the comparison between metastatic ALNs with pCR
and with non pCR was analysed. In addition, the levels of infiltrating FOXP3⁺ and
CTLA4⁺ Tregs in tumour and tumour-draining ALNs were analysed for correlations
with the levels of blood FOXP3⁺ Tregs and CTLA4⁺ Tregs from 16 of these 33
patients documented in a previous study by Verma et al. (2013) [15]. Tumour
specimens prior to and after NAC were stained with conventional H&E using the
Leica Auto Stainer XL (Figure 2.3) and scored to evaluate the degree of TILs present
in tumour specimens before commencing the immune-staining. All stained sections
were scored and photographs were taken using the Nikon Eclipse 80i microscope with
a digital camera system (Figure 2.4).
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Figure 2.2 LEICA® RM2125 Microtome
Figure 2.3 Leica Auto Stainer XL
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Figure 2.4 Nikon Eclipse 80i microscope with digital camera system
2.3.1 Primary antibodies, optimisations and controls used
A total of 22 primary antibodies were used to specifically identify cellular markers
and cytokines and biological molecules in this study. These have been validated and
guaranteed for usage in IHC assessment of paraffin-embedded specimens from the
commercial suppliers. Each antibody was evaluated and titrated for optimal
concentration, incubation period and antigen retrieval for the studied specimens. The
optimisation started with the recommended concentration/ dilution from previously
published studies using these primary antibodies and/ or available data sheets of
antibody validation from the commercial suppliers. The concentrations/ dilutions were
adjusted for optimal staining intensity and clear staining background. For incubation
times, the optimisations began with 30 minutes at RT and then, decreased or increased
to overnight in a cold room if the studied sections were not properly immuno-stained.
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Positive staining controls were carried out with known positive tissue sections
available from the Nottingham Health Science Biobank (paraffin-embedded tonsil/
lymphoid tissue, liver, normal colon, colon carcinoma and kidney carcinoma,
depending on which primary antibody was being evaluated). They were
simultaneously assessed along with every immune-staining run. Negative controls
were demonstrated by omitting the primary antibodies. The detailed data for the
primary antibodies used are shown in Tables 2.2 and 2.3. The optimal concentration of
the primary antibodies, incubation periods, epitope retrieval method and type of
positive control sections, which were used in this study, are shown in Table 2.4.
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Table 2.2 Primary Antibodies Used in the Study to Phenotypically Characterise
Immune Cells
Table 2.3 Primary Antibodies Used in the Study to Characterise Cytokines and
Biological Molecules
IL-1 (monocytes, macrophages), IL-2 and IFN-γ expressions represent Th1 profile; IL-4 and IL-10
expressions represent Th2 profile
Cellular
Markers
Primary Antibody
(Unconjugated ) Clones Reported Markers Cellular Localization
Suppliers
(Cataloque No.)
CD4 Mouse monoclonal
antibody
4B12 CD4⁺ T cells Cell membrane Dako (M7310)
CD8 Mouse monoclonal
antibody
C8/144B CD8⁺ T cells Cell membrane Dako (M7103)
FOXP3 Mouse monoclonal
antibody
236A/E7 FOXP3⁺ T regulatory cells Nucleus Abcam (ab20034)
CTLA-4 Mouse monoclonal
antibody
F-8 CTLA-4⁺ T regulatory cells Cell membrane Santa Cruz Bio.(sc-376016)
CD68 Mouse monoclonal
antibody
KP1 Macrophages Cell membrane Abcam (ab955)
CD163 Mouse monoclonal
antibody
10D6 M2 type macrophages Cell membrane Abcam (ab74604)
CD56 Mouse monoclonal
antibody
123C3 NK cells Cell membrane Dako (M7304)
CD1a Mouse monoclonal
antibody
010 Dendritic cells Cell membrane Dako (M3571)
PD1 Mouse monoclonal
antibody
NAT105 Activated PD1⁺ T cells Cell membrane Abcam (ab52587)
CD66b Mouse monoclonal
antibody
80H3 Neutrophils Cell membrane LS Bio (LS-B7134)
CD24 Mouse monoclonal
antibody
8.B.76 Negative marker in stem cells Cell membrane/ cytoplasm Abcam (ab31622)
CD44 Mouse monoclonal
antibody
F10-44-2 Mesenchymal stem cells Cell membrane Abcam (ab6124)
Cytokines/
Molecules
Primary Antibody
(Unconjugated ) Clones
Reported
Expressions Cellular Localization
Suppliers
(Cataloque No.)
IL-1 Mouse monoclonal
antibody
11E5 IL-1 Cell membrane and
cytoplasm (secreted)
Abcam (ab8320)
IL-2 Rabbit monoclonal
antibody
ERP2780 IL-2 Cell membrane and
cytoplasm (secreted)
Abcam (ab92381)
IL-4 Rabbit polyclonal
antibody
Polyclonal IL-4 Cell membrane and
cytoplasm (secreted)
Abcam (ab9622)
IL-10 Rabbit polyclonal
antibody
Polyclonal IL-10 Cell membrane and
cytoplasm (secreted)
Abcam (ab34843)
IL-17 Rabbit polyclonal
antibody
Polyclonal IL-17 Cell membrane and
cytoplasm (secreted)
Abcam (ab9565)
TGF-β
Mouse monoclonal
antibody
2Ar2 TGF-β
Cell membrane and
cytoplasm (secreted)
Abcam (ab64715)
IFN-γ
Rabbit polyclonal
antibody
Polyclonal IFN-γ
Cell membrane and
cytoplasm (secreted)
Abcam (ab9657)
VEGF Mouse monoclonal
antibody
VG1 VEGF Cell membrane and
cytoplasm (secreted)
Dako (M7273)
IDO Mouse monoclonal
antibody
No data IDO Cell membrane and
cytoplasm (secreted)
Abcam (ab55305)
PDL1 Rabbit polyclonal
antibody
Polyclonal PDL1 molecules Cell membrane/
possible cytoplasm
Abcam (ab58810)
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Table 2.4 The Details of the Optimal Immuno-staining Conditions from Optimisation
of 22 Primary Antibodies Reactive with Breast Tumour and ALN Specimens
HIER: Heat-induced epitope retrieval; RT: Room temperature; ALNs: Axillary lymph nodes
Antibodies Positive Control
Sections
Antigen
Retrieval
Dilution/
Concentration
Incubation
Periods
Anti CD4 Tonsil HIER with
citrate buffer
1:80 30 minutes at RT
Anti CD8 Tonsil HIER with
citrate buffer
1:100 30 minutes at RT
Anti FOXP3 Tonsil HIER with
citrate buffer
20 µg/ml 30 minutes at RT
Anti CTLA-4 Colon carcinoma HIER with
citrate buffer
1:300 for breast
1:200 for ALNs
30 minutes at RT
Anti CD68 Tonsil HIER with
citrate buffer
1:300 30 minutes at RT
Anti CD163 Liver HIER with
citrate buffer
Pre-diluted 30 minutes at RT
Anti CD56 Tonsil HIER with
citrate buffer
1:50 30 minutes at RT
Anti CD1a Tonsil HIER with
citrate buffer
1:200 15 minutes at RT
Anti PD1 Tonsil HIER with
citrate buffer
1:100 30 minutes at RT
Anti CD66b Tonsil HIER with
citrate buffer
10 µg/ml 30 minutes at RT
Anti CD24 Tonsil HIER with
citrate buffer
1:200 16 minutes at RT
Anti CD44 Kidney cancer HIER with
citrate buffer
1.25 µg/ml 15 minutes at RT
Anti IL-1 Kidney cancer HIER with
citrate buffer
1:150 Overnight at 4˚C
Anti IL-2 Tonsil HIER with
citrate buffer
1:500 30 minutes at RT
Anti IL-4 Kidney cancer HIER with
citrate buffer
4 µg/ml 30 minutes at RT
Anti IL-10 Normal colon HIER with
citrate buffer
1:400 30 minutes at RT
Anti IL-17 Normal colon HIER with
citrate buffer
1:100 30 minutes at RT
Anti TGF-β Kidney cancer
HIER with
citrate buffer
12 µg/ml Overnight at 4˚C
Anti IFN-γ Tonsil
HIER with
citrate buffer
4 µg/ml 30 minutes at RT
Anti VEGF Tonsil HIER with
citrate buffer
1:50 30 minutes at RT
Anti IDO Normal colon HIER with
citrate buffer
0.75 µg/ml 15 minutes at RT
Anti PDL1 Tonsil HIER with
citrate buffer
2.5 µg/ml 15 minutes at RT
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2.3.2 Immunohistochemical staining procedure
Immunohistochemical staining was performed on 4-µm tissue sections. Briefly, tissue
sections were heated on a 60˚C hotplate (Figure 2.5) for 10 minutes and subsequently 
dewaxed and rehydrated using xylene and graded alcohol via the Leica Auto Stainer
XL. The sections were then boiled in 0.01M citrate buffer, pH 6.0, at 98˚C for 20 
minutes in a microwave oven (1000w Whirlpool® Jet Stream) to achieve HIER. After
the sections were cooled down with running tap water, they were loaded onto the
cover-plates (Shandon Sequenza® Figure 2.6). Serial blocking was carried out with
peroxidase (3-4% hydrogen peroxide) and protein [0.4% casein in phosphate-buffered
saline (PBS)]. The sections were then incubated with the primary antibody against the
specific marker/ protein of interest for an optimal period of time and temperature
(depending on the antibody used; data shown in Tables 2.2-2.4). The NovolinkTM
polymer detection system, Leica RE7280-K with polymeric HRP-linker antibody
conjugates and DAB chromogen was used for enzyme-substrate labelling. Finally, the
sections were counterstained with haematoxylin, dehydrated and mounted in non-
aqueous DPX (dibutyl phthalate and xylene) mounting medium. More information
about the IHC staining procedure is detailed in Appendix 2.
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Figure 2.5 Leica® Hotplate and Sequenza CoverplateTM
Figure 2.6 Immune-staining using Sequenza cover-plates and trays
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2.3.3 Quantitative, semi-quantitative scoring systems
The quantitative/ semi-quantitative evaluations were done in stained sections of Tru-
Cut core biopsy tissues (before chemotherapy) and in surgical tissues (after
chemotherapy). All scored sections were blinded to the patients’ clinical and
pathological parameters and the pathological results were reviewed by a consultant
breast pathologist (Dr G. Cowley). The scoring systems used in establishing the
biological markers present in breast tumours and metastatic tumours (in ALNs), and
ALNs in this investigation, followed previously published studies documenting these
corresponding biological markers.
2.3.3.1 Breast tumour assessment prior to and after NAC
Semi-quantification of TILs
Semi-quantitative scoring of the lymphocyte infiltrates were performed on H&E–
stained sections. Intratumoural lymphocytes (ITu-Ly) were defined as intraepithelial
mononuclear cells within tumour cell nests or in direct contact with tumour cells and
were reported as the percentage of the tumour epithelial nests that contained
infiltrating lymphocytes. Stromal lymphocytes (Str-Ly) were defined as the
percentage of tumour stromal area that contained a lymphocytic infiltrate without
direct contact with tumour cells [19, 385]. Granulocyte infiltrates were excluded and
inflammatory infiltrates in the stroma of non-invasive lesions and normal breast
structures were excluded. Scores of more than 60% were considered as high levels of
infiltration whilst 60% or less were considered as low levels of infiltration for both
ITu-Ly and Str-Ly. Cases were defined as High-TIL [lymphocyte-predominant breast
cancer (LPBC)] when ITu-Ly and/or Str-Ly >60%, and as Low-TIL (non-LPBC) if
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both ITu-Ly and Str-Ly ≤60% [387]. The semi-quantitative scoring used followed the 
methodological recommendations for evaluating TILs in breast cancer by an
International TILs Working Group 2014 [422].
Quantification of FOXP3, CTLA-4, CD8, CD4, CD56, PD1, CD1a and CD66b
positive cells
Positively stained cells in contact with tumour cells or within the tumour cell nests
were scored as “intratumoural” whereas positively stained cells in the interstitial
space/stromal area without direct contact with tumour cells were defined as
“peritumoural”. At least five non-overlapping intratumoural and peritumoural fields
were assessed at x400 high power magnification (0.239 mm2; a 22mm (10x) eyepiece
with a 40x objective enabled a circular field of 22 ÷ 40 = 0.55 mm diameter to be
evaluated). Positive staining was observed as dark-brown coloured mononuclear cells
(membrane, cytoplasm or nucleus depending on the antibodies used). Infiltrations in
each of 5 high-power fields (HPFs) were counted and the average number of
positively-stained cells per HPF was calculated. For CD56⁺, CTLA-4⁺, CD1a⁺ and
CD66b⁺ cells, which were present in low numbers, the total number of positively-
stained cells in 5 HPFs was calculated. The median number of positively-stained cells
for the entire study group (for pre-chemotherapy and for post-chemotherapy tissue
separately) was determined. Values below the median level were defined as a low
level of infiltration and values equal to or above the median value were defined as a
high level of infiltration (for multivariate analyses). Evaluation of infiltrations in post-
NAC specimens was undertaken on residual tumour nests and in the case with pCR
(complete disappearance of invasive tumour cells in the surgical specimen) in the
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tumour bed, which was characterized histologically by a hyalinised, amorphous area
with haemosiderin deposits (intratumoural) and adjacent stromal tissue (peritumoural)
[13, 396]. Evaluation of immune cell infiltration in metastatic tumours in ALNs was
undertaken only on tumour nests (intratumoural infiltration) present in a lymphoid
background of ALNs.
Semi-quantification of TIMs (CD68 and CD163)
The majority of macrophages present in breast tumours were located along the border
of tumour nests. Immune-staining for TIMs was evaluated along the tumour front (TF)
over the whole section (7-10 view fields per section). This evaluation followed
previously published studies documenting the level of TIMs. Tumour tissue
containing small areas of prominent infiltration of CD68⁺ or CD163⁺ cells, which was
considerably higher than the average level of CD68⁺/ CD163⁺ cells, was defined as
hotspots (TF hotspot). All sections were evaluated at a distance away from areas of
necrosis. The TF hotspots of the two view fields with the highest measurements at
x200 magnification were averaged out (CD68 or CD163 TF mean).
The average infiltration (CD68 or CD163 TF mean) was semi-quantitatively graded as
no/weak (grade 1), moderate (grade 2), strong/robust (grade 3), and massive
infiltration (grade 4). Tumours classified as 1 included totally negative specimens as
well as specimens containing some scattered positively-stained cells along the tumour
margin. Tumours were classified as 2 when CD68 or CD163 staining was continuous
along the tumour margin but did not extend from the tumour front for more than one
123
cell layer on average. CD68 or CD163 staining that, on average, extended two to three
cell layers from the tumour margin over the whole section was classified as 3; CD68
or CD163 staining extending more than three cell layers from the tumour margin in all
fields was classified as 4. For statistical analysis, grade 1 and 2 were defined as low
level of infiltration whereas grade 3 and 4 were defined as high level of infiltration
[264, 423, 424].
Semi-quantification of CD24 and CD44 positive cells
The whole section (7-10 HPFs per section) was analysed. CD24⁺ and CD44⁺ staining
was observed in tumour cells, TILs and non-tumourous breast tissue. The expression
of CD24 was evaluated as membrane and/or cytoplasmic staining in tumour cells and
CD44 as membrane staining in tumour cells. The pattern of expression was evaluated
according to staining intensity and distribution. The intensity score was determined as
0 (no staining), 1 (weak staining), 2 (moderate staining), and 3 (strong staining). The
distribution (proportion) score was determined as 1 (<30% of tumour cells) and 2
(>30% of tumour cells). The intensity and distribution scores were multiplied together
for a total score, which was 0-1 (negative/ low expression) and 2-6 (positive/ high
expression) [376, 379, 381, 425].
Semi-quantification of CD274 (PDL1) positive cells
CD274 was expressed on tumour cells and immune cells, as well as non-tumourous
breast tissue. The expression of CD274 was evaluated as membrane and/or
cytoplasmic staining in tumour cells, TILs and TIMs on a whole section (7-10 HPFs
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per section). The expression of CD274 was graded as negative/ low expression when
samples showed either no detectable CD274 or weak CD274 staining. A score of
positive/ high expression represented moderate to strong staining. The staining grade
was defined according to the majority of the DAB staining intensity throughout a
specimen. This grading system followed the studies previously published [426, 427].
Semi-quantification of cytokines (IL-1, IL-2, IL-4, IL-10, IL-17, IFN-γ, TGF-β), 
VEGF and IDO
The whole section (7-10 HPFs per section) was analysed for the presence of
cytokines, VEGF and IDO in breast cancer tissues (expressed by immune cells and
tumour cells) and semi-quantified by using the previously published H scoring system
[428]. Briefly, the H score is calculated by multiplying the percentage of positive cells
by a factor representing the intensity of immune-reactivity (1 for weak, 2 for moderate
and 3 for strong), giving a maximum score of 300. A score of <50 was considered
negative and a score of 50–100 was considered weakly positive (1+). A score of 101–
200 was scored as moderately positive (2+) and a score of 201–300 as strongly
positive (3+). In the final analysis, a score of negative and 1+ was considered as
negative/ low expression and a score of 2+ and 3+ was considered as high expression.
2.3.3.2 Axillary lymph node (ALN) assessment
ALNs consisted of several lymphoid lobules surrounded by lymph-filled subcapsular
sinuses and enclosed by a capsule. Lymphoid follicles and inter-follicular cortex
present in these lobules constituted the superficial cortex of the ALNs. The deep
125
cortical portion of the lobules formed the para-cortex. The medulla of ALNs
comprised the medullary cords and medullary sinuses. The complex three-dimensional
lobules and the surrounding sinuses presented a variety of appearances in tissue
sections depending on the plane of section. Distinct populations of immune cells
reside in these three compartments [the cortex (superficial cortex), para-cortex (deep
cortex) and medulla]. B lymphocytes and plasma cells home to follicles in the
superficial cortex where they interact with follicular DCs. The majority of the T
lymphocytes were present in the deep cortex whilst macrophages were present in the
subcapsular sinus and medulla [429, 430].
Positively-stained cells in ALNs were quantified as the average % of all cells in 5
HPFs (×400 magnification) in non-metastatic para-cortical areas of ALNs (CD4⁺,
CD8⁺ and FOXP3⁺ lymphocytes) and in non-metastatic medullary areas of ALNs
(CD68⁺ and CD163⁺ macrophages). The average number of cell counts in 5 HPFs in
non-metastatic areas with the greatest accumulations of positively-stained cells on
scanning at low magnification for infrequent cell populations (CD56+, PD1+, CTLA-
4+, CD66b+ and CD1a+ cells) was determined. These quantitative evaluations followed
the methodological scoring for documenting various immune cell subsets present in
ALNs in patients with breast cancer [282, 431].
The evaluation of CD274 expression (according to the evaluation of corresponding
expression in breast tumour) in ALNs, positively-stained lymphocytes in non-
metastatic para-cortical areas of the ALNs were scored as negative/low expression
when either no detectable or weak staining was documented and high expression when
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moderate to strong staining was documented. The staining grade was defined
according to the majority of the DAB staining intensity throughout a specimen.
The expression of cytokines, VEGF and IDO in ALNs was assessed in non-metastatic,
para-cortical areas and semi-quantified by using the H scoring system (described
above) and a score of negative and 1+ was considered as negative/low expression and
a score of 2+ and 3+ was considered as high expression.
2.3.4 Statistical analyses and sample size/power calculation
Statistical analyses were performed with the IBM SPSS statistics software, version 21
(SPSS Inc., Chicago, IL, USA). Where the data did not follow a normal distribution
(Shapiro-Wilk test, p ≤ 0.05), non-parametric tests [Mann-Whitney U test (compared 
between two groups) and Kruskal-Wallis test (compared among three or more
groups)] were used to compare the groups based on pathological response to NAC and
clinico-pathological parameters. The Pearson Chi-Square test was performed to
compare the binomial data (negative/low versus high expression) of cytokines, IDO,
PDL1 and VEGF between groups. Univariate and multivariate logistic regression
analyses were carried out to determine whether a factor/variable was associated with
and significantly predicted a pCR. To evaluate and compare the related-sample data
between pre-NAC and post-NAC groups, as well as between primary breast tumours
and axillary metastatic tumours, the Related-Samples Wilcoxon Signed Rank test and
Related-Samples McNemar test were performed for comparing the number of cell
counts (continuous data) and the expression of cytokines, IDO, PDL1 and VEGF
(binomial data), respectively. The correlations between tumour-infiltrating immune
subsets (continuous data) and grade (1-5) of pathological responses (ordinal data), as
127
well as between tumour-infiltrating and peripheral circulating Tregs, were carried out
using Spearman's Correlation Coefficient (rho). A probability value (p value) of equal
to or less than 0.05 (p ≤ 0.05, 2-tailed) was considered statistically significant. 
A sample size of at least 7 in each group, which will have an 80% power to detect a
difference in means of 0.66 (assuming that the common standard deviation is 0.5) for a
two independent samples test with a significance level of p value ≤ 0.05 (2-sided), was 
carried out with N Query Advisor 6.0 analysis software. This is based on an example
of a primary outcome variable of circulating FOXP3+ Tregs from a previous study in
our laboratory [15].
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CHAPTER 3: RESULTS
3.1 Analyses of Breast Tumours
3.1.1 Immune cell infiltrations
High level of TILs was associated with good pathological responses and pCRs in
pre-NAC tumours (n=33)
A high level of TILs documented in pre-NAC specimens was significantly associated
with a pCR following NAC. This was seen with both intratumoural TILs (p=0.001)
and stromal TILs (p<0.001). This significant association was also found when
comparing patients with good and poor pathological responses (PPRs) [intratumoural
TILs (p=0.002); stromal TILs (p=0.012)] in breast cancers following NAC. Moreover,
when the tumours were classified as LPBCs (ITu-Ly and/or Str-Ly >60%) they were
shown to be significantly associated with both pCRs [81.3% (13 out of 16) versus
17.6% (3 out of 17), p<0.001] and good pathological responses (GPRs) [66.7% (14
out of 21) versus 16.67% (2 out of 12), p=0.006] (Table 3.1).
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Table 3.1 Association of Tumour-infiltrating Lymphocytes (TILs) and Pathological Response to NAC(1)
(1) NAC: Neoadjuvant chemotherapy; (2) LPBC: Lymphocyte-predominant breast cancer; * Statistically significant
Low
Infiltration (n)
High
Infiltration (n)
Pearson Chi-Square Value
(GPR versus PPR, PCR
versus Non PCR)
P Value
Low
Infiltration (n)
High
Infiltration (n)
Pearson Chi-Square Value
(GPR versus PPR, PCR
versus Non PCR)
P Value
Good Pathological Response
(GPR: n=21, n=9) 10 11 9 0
Poor Pathological Response
(PPR: n=12, n=7) 12 0 6 1
Pathological Complete Response
(PCR: n=16, n=6) 6 10 6 0
Non Pathological Complete Response
(Non PCR: n=17, n=10) 16 1 9 1
Good Pathological Response
(GPR: n=21, n=9) 8 13 9 0
Poor Pathological Response
(PPR: n=12, n=7) 10 2 5 2
Pathological Complete Response
(PCR: n=16, n=6) 3 13 6 0
Non Pathological Complete Response
(Non PCR: n=17, n=10) 15 2 8 2
Good Pathological Response
(GPR: n=21, n=9) 7 14 9 0
Poor Pathological Response
(PPR: n=12, n=7) 10 2 5 2
Pathological Complete Response
(PCR: n=16, n=6) 3 13 6 0
Non Pathological Complete Response
(Non PCR: n=17, n=10) 14 3 8 2
0.086
16.051 <0.001*
Groups
Pre-NAC (n=33) Post-NAC (n=16)
TILs:
Intratumoural
9.429 0.002* 1.371 0.242
11.890 0.001* 0.640 0.424
0.242
1.371 0.242
TILs: LPBC(2)
7.643 0.006* 2.939 0.086
13.350 <0.001* 1.371
TILs: Stromal
6.303 0.012* 2.939
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There was no significant association between the level of TILs in the post-NAC
specimens and the pathological responses (pCR versus non pCR; GPR versus PPR)
documented following NAC (p>0.05) (Table 3.1).
No significant effect of NAC on the level of TILs (n=16)
The impact of NAC on the levels of TILs is demonstrated by the changes in the level
of TILs between pre- and post-NAC samples, as shown in Table 3.2. The levels of
both intratumoural TILs and stromal TILs were not significantly altered, when pre-
NAC samples were compared with post-NAC samples. Five out of 16 patients with a
high level of TILs were subsequently altered to a low level of TILs after NAC whilst 1
out of 16 changed from a low to a high level of TILs (p=0.219). This finding shows
that NAC did not significantly affect the total TILs, albeit the number with high levels
of infiltration was less in the post-NAC samples (Table 3.2).
Table 3.2 Alteration of Tumour Infiltrating Lymphocytes (TILs) in LLABCs(1)
Undergoing NAC(2)
(1) LLABCs: Large and locally advanced breast cancers; (2) NAC: Neoadjuvant chemotherapy; (3)
Related-Samples McNemar Test
Low
Infiltraion (n)
High
Infiltration (n)
Low
Infiltraion (n)
10 1
High
Infiltration (n)
5 0
Low
Infiltraion (n)
9 1
High
Infiltration (n)
5 1
TILs: Stromal
(n=16)
Pre-NAC 0.219
Groups
Post NAC
P Value(3)
(Pre- versus Post-NAC)
TILs: Intratumoural
(n=16)
Pre-NAC 0.219
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Intratumoural TILs positively correlated with stromal TILs (n=16)
There were significantly positive correlations between pre-NAC intratumoural TILs
and stromal TILs (correlation coefficient (rho) = 0.592, p=0.016) and also between
post-NAC intratumoural TILs and stromal TILs (correlation coefficient (rho) = 0.683,
p=0.004). However, no significant correlation was found between pre-NAC TILs and
post-NAC TILs (Table 3.3).
Table 3.3 Correlation Between Intratumoural and Stromal TILs(1) [Spearman's
Correlation Coefficient (rho)] in Patients with LLABCs(2) Undergoing NAC(3) (n=16)
(1) TILs: Tumour-infiltrating lymphocytes; (2) LLABCs: Large and locally advanced breast cancers; (3)
NAC: Neoadjuvant chemotherapy; (4) NA: Not applicable; * Statistically significant
Intratumoural
infiltrating
Stromal
infiltrating
Intratumoural
infiltrating
Stromal
infiltrating
Intratumoural infiltrating
Correlation Coefficient NA(4) 0.592 -0.174 -0.255
P Value (2-tailed) NA 0.016* 0.519 0.341
Stromal infiltrating
Correlation Coefficient 0.592 NA -0.200 0.098
P Value (2-tailed) 0.016* NA 0.458 0.719
Intratumoural infiltrating
Correlation Coefficient -0.174 -0.200 NA 0.683
P Value (2-tailed) 0.519 0.458 NA 0.004*
Stromal infiltrating
Correlation Coefficient -0.255 0.098 0.683 NA
P Value (2-tailed) 0.341 0.719 0.004* NA
Post-NAC
Groups
Pre-NAC Breast Post-NAC Breast
Pre-NAC
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Figure 3.1 TILs in the sections of LLABCs, using H&E staining, at 200x (A, B) and 400x (C, D)
magnifications; A, C: low level of lymphocytic infiltration; B, D: high level of lymphocytic infiltration.
Low level of TILs defined as ≤ 60% of tumour nests (Itu: intratumoural) and/or stromal areas (Str: 
stromal) infiltrated by lymphocytes. High level of TILs defined as > 60% of tumour nests and/or
stromal areas infiltrated by lymphocytes.
Pre-NAC TIL subsets modified the pathological response to NAC (n=33)
Amongst the various TIL immune cell subsets (CD4⁺, CD8⁺, FOXP3⁺, CTLA-4⁺,
PD1⁺ T cells and CD56⁺ NK cells) present in pre-NAC specimens, a higher level of
intratumoural and peritumoural CD4⁺ T cells (p=0.023, p=0.001) and CD8⁺ T cells
(p=0.008, p=0.002) was significantly associated with a pCR (Table 3.4). High levels
of intratumoural and peritumoural CD56⁺ NK cells were associated with both pCR
(p=0.001, p<0.001) and good pathological responses (p=0.004, p=0.004) (Table 3.5).
The infiltration of CD4⁺ T cells was found intratumourally to range from 0.6 to 171,
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with a median of 8.8 cells/HPF, and peritumourally from 1 to 242, with a median of 17
cells/HPF. The infiltration of CD8⁺ T cells was found intratumourally to range from
0.4 to 202.4, with a median of 19.4 cells/HPF, and peritumourally from 1.8 to 201.6,
with a median of 22.4 cells/HPF. The median number of both intratumoural and
peritumoural CD56⁺ NK cells was 3 cells/5 HPFs [intratumoural: 3 (0-17) cells/5
HPFs; peritumoural: 3 (0-45) cells/5 HPFs].
Pre-NAC FOXP3+ Tregs failed to modify the pathological response to NAC
(n=33)
The level of pre-NAC tumour-infiltrating FOXP3⁺ Tregs (intratumoural and
peritumoural) showed no significant difference amongst the various pathological
response groups (p>0.05) while only peritumoual CTLA-4⁺ Tregs were significantly
associated with a pCR (p=0.041) (Table 3.4 and 3.5). The infiltration of FOXP3⁺ 
Tregs were found to range intratumourally from 0.4 to 96.8, with a median of 5.6
cells/HPF, and peritumourally from 0.8 to 110.6, with a median of 11.2 cells/HPF. The
median number of intratumoural and peritumoural CTLA-4⁺ Tregs was 2 (0-20) and 4
(0-50) cells/5 HPFs, respectively.
PD1⁺ T cells, CD66b⁺ PMNs and CD1a⁺ DCs were not associated with a
pathological response to NAC (n=16)
The pre-NAC intratumoural and peritumoural tumour-infiltrating PD1⁺ T cells,
CD66b⁺ PMNs and CD1a⁺ DCs, were found to be not different between the pCR and
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non pCR groups, as well as the good and poor pathological response groups (p>0.05)
(Tables 3.4 and 3.5).
Table 3.4 Association of Pre-NAC(1) Tumour-infiltrating T Cell Subsets and
Pathological Response to NAC
(1) NAC: Neoadjuvant chemotherapy; (2) Average cell count per 400x high-power field; (3) Mann-
Whitney U test; * Statistically significant
T Cell
Subsets Groups
Pre-NAC
Intratumoural
Median (Range)(2)
P Value(3)
(GPR versus PRR,
PCR versus Non PCR)
Pre-NAC
Peritumoural
Median (Range)(2)
P Value(3)
(GPR versus PRR,
PCR versus Non PCR)
Good Pathological Response
(GPR, n=21) 16.8 (0.6-171.0) 23.0 (1.0-242.0)
Poor Pathological Response
(PPR, n=12) 5.9 (1.4-166.2) 11.3 (1.0-113.0)
Pathological Complete Response
(PCR, n=16) 45.2 (1.6-171.0) 43.4 (1.0-242.0)
Non Pathological Complete Response
(Non PCR, n=17) 5.8 (0.6-166.2) 10.4 (1.0-113.0)
Good Pathological Response
(GPR, n=21) 26.0 (0.4-202.4) 65.2 (2.8-201.6)
Poor Pathological Response
(PPR, n=12) 12.9 (0.8-99.2) 12.6 (1.8-110.0)
Pathological Complete Response
(PCR, n=16) 40.6 (5.2-202.4) 75.5 (5.6-201.6)
Non Pathological Complete Response
(Non PCR, n=17) 12.8 (0.4-99.2) 12.2 (1.8-110.0)
Good Pathological Response
(GPR, n=21) 5.6 (0.4-96.8) 10.0 (0.8-110.6)
Poor Pathological Response
(PPR, n=12) 5.5 (0.8-45.6) 13.0 (0.8-44.8)
Pathological Complete Response
(PCR, n=16) 6.3 (0.4-96.8) 12.5 (0.8-110.6)
Non Pathological Complete Response
(Non PCR, n=17) 5.4 (0.8-45.6) 10.8 (0.8-44.8)
Good Pathological Response
(GPR, n=9) 2.0 (0.0-57.4) 1.8 (0.0-81.2)
Poor Pathological Response
(PPR, n=7) 0.4 (0.0-1.0) 0.8 (0.0-3.6)
Pathological Complete Response
(PCR, n=6) 2.6 (0.0-57.4) 1.9 (0.4-81.2)
Non Pathological Complete Response
(Non PCR, n=10) 0.5 (0.0-3.2) 0.9 (0.0-3.6)
CD4+
(n=33)
0.213 0.131
0.023* 0.001*
CD8+
(n=33)
0.075 0.082
0.008* 0.002*
FOXP3+
(n=33)
1.000 0.897
0.958 0.363
PD1+
(n=16)
0.114 0.174
0.118 0.093
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Figure 3.2 Summary of the median numbers of pre-NAC tumour-infiltrating T cell subsets between
pCR and non pCR groups; Itu: Intratumoural, Str: Stromal/peritumoural
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Figure 3.3 CD4⁺ T lymphocytes in the sections of LLABCs, using IHC staining, at 400x magnification.
Briefly, heat-mediated antigen retrieval was performed using citrate buffer, pH 6 (20 mins). The
sections were then incubated with MAbs to CD4 (Dako, M7310) at a 1:80 dilution for 30 mins at RT.
Polymeric HRP-linker antibody conjugate was used as secondary antibody. DAB chromogen was used
to visualize the staining. The sections were counterstained with haematoxylin. A: low level of CD4⁺ T
cell infiltration; B: high level of CD4⁺ T cell infiltration. The average number of brown membrane-
stained cells, regardless of intensity, in contact with tumour cells or within tumour cell nests (Itu:
intratumoural) and in the interstitial stroma (Str: stromal/peritumoural) per HPF were counted.
Figure 3.4 CD8+ T lymphocytes in the sections of LLABCs, using IHC staining, at 400x magnification.
Briefly, heat-mediated antigen retrieval was performed using citrate buffer, pH 6 (20 mins). The
sections were then incubated with MAbs to CD8 (Dako, M7103) at a 1:100 dilution for 30 mins at RT.
Polymeric HRP-linker antibody conjugate was used as secondary antibody. DAB chromogen was used
to visualize the staining. The sections were counterstained with haematoxylin. A: low level of CD8+ T
cell infiltration; B: high level of CD8+ T cell infiltration. The average number of brown membrane-
stained cells, regardless of intensity, in contact with tumour cells or within tumour cell nests (Itu:
intratumoural) and in the interstitial stroma (Str: stromal/peritumoural) per HPF were counted.
137
Figure 3.5 FOXP3⁺ Tregs in the sections of LLABCs, using IHC staining, at 400x magnification.
Briefly, heat-mediated antigen retrieval was performed using citrate buffer, pH 6 (20 mins). The
sections were then incubated with MAbs to FOXP3 (Abcam, ab20034) at a concentration of 20 µg/ml
for 30 mins at RT. Polymeric HRP-linker antibody conjugate was used as secondary antibody. DAB
chromogen was used to visualize the staining. The sections were counterstained with haematoxylin. A:
low level of FOXP3⁺ Treg infiltration; B: high level of FOXP3⁺ Treg infiltration. The average number
of brown nuclear-stained cells, regardless of intensity, in contact with tumour cells or within tumour
cell nests (Itu: intratumoural) and in the interstitial stroma (Str: stromal/peritumoural) per HPF were
counted.
Figure 3.6 PD1⁺ T cells in the sections of LLABCs, using IHC staining, at 400x magnification. Briefly,
heat-mediated antigen retrieval was performed using citrate buffer, pH 6 (20 mins). The sections were
then incubated with MAbs to PD1 (Abcam, ab52587) at a 1:100 dilution for 30 mins at RT. Polymeric
HRP-linker antibody conjugate was used as secondary antibody. DAB chromogen was used to visualize
the staining. The sections were counterstained with haematoxylin. A: low level of PD1⁺ T cell
infiltration; B: high level of PD1⁺ T cell infiltration. The average number of brown membrane-stained
cells, regardless of intensity, in contact with tumour cells or within tumour cell nests (Itu:
intratumoural) and in the interstitial stroma (Str: stromal/peritumoural) per HPF were counted.
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Table 3.5 Association of Pre-NAC(1) Tumour-infiltrating CTLA-4+ Tregs, CD56+ NK
Cells, CD1a+ DCs and CD66b+ PMNs and Pathological Response to NAC
(1) NAC: Neoadjuvant chemotherapy; (2) Total cell count per 5 high-power fields; (3) Mann-Whitney U
test; * Statistically significant
Immune
Cell
Subsets
Groups
Pre-NAC
Intratumoural
Median (Range)(2)
P Value(3)
(GPR versus PRR,
PCR versus Non PCR)
Pre-NAC
Peritumoural
Median (Range)(2)
P Value(3)
(GPR versus PRR,
PCR versus Non PCR)
Good Pathological Response
(GPR, n=21) 2.0 (0.0-20.0) 6.0 (0.0-50.0)
Poor Pathological Response
(PPR, n=12) 1.5 (0.0-11.0) 2.5 (0.0-9.0)
Pathological Complete Response
(PCR, n=16) 2.5 (0.0-20.0) 7.0 (0.0-50.0)
Non Pathological Complete Response
(Non PCR, n=17) 2.0 (0.0-11.0) 2.0 (0.0-11.0)
Good Pathological Response
(GPR, n=21) 6.0 (0.0-17.0) 9.0 (0.0-45.0)
Poor Pathological Response
(PPR, n=12) 1.0 (0.0-8.0) 1.0 (0.0-11.0)
Pathological Complete Response
(PCR, n=16) 7.0 (1.0-17.0) 15.0 (2.0-45.0)
Non Pathological Complete Response
(Non PCR, n=17) 1.0 (0.0-8.0) 1.0 (0.0-11.0)
Good Pathological Response
(GPR, n=9) 3 (1-104) 1 (1-16)
Poor Pathological Response
(PPR, n=7) 11 (0-63) 2 (0-11)
Pathological Complete Response
(PCR, n=6) 3 (1-104) 1.5 (1-16)
Non Pathological Complete Response
(Non PCR, n=10) 4 (0-63) 1.5 (0-11)
Good Pathological Response
(GPR, n=9) 2 (0-53) 2 (0-71)
Poor Pathological Response
(PPR, n=7) 1 (0-3) 1 (0-2)
Pathological Complete Response
(PCR, n=6) 3 (0-53) 5 (0-71)
Non Pathological Complete Response
(Non PCR, n=10) 1 (0-3) 1 (0-2)
CTLA-4+
(n=33)
0.187 0.075
0.068 0.041*
CD56+
(n=33)
0.004* 0.004*
0.001* <0.001*
CD1a+
(n=16)
0.837 0.837
0.713 0.492
CD66b+
(n=16)
0.174 0.408
0.181 0.118
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Figure 3.7 Summary of the median numbers of pre-NAC tumour-infiltrating immune cell subsets
between pCR and non pCR groups; Itu: Intratumoural, Str: Stromal/peritumoural
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Figure 3.8 CTLA-4+ Tregs in the sections of LLABCs, using IHC staining, at 400x magnification.
Briefly, heat-mediated antigen retrieval was performed using citrate buffer, pH 6 (20 mins). The
sections were then incubated with MAbs to CTLA-4 (Santa Cruz Bio, sc-376016) at a 1:300 dilution for
30 mins at RT. Polymeric HRP-linker antibody conjugate was used as secondary antibody. DAB
chromogen was used to visualize the staining. The sections were counterstained with haematoxylin. A:
low level of CTLA-4+ Treg infiltration; B: high level of CTLA-4+ Treg infiltration. The total number of
brown membrane-stained cells, regardless of intensity, in contact with tumour cells or within tumour
cell nests (Itu: intratumoural) and in the interstitial stroma (Str: stroma/peritumoural) in 5 HPFs were
counted.
Figure 3.9 CD56⁺ NK cells in the sections of LLABCs, using IHC staining, at 400x magnification.
Briefly, heat-mediated antigen retrieval was performed using citrate buffer, pH 6 (20 mins). The
sections were then incubated with MAbs to CD56 (Dako, M7304) at a 1:50 dilution for 30 mins at RT.
Polymeric HRP-linker antibody conjugate was used as secondary antibody. DAB chromogen was used
to visualize the staining. The sections were counterstained with haematoxylin. A: low level of CD56⁺
NK cell infiltration; B: high level of CD56⁺ NK cell infiltration. The total number of brown membrane-
stained cells, regardless of intensity, in contact with tumour cells or within tumour cell nests (Itu:
intratumoural) and in the interstitial stroma (Str: stromal/peritumoural) in 5 HPFs were counted.
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Figure 3.10 CD1a⁺ DCs in the sections of LLABCs, using IHC staining, at 400x magnification.
Briefly, heat-mediated antigen retrieval was performed using citrate buffer, pH 6 (20 mins). The
sections were then incubated with MAbs to CD1a (Dako, M3571) at a 1:200 dilution for 15 mins at RT.
Polymeric HRP-linker antibody conjugate was used as secondary antibody. DAB chromogen was used
to visualize the staining. The sections were counterstained with haematoxylin. A: low level of CD1a⁺
DC infiltration; B: high level of CD1a⁺ DC infiltration. The total number of brown membrane-stained
cells, regardless of intensity, in contact with tumour cells or within tumour cell nests (Itu:
intratumoural) and in the interstitial stroma (Str: stromal/peritumoural) in 5 HPFs were counted.
Figure 3.11 CD66b⁺ neutrophils in the sections of LLABCs, using IHC staining, at 400x magnification.
Briefly, heat-mediated antigen retrieval was performed using citrate buffer, pH 6 (20 mins). The
sections were then incubated with MAbs to CD66b (LS Bio, LS-B7134) at a concentration of 10 µg/ml
for 30 mins at RT. Polymeric HRP-linker antibody conjugate was used as secondary antibody. DAB
chromogen was used to visualize the staining. The sections were counterstained with haematoxylin. A:
low level of CD66b⁺ neutrophil infiltration; B: high level of CD66b⁺ neutrophil infiltration. The total
number of brown membrane-stained cells, regardless of intensity, in contact with tumour cells or within
tumour cell nests (Itu: intratumoural) and in the interstitial stroma (Str: stromal/ peritumoural) in 5
HPFs were counted.
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High CD8⁺ T cell: FOXP3⁺ Treg ratio was associated with a good pathological
response and pCR
The CD8⁺ T cell: FOXP3⁺ Treg ratio was calculated from the number of cell counts
per HPF of tumour-infiltrating CD8+ T cells and FOXP3+ Tregs in the same tissue
section. In the pCR group, the intratumoural CD8⁺ T cell: FOXP3⁺ Treg median ratio
was 7.40. This was significantly higher than the median ratio in the non pCR group
(7.40 versus 1.48, p=0.002). Concomitant findings were also demonstrated in the
peritumoural CD8⁺ T cell: FOXP3⁺ Treg median ratio (5.37 versus 1.67, p=0.001).
Comparable significant differences were found in the GPRs versus PPRs in both the
intratumoural (p=0.027) and peritumoural (p=0.027) ratios in pre-NAC specimens
(Table 3.6).
Table 3.6 The Association of Pre-NAC(1) Tumour-infiltrating CD8+ T Cell: FOXP3+
Treg Ratio and Pathological Response to NAC
(1) NAC: Neoadjuvant chemotherapy; (2) CD8⁺ T cell: FOXP3⁺ Treg ratio; (3) Mann-Whitney U test; *
Statistically significant
Groups
Intratumoural
Median (Range)(2)
P Value(3)
(GPR versus PRR,
PCR versus Non PCR)
Peritumoural
Median (Range)(2)
P Value(3)
(GPR versus PRR,
PCR versus Non PCR)
Good Pathological Response
(GPR, n=21) 3.26 (0.18-45.00) 4.67 (0.53-23.29)
Poor Pathological Response
(PPR, n=12) 1.37 (0.67-6.04) 1.81 (0.10-6.78)
Pathological Complete
Response (PCR, n=16) 7.40 (0.27-45.00) 5.37 (1.08-23.29)
Non Pathological Complete
Response (Non PCR, n=17) 1.48 (0.18-6.04) 1.67 (0.10-6.78)
CD8/FOXP3
ratio (n=33)
0.027* 0.027*
0.002* 0.001*
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NAC reduced immune cells (CD4⁺, FOXP3⁺, CTLA-4⁺ and PD1⁺) in the tumour
microenvironment but not CD8+ T lymphocytes (n=16)
Following 8 cycles of NAC, the levels of different TIL subsets in post-NAC
specimens were significantly reduced, compared with their related pre-NAC
specimens, apart from the CD8⁺ subset. Table 3.7 shows that NAC significantly
reduced both intratumoural (p=0.001) and peritumoural (p=0.001) FOXP3⁺ Tregs,
peritumoural (p=0.029) CTLA-4⁺ Tregs, and both intratumoural (p=0.005) and
peritumoural (p=0.016) PD1⁺ T cells. The CD4⁺ T cell subset infiltration was also
significantly reduced both intratumourally (p=0.01) and peritumourally (p=0.006).
Moreover, the intratumoural infiltration of the CD56⁺ NK cell subset was also
significantly reduced (p=0.018). NAC, however, did not significantly affect the level
of CD8⁺ T cells (p>0.05) albeit there was some reduction in numbers. The
intratumoural CD1a+ DC subset was significantly reduced by NAC (p=0.001) while
the peritumoural component remained unchanged (p=0.184).
Contrary to the lymphocyte subsets, CD66b⁺ PMN infiltrations were increased both
intratumourally and peritumourally after NAC but these differences did not reach
statistical significance (p=0.125, p=0.47) (Table 3.7).
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Table 3.7 Alteration of Cellular Infiltrations in LLABCs(1) Undergoing NAC(2)
(1) LLABCs: Large and locally advanced breast cancers; (2) NAC: Neoadjuvant chemotherapy; (3)
Average cell count per 400x high-power field; (4) Wilcoxon signed rank test; * Statistically significant
Cell Subsets
(n=16)
Groups
Pre-NAC
Median (Range)(3)
Post-NAC
Median (Range)(3)
P Value(4)
(Pre- versus Post-NAC)
Intratumoural Infiltration 15.4 (2.6-171.0) 3.0 (0.0-71.6) 0.010*
Peritumoural Infiltration 45.6 (6.8-242.0) 6.3 (1.2-236.0) 0.006*
Intratumoural infiltration 20.2 (3.4-202.4) 10.3 (0.0-83.6) 0.278
Peritumoural Infiltration 43.6 (1.8-201.6) 27.1 (1.6-144.6) 0.326
Intratumoural infiltration 14.8 (2.4-96.8) 0.7 (0.0-22.2) 0.001*
Peritumoural Infiltration 15.9 (2.2-110.6) 1.4 (0.4-28.4) 0.001*
Intratumoural infiltration 0.4 (0.0-4.0) 0.1 (0.0-1.2) 0.060
Peritumoural Infiltration 0.6 (0.2-10.0) 0.1 (0.0-5.2) 0.029*
Intratumoural infiltration 0.3 (0.0-3.4) 0.0 (0.0-0.6) 0.018*
Peritumoural Infiltration 0.3 (0.0-3.4) 0.2 (0.0-0.6) 0.151
Intratumoural infiltration 0.7 (0.0-20.8) 0.0 (0.0-0.4) 0.001*
Peritumoural Infiltration 0.3 (0.0-3.2) 0.2 (0.0-1.4) 0.184
Intratumoural infiltration 0.7 (0.0-57.4) 0.0 (0.0-0.6) 0.005*
Peritumoural Infiltration 1.5 (0.0-81.2) 0.0 (0.0-4.0) 0.016*
Intratumoural infiltration 0.2 (0.0-10.6) 0.9 (0.0-10.0) 0.125
Peritumoural Infiltration 0.3 (0.0-14.2) 0.5 (0.0-16.4) 0.470
CD66b+
Neutrophils
CD56+ NK Cells
CD1a+ DCs
PD1+ T
Lymphocytes
CD8+ T
Lymphocytes
FOXP3+ Tregs
CTLA-4+ Tregs
CD4+ T
Lymphocytes
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Figure 3.12 Summary of the median numbers of tumour-infiltrating immune cell subsets between pre-
NAC and post-NAC; Itu: Intratumoural, Str: Stromal/peritumoural
CD163⁺ but not CD68⁺ pre-NAC TIMs were significantly associated with
pathological responses to NAC
High level of infiltration (grade 3 and 4) of CD163⁺ (M2 polarised) TIMs in pre-NAC
specimens was found to have a significant association with pathological responses
[76.2% (16 out of 21) in the good pathological response group versus 25% (3 out of
12) in the poor pathological response group, p=0.004]. This association was also
documented in the pCR group (p=0.008). While high levels of pre-NAC CD163⁺
TIMs were associated with a GPR and pCR following NAC, CD68⁺ TIMs did not
show these patterns of responses. There was also no significant association between
the levels of TIMs (CD163⁺, CD68⁺) and the pathological responses documented in
the post-NAC specimens (Table 3.8).
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Table 3.8 Analyses of Tumour-infiltrating CD68+ and CD163+ Macrophages in the Breast Tumours Pre- and Post-NAC(1)
(1) NAC: Neoadjuvant chemotherapy; * Statistically significant
Low
Infiltration (n)
High
Infiltration (n)
Pearson Chi-Square Value
(GPR versus PPR, PCR
versus Non PCR)
P Value Low
Infiltration (n)
High
Infiltration (n)
Pearson Chi-Square Value
(GPR versus PPR, PCR
versus Non PCR)
P Value
Good Pathological Response
(GPR: n=9, n=9)
5 4 9 0
Poor Pathological Response
(PPR: n=7, n=7) 6 1 5 2
Pathological Complete Response
(PCR: n=6, n=6) 3 3 6 0
Non Pathological Complete Response
(Non PCR: n=10, n=10) 8 2 8 2
Good Pathological Response
(GPR: n=21, n=9) 5 16 7 2
Poor Pathological Response
(PPR: n=12, n=7) 9 3 3 4
Pathological Complete Response
(PCR: n=16, n=6) 3 13 5 1
Non Pathological Complete Response
(Non PCR: n=17, n=10) 11 6 5 5
0.197 2.939 0.086
Macrophages Groups
Pre-NAC Post-NAC
0.008* 1.778 0.182
1.571 0.210 1.371 0.242
CD163+
(n=33)
8.192 0.004* 2.049 0.152
7.127
CD68+
(n=16)
1.667
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NAC did not influence the level of TIMs in LLABCs (n=16)
There were no significant changes in the levels of either the CD163⁺ or CD68⁺ TIMs
following NAC. The levels of pre-NAC TIMs were not significantly different from the
related post-NAC specimens, suggesting that NAC had no effect. With CD68⁺ TIMs,
5 out of 16 cases demonstrated alteration in the level of infiltration after NAC (4 cases
changed from high to low, 1 case from low to high, p=0.375). In 8 out of 16 cases of
CD163⁺ TIMs the level of infiltration was altered (6 cases from high to low, 2 cases
from low to high, p=0.289) (Table 3.9). This finding suggests that the M2 polarisation
of macrophages (express CD163) persisted after NAC.
Table 3.9 Alteration of Tumour-infiltrating CD68+ and CD163+ Macrophages in
LLABCs(1) Undergoing NAC(2)
(1) LLABCs: Large and locally advanced breast cancers; (2) NAC: Neoadjuvant chemotherapy; (3)
Related-Samples McNemar Test
Low
Infiltraion (n)
High
Infiltration (n)
Low
Infiltraion (n)
10 1
High
Infiltration (n)
4 1
Low
Infiltraion (n)
4 2
High
Infiltration (n)
6 4
CD163+ (n=16) Pre-NAC 0.289
Post-NAC
P Value(3)
(Pre versus Post NAC)
CD68+ (n=16) Pre-NAC 0.375
GroupsMacrophages
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Figure 3.13 CD68⁺ macrophages in the sections of LLABCs, using IHC staining, at 200x
magnification. Briefly, heat-mediated antigen retrieval was performed using citrate buffer, pH 6 (20
mins). The sections were then incubated with MAbs to CD68 (Abcam, ab955) at a 1:300 dilution for 30
mins at RT. Polymeric HRP-linker antibody conjugate was used as secondary antibody. DAB
chromogen was used to visualize the staining. The sections were counterstained with haematoxylin. A:
low level of CD68+ macrophage infiltration; B: high level of CD68⁺ macrophage infiltration. Tumours
were classified as low level of infiltration when the positively brown membrane-stained cells were
scattered or continuous along the tumour margin but did not extend from the tumour front (TF) for
more than one cell layer. Extension for two or more layers from the TF was classified as a high level of
infiltration.
Figure 3.14 CD163⁺ macrophages in the sections of LLABCs, using IHC staining, at 200x
magnification. Briefly, heat-mediated antigen retrieval was performed using citrate buffer, pH 6 (20
mins). The sections were then incubated with MAbs to CD163 (Abcam, ab74604) at a pre-diluted
concentration for 30 mins at RT. Polymeric HRP-linker antibody conjugate was used as secondary
antibody. DAB chromogen was used to visualize the staining. The sections were counterstained with
haematoxylin. A: low level of CD163+ macrophage infiltration; B: high level of CD163⁺ macrophage
infiltration. Tumours were classified as low level of infiltration when the positively brown membrane-
stained cells were scattered or continuous along the tumour margin but did not extend from the tumour
front (TF) for more than one cell layer. Extension for two or more layers from the TF was classified as
a high level of infiltration.
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Immune cell subsets associated with a pCR showed a positive correlation with
grade of pathological response (n=33)
The levels of pre-NAC tumour-infiltrating CD4+ (peritumoural only) and CD8+ T cells
and CD56+ NK cells, as well as CD8+ T cell: FOXP3+ Treg ratio which had been
found to have a significant association with a pCR, also showed a significant positive
correlation with the grade (1-5) of pathological response elicited in the breast cancers
with NAC. Higher levels of these immune cell infiltrations were significantly
associated with higher grades of pathological response to NAC (Table 3.10).
Table 3.10 Correlation Between Tumour-infiltrating CD4+ and CD8+ T Cells, CD56+
NK Cells, CD8:FOXP3 Ratio and Grade of Pathological Response [Spearman's
Correlation Coefficient (rho)] in Women with LLABCs(1) Pre-NAC(2)
(1) LLABCs: Large and locally advanced breast cancers; (2) NAC: Neoadjuvant chemotherapy; (3)
Pathological responses were graded from grade 1 (no pathological response) to grade 5 (complete
pathological response); * Statistically significant
Correlation Coefficient P Value (2-tailed)
Intratumoural Infiltrating 0.316 0.073
Peritumoural Infiltrating 0.468 0.006*
Intratumoural Infiltrating 0.446 0.009*
Peritumoural Infiltrating 0.471 0.006*
Intratumoural Infiltrating 0.602 <0.001*
Peritumoural Infiltrating 0.702 <0.001*
Intratumoural Infiltrating 0.511 0.002*
Peritumoural Infiltrating 0.484 0.004*
Immune Cell Subsets
(n=33)
Groups
CD8+ T cells
CD8+ T cell: FOXP3+
Treg ratio
Grade of Pathological Response (3)
CD4+ T cells
CD56+ NK cells
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Clinical and pathological parameters and the association with pre-NAC TILs,
CD163⁺ TIMs, FOXP3⁺ Tregs, CD8⁺ T cells in the tumour microenvironment and
pCR (n=33)
Amongst the various clinical and pathological parameters investigated, TIL levels
were found to have a significant association with tumour grade (p=0.001) and ER
status (p=0.007). High levels of TILs (LPBCs) were found in 81.2% (9 out of 11) of
ER-ve tumours compared with only 31.8% (7 out of 22) of ER+ve tumours. 77.8% (14
out of 18) of high histological grade (grade 3) tumours were LPBCs while only 13.3%
(2 out of 15) with low histological grade (grade 1, 2) of tumours had prominent TILs.
ER status and tumour grade also showed a significant relationship with levels of
CD163⁺ TIMs. A high level of TIMs was found in 81.2% (9 out of 11) of ER-ve
tumours compared with 45.5% (10 out of 22) of ER+ve tumours (p=0.046) and 83.3%
(15 out of 18) of high grade tumours compared with 26.7% (4 out of 15) of moderate
and low grade tumours (p=0.004). Both ER-ve and high histological grade tumours
were significantly associated with a pCR (p=0.049 and p=0.01, respectively).
Nevertheless, the levels of TILs and CD163⁺ TIMs were not found to be significantly
associated with tumour recurrence or survival at 4 years of follow-up (a median
follow-up of 51 months), (Table 3.11).
The levels of peritumoural FOXP3⁺ Tregs (p=0.018), intratumoural (p=0.038) and
peritumoural (p=0.032) CD8⁺ T cells were significantly associated with tumour grade
(Table 3.12). There was no significant association between age, BMI, menopausal
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status, tumour size, nodal status (clinical), HER2 status, NAC regimen and the level of
immune cell infiltrations (TILs, CD163+ TIMs, FOXP3+ Tregs and CD8+ T cells)
(Tables 3.11 and 3.12). Tumour type was excluded from statistical analysis because
the majority of specimens were ductal. Only 2 cases were lobular cancers.
The presence of TILs (LPBCs) and TIMs (CD163+) was strongly associated with the
absence of ERs and the presence of high grade tumours. These tumours (ER-ve and
high grade) were associated with a high pCR rate. TILs and TIMs (CD163+),
therefore, probably played a key role in inducing a pCR with NAC in women with
LLABCs.
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Table 3.11 Clinical and Pathological Parameters of Patients (n=33) Studied and the Association of Pre-NAC(1) Tumour-infiltrating
Lymphocytes (TILs),Tumour-infiltrating CD163+ Macrophages (TIMs) and Pathological Complete Response (pCR)
(1) NAC: Neoadjuvant chemotherapy; (2) BMI: Body mass index (≤30: Non-obese, >30: Obese); (3) AC-TX: Doxorubicin, cyclophosphamide, taxotere and
Xeloda® (capecitabine), respectively; (4) 4 years follow-up; * Statistically significant
Low
Infiltration (n)
High
Infiltration (n)
Pearson Chi-
Square Value
P Value
Low
Infiltration (n)
High
Infiltration (n)
Pearson Chi-
Square Value
P Value Non PCR (n) PCR (n)
Pearson Chi-
Square Value
P Value
Age (years)
<50 7 7 6 8 8 6
≥50 10 9 8 11 9 10
BMI(2) (kg/m2)
 ≤30 11 9 10 10 11 9
>30 6 7 4 9 6 7
Menopausal status
pre 6 10 5 11 8 8
post 11 6 9 8 9 8
Tumour size
<40 mm 10 8 8 10 9 9
≥40 mm 7 8 6 9 8 7
Nodal status
negative 6 4 5 5 5 5
positive 11 12 9 14 12 11
Tumour grade
1 (low) 1 1 1 1 2 0
2 (moderate) 12 1 10 3 10 3
3 (high) 4 14 3 15 5 13
Oestrogen receptor
negative 2 9 2 9 3 8
positive 15 7 12 10 14 8
HER-2 receptor
negative 13 10 10 13 13 10
positive 4 6 4 6 4 6
NAC regimen
AC-TX(3) 7 9 6 10 6 10
AC-T 10 7 8 9 11 6
Recurrent disease (4)
no 9 13 8 14 7 15
yes 8 3 6 5 10 1
Death(4)
no 13 14 11 16 12 15
yes 4 2 3 3 5 1
0.750 0.387 0.308 0.579 2.443 0.118
0.247 0.619 1.193 0.275 0.247 0.619
2.443 0.118 1.588
0.674 0.412 0.172 0.678 2.972 0.085
2.972 0.085 0.992 0.319 10.252 0.001*
0.383
7.340 0.007* 3.970 0.046* 3.882 0.049*
0.762 0.383 0.035 0.853 0.762
0.010*
0.414 0.520 0.337 0.561 0.013 0.909
14.847 0.001* 11.270 0.004* 9.303
0.579
0.259 0.611 0.066 0.797 0.036 0.849
0.208 0.029 0.866
0.022 0.881 0.002 0.966 0.308
Groups
TILs TIMs PCR
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Table 3.12 Clinical and Pathological Parameters of Patients (n=33) Studied and the
Presence of Pre-NAC(1) Tumour-infiltrating FOXP3+ Tregs and CD8+ T Cells
(1) NAC: Neoadjuvant chemotherapy; (2) Average cell count per 400x high-power field; (3) Mann-
Whitney U test; (4) BMI: Body mass index (≤30: Non-obese, >30: Obese); (5) Kruskal-Wallis test; (6)
AC-TX: Doxorubicin, cyclophosphamide, taxotere and Xeloda® (capecitabine), respectively; (7) 4 years
follow-up; * Statistically significant
Pre-NAC
Intratumoural
Median (Range)(2)
P
Value(3)
Pre-NAC
Peritumoural
Median (Range)(2)
P
Value(3)
Pre-NAC
Intratumoural
Median (Range)(2)
P
Value(3)
Pre-NAC
Peritumoural
Median (Range)(2)
P
Value(3)
Age (years)
<50 14 5.6 (0.4-26.2) 12.6 (0.8-26.8) 24.1 (0.8-97.4) 17.7 (1.8-110.0)
≥50 19 4.8 (0.8-96.8)   11.2 (0.8-110.6)   14.4 (0.4-202.4) 26.2 (2.0-201.6)
BMI(4) (kg/m2)
 ≤30 20 6.3 (0.8-96.8) 14.3 (0.8-110.6) 20.3 (0.4-202.4) 22.8 (2.0-127.2)
>30 13 4.8 (0.4-60.4) 6.6 (0.8-27.8) 14.4 (0.8-197.2) 22.4 (1.8-201.6)
Menopausal status
pre 16 9.1 (0.4-60.4) 14.7 (0.8-27.8) 31.7 (0.8-197.2) 41.8 (1.8-201.6)
post 17 4.6 (0.8-96.8) 6.6 (0.8-110.6) 12.8 (0.4-202.4) 22.4 (2.0-127.2)
Tumour size
<40 mm 18 4.4 (0.8-77.0) 9.3 (0.8-110.6) 20.8 (0.8-202.4) 22.8 (1.8-201.6)
      ≥40 mm 15 11.2 (0.4-96.8) 14.2 (0.8-44.8) 19.4 (0.4-99.2) 22.4 (3.4-114.0)
Nodal status
negative 10 8.8 (2.4-77.0) 12.7 (3.0-110.6) 13.9 (3.4-202.4) 43.6 (1.8-201.6)
positive 23 5.6 (0.4-96.8) 10.0 (0.8-32.0) 21.2 (0.4-112.6) 18.4 (2.0-118.8)
Tumour grade
1 (low) 2 32.5 (19.4-45.6) 35.8 (26.8-44.8) 64.0 (28.8-99.2) 88.0 (87.2-88.8)
2 (moderate) 13 4.2 (0.4-26.2) 5.2 (0.8-21.8) 10.4 (0.8-78.4) 11.2 (2.6-110.0)
3 (high) 18 6.3 (0.8-96.8) 14.0 (0.8-110.6) 31.9 (0.4-202.4) 70.5 (1.8-199.8)
Oestrogen receptor
negative 11 5.6 (0.8-96.8) 11.2 (0.8-110.6) 29.6 (1.0-202.4) 65.2 (2.0-127.2)
positive 22 5.5 (0.4-60.4) 11.2 (0.8-44.8) 13.7 (0.4-197.2) 18.9 (1.8-201.6)
HER-2 receptor
negative 23 7.4 (0.4-96.8) 11.6 (0.8-110.6) 19.4 (0.4-202.4) 26.2 (2.6-201.6)
positive 10 3.6 (0.8-11.6) 9.3 (0.8-17.4) 14.3 (1.0-97.4) 15.0 (1.8-86.4)
NAC regimen
AC-TX(6) 16 7.2 (0.4-60.4) 12.7 (0.8-44.8) 25.4 (0.8-197.2) 47.8 (2.6-201.6)
AC-T 17 4.8 (0.8-96.8) 10.8 (0.8-110.6) 13.4 (0.4-202.4) 19.4 (1.8-127.2)
Recurrent disease (7)
no 22 7.2 (0.4-77.0) 11.4 (0.8-110.6) 25.4 (0.8-202.4) 65.0 (2.6-201.6)
yes 11 4.8 (0.8-96.8) 10.8 (0.8-26.8) 7.4 (0.4-78.4) 12.2 (1.8-114.0)
Death(7)
no 27 5.6 (0.4-77.0) 11.6 (0.8-110.6) 21.2 (0.8-202.4) 64.8 (1.8-201.6)
yes 6 5.1 (0.8-96.8) 8.6 (0.8-22.2) 9.8 (0.4-78.4) 10.5 (2.0-114.0)
Groups N
FOXP3+ Tregs CD8 + T cells
0.109(5) 0.018* 0.038* 0.032*
0.957 0.900 1.000 0.397
0.190 0.486 0.817 0.901
0.144 0.221 0.576 0.603
0.721 0.866 0.281 0.440
0.173
0.638 0.665 0.530 0.154
0.929 0.817 0.326 0.657
0.703 0.118 0.899 0.730
0.326 0.423 0.157 0.958
0.114 0.221 0.428 0.133
0.946 0.538 0.205
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TILs are an independent predictive factor for a pCR
Various clinical and pathological parameters have been shown to be associated with a
high pCR rate (young age, small tumour size, high histological grade, ER-ve and
HER2+ve tumours) [19]. Our data showed that high histological grade, ER-negativity
and a high level of TILs were significantly predictive of a pCR in univariate analysis
(p=0.005, 0.049 and 0.001, respectively). TILs, furthermore, was an independent
predictive factor for pCR in a multivariate analysis [Odds ratio (OR) 11.17 (95%
confidence interval (CI) 1.41 to 88.49), p=0.022; adjusted for tumour grade and ER
status as confounding factors, adjusted R2: 0.375]. Tumours with a high level of TILs
were more likely to achieve a pCR with NAC (>11 fold increase), when compared
with tumours with a low level of TILs. The logistic regression analysis confirmed
TILs to be a significant independent predictor of a pCR, in both univariate and
multivariate analyses (Table 3.13).
Table 3.13 Univariate and Multivariate (Logistic Regression) Analyses of Predictive
Factors for Pathological Complete Response to NAC(1) in LLABCs(2) (n=33)
(1) NAC: Neoadjuvant chemotherapy; (2) LLABCs: Large and locally advanced breast cancers; (3) OR:
Odds ratio (4) CI: Confidence interval; (5) TILs: Tumour-infiltrating Lymphocytes ; (6) LPBC:
Lymphocyte-predominant breast cancer; (7) ER: Oestrogen receptor; (8) AC-TX: Doxorubicin,
cyclophosphamide, taxotere and Xeloda® (capecitabine), respectively; * Statistically significant; NA:
Not applicable
OR(3) 95% CI(4) P Value OR 95% CI P Value
TILs(5): high (LPBC(6)) versus low 20.22 3.45-118.65 0.001* 11.17 1.41-88.49 0.022*
Age: <50 versus ≥50 0.68 0.17-2.71 0.579 NA NA NA
Tumour size: <40mm versus ≥40mm 1.14 0.29-4.51 0.849 NA NA NA
Tumour grade: 3 versus 1/2 10.4 2.03-53.20 0.005* 2.99 0.33-27.00 0.328
ER(7) status: negative versus positive 4.67 0.96-22.79 0.049* 1.01 0.11-9.63 0.994
HER-2 status: positive versus negative 1.95 0.43-8.83 0.386 NA NA NA
NAC regimen: AC-TX(8) versus AC-T 3.06 0.74-12.63 0.123 NA NA NA
Parameters
Univariate Analysis Multivariate Analysis
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Tumour-infiltrating CD56+ NK cells are an independent predictive factor for a
pCR
In univariate analysis, the immune cell subsets which were significantly associated
with a pCR, have been confirmed to be significant predictors for a pCR with NAC (a
median value of infiltration used as a cut-off point for high and low levels of
infiltration). Among these immune cell subsets, peritumoural tumour-infiltrating
CD56+ NK cells (≥3 cells/5HPFs) appeared to have the highest OR [32.67 (95% CI 
4.71-226.52), p<0.001]. Moreover, only CD56+ NK cell infiltration was an
independent predictor in a multivariate model with a 17.5 fold of estimated effect on
achieving a pCR [OR 17.5 (95% CI 2.06-148.49), p=0.009; adjusted R2: 0.497]. Thus,
tumour-infiltrating CD56+ NK cells are an important subset of TILs and play a key
role in inducing a pCR with NAC (Table 3.14).
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Table 3.14 Univariate and Multivariate (Logistic Regression) Analyses of Predictive
Immunological Parameters for Pathological Complete Response to NAC(1) in
LLABCs(2) (n=33)
(1) NAC: Neoadjuvant chemotherapy; (2) LLABCs: Large and locally advanced breast cancers; (3) OR:
Odds ratio (4) CI: Confidence interval; (5) HPF: High-power field; * Statistically significant; NA: Not
applicable
Note: The median value was used as cut-off point for high and low levels of infiltration. The
intratumoural infiltration was not included in multivariate analysis because it was correlated with
peritumoural infiltration. In a separate multivariate analysis, the parameters CD4+, CD8+ and CD56+
intratumoural infiltration were not statistically significant (data not shown).
Absence of CD44⁺, CD24-/low expression in breast tumours with a pCR (n=16)
Pre-NAC breast tumours that expressed high levels of CD24 had a significantly higher
pCR rate than those that did not [62.5% (5 out of 8) versus 12.5% (1 out of 8),
p=0.039]. In the case of CD44 expression, no significant association was found with
regard to response to NAC. None of the breast tumours (0 out of 4) which expressed
high CD44 and negative/low CD24 concurrently (putative CSCs), demonstrated a
pCR. Conversely, none of the breast cancers which showed a pCR (0 out of 6)
OR(3) 95% CI(4) P Value OR 95% CI P Value
CD4+ Intratumoural Infiltrating: high (≥8.8 
cells/HPF) versus low (<8.8 cells/HPF(5))
10.40 2.03-53.20 0.005* NA NA NA
CD4+ Peritumoural Infiltrating: high (≥17.0 
cells/HPF) versus low (<17.0 cells/HPF)
14.08 2.61-75.77 0.002* 2.56 0.11-59.47 0.558
CD8+ Intratumoural Infiltrating: high (≥19.4 
cells/HPF) versus low (<19.4 cells/HPF)
7.20 1.54-33.56 0.012* NA NA NA
CD8+ Peritumoural Infiltrating: high (≥22.4 
cells/HPF) versus low (<22.4 cells/HPF)
14.08 2.61-75.77 0.002* 2.56 0.11-59.47 0.558
CD56+ Intratumoural Infiltrating: high (≥3.0 
cells/5HPFs) versus low (<3.0 cells/5HPFs)
7.94 1.60-39.42 0.011* NA NA NA
CD56+ Peritumoural Infiltrating: high (≥3.0 
cells/5HPFs) versus low (<3.0 cells/5HPFs)
32.67 4.71-226.52 <0.001* 17.50 2.06-148.49 0.009*
CD163+ Macrophages: high (grade 3 and 4)
versus low (grade 1 and 2)
7.94 1.60-39.42 0.011* 2.49 0.22-28.63 0.462
Parameters
Univariate Analysis Multivariate Analysis
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concurrently expressed high CD44 and negative/low CD24 (Table 4.15). Nonetheless,
when comparing breast cancers with a pCR against breast cancers not showing a pCR,
the difference of expression (CD44⁺, CD24-/low) did not reach statistical significance
(p=0.074) (Table 3.15).
No further significant differences in responses to NAC were found in the analyses of
post-NAC tumours, n=10 (post-NAC tumour specimens with pCR were excluded from
analyses as there was no residual invasive tumour present) (Table 3.16).
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Table 3.15 Association of Pre-NAC(1) CD24 and CD44 Expressions and Pathological
Response to NAC
(1) NAC: Neoadjuvant chemotherapy; * Statistically significant
Low/Negative
Expression (n)
High/ Positive
Expression (n)
Pearson Chi-Square Value
(GPR versus PPR, PCR
versus Non PCR)
P Value
Good Pathological Response
(GPR, n=9) 3 6
Poor Pathological Response
(PPR, n=7)
5 2
Pathological Complete Response
(PCR, n=6)
1 5
Non Pathological Complete Response
(Non PCR, n=10)
7 3
Good Pathological Response
(GPR, n=9)
5 4
Poor Pathological Response
(PPR, n=7)
3 4
Pathological Complete Response
(PCR, n=6)
3 3
Non Pathological Complete Response
(Non PCR, n=10)
5 5
Good Pathological Response
(GPR, n=9)
8 1
Poor Pathological Response
(PPR, n=7)
4 3
Pathological Complete Response
(PCR, n=6)
6 0
Non Pathological Complete Response
(Non PCR, n=10)
6 4
Tumours
(n=16)
Groups
Pre-NAC
CD24+
2.286 0.131
4.267 0.039*
3.200 0.074
0.000 1.000
CD44+, CD24-/ low
2.116 0.146
CD44+
0.254 0.614
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Table 3.16 Association of Post-NAC(1) CD24 and CD44 Expressions and Pathological
Response to NAC
(1) NAC: Neoadjuvant chemotherapy; NA: Not applicable
No effect of NAC on expression of CSCs in breast tumours with non pCR
The changes in the levels of expression of CD24 and CD44 between pre-NAC
tumours and related post-NAC residual tumours (non pCR) were analysed in the non
pCR group (n=10). The expression of CD44 trended to alter [50% (5 out of 10)
changed to high level of expression] in residual tumours present in the post-NAC
specimens (p=0.063). No significant changes in CD44⁺ CD24-/low expression in non
pCR tumours undergoing NAC was documented (p=0.125) (Table 3.17).
Low/Negative
Expression (n)
High/ Positive
Expression (n)
Pearson Chi-Square Value
(GPR versus PPR) P Value
Good Pathological Response
(GPR, n=3)
3 0
Poor Pathological Response
(PPR, n=7)
5 2
Good Pathological Response
(GPR, n=3)
0 3
Poor Pathological Response
(PPR, n=7)
0 7
Good Pathological Response
(GPR, n=3)
0 3
Poor Pathological Response
(PPR, n=7)
2 5
Tumours
(n=10) Groups
Post-NAC
1.071 0.301CD24+
NA NA
1.071 0.301
CD44+
CD44+,CD24-/ low
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Table 3.17 Alteration of CD24 and CD44 Expression in LLABCs(1) Undergoing
NAC(2)
(1) LLABCs: Large and locally advanced breast cancers; (2) NAC: Neoadjuvant chemotherapy; (3)
Related-Samples McNemar Test
Figure 3.15 CD24⁺ tumour cells in the sections of LLABCs, using IHC staining, at 400x magnification.
Briefly, heat-mediated antigen retrieval was performed using citrate buffer, pH 6 (20 mins). The
sections were then incubated with MAbs to CD24 (Abcam, ab31622) at a 1:200 dilution for 16 mins at
RT. Polymeric HRP-linker antibody conjugate was used as secondary antibody. DAB chromogen was
used to visualize the staining. The sections were counterstained with haematoxylin. A: low level of
CD24 expression; B: high level of CD24 expression. The expression was evaluated according to
staining intensity and distribution of the brown membrane and/or cytoplasmic-stained tumour cells. The
Low/Negative
Expression (n)
High/ Positive
Expression (n)
Low/Negative
Expression (n)
6 1
High/ Positive
Expression (n)
2 1
Low/Negative
Expression (n)
0 5
High/ Positive
Expression (n)
0 5
Low/Negative
Expression (n)
2 4
High/ Positive
Expression (n)
0 4
Post-NAC
P Value(3)
(Pre- versus Post-NAC)
CD24+ Pre-NAC 1.000
Groups
Tumours
(n=10)
CD44+ Pre-NAC 0.063
CD44+, CD24-/low Pre-NAC 0.125
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intensity score was determined from 0 (no staining) to 3 (strong staining). The distribution score was
determined as 1 (<30% of tumour cells) and 2 (>30% of tumour cells). The intensity score and
distribution score were multiplied together for a total score, which was 0–1 for negative/low expression
and 2–6 for positive/high expression. Scoring performed on a whole tissue section (7-10 HPFs); Tu:
tumour.
Figure 3.16 CD44⁺ tumour cells in the sections of LLABCs, using IHC staining, at 400x magnification.
Briefly, heat-mediated antigen retrieval was performed using citrate buffer, pH 6 (20 mins). The
sections were then incubated with MAbs to CD44 (Abcam, ab6124) at a concentration of 1.25 µg/ml
for 15 mins at RT. Polymeric HRP-linker antibody conjugate was used as secondary antibody. DAB
chromogen was used to visualize the staining. The sections were counterstained with haematoxylin. A:
low level of CD44 expression; B: high level of CD44 expression. The expression was evaluated
according to staining intensity and distribution of the brown membrane-stained tumour cells. The
intensity score was determined from 0 (no staining) to 3 (strong staining). The distribution score was
determined as 1 (<30% of tumour cells) and 2 (>30% of tumour cells). The intensity score and
distribution score were multiplied together for a total score, which was 0–1 for negative/low expression
and 2–6 for positive/high expression. Scoring performed on a whole tissue section (7-10 HPFs); Tu:
tumour.
3.1.2 The expression of cytokines, IDO, VEGF and PDL1
Expression of the Th1 cytokines (IL-2, IFN-γ) was not associated with a good 
pathological response elicited with NAC (n=16)
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IL-1 (produced by macrophages, B cells and DCs), IL-2 and IFN-γ (produced also by 
CTLs and NK cells) in the tumour specimens were found to be expressed by both
immune cells and tumour cells. The level of IL-1, IL-2 and IFN-γ expression, when 
comparing pCR versus non pCR groups and good versus poor pathological response
groups, showed no significant differences of expression in both pre-NAC and post-
NAC analyses (p>0.05) of tumour specimens (Table 3.18).
High expression of the Th2 cytokine IL-10 was associated with a poor
pathological response to NAC
For the Th2 cytokines (IL-4 and IL-10) and TGF-β (produced by Tregs, TIMs and 
tumour cells), only the expression of IL-10 in post-NAC specimens showed a
significant difference. The significantly higher level of expression of IL-10 was
demonstrated in the poor pathological response group, when compared with the good
pathological response group [100% (7 out of 7) versus 12.5% (1 out of 8), p<0.001]
and in the non pCR group, when compared with the pCR group [70% (7 out of 10)
versus 16.7% (1 out of 6), p=0.039]. TGF-β expression in the post-NAC specimens 
tended to be more prominent in the non pCR group [80% (8 out of 10) versus 33.3%
(2 out of 6), p=0.062] (Table 3.19).
High expression of VEGF was associated with a pCR
Pre-NAC VEGF expression was significantly associated with pCR responses
(p=0.018). 66% of tumours in the pCR group highly expressed VEGF whereas only
10% (1 out of 10) in the non pCR group had high VEGF expression. No significant
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difference of VEGF expression was documented in the post-NAC specimens (Table
3.20).
High expression of IL-17 was associated with poor pathological responses to NAC
Post-NAC IL-17 expression was found to be significantly associated with pathological
response to NAC. Higher levels of expression were found in the poor pathological
response group (p=0.036) and in tumours lacking a pCR (p=0.013). There was no
association demonstrated in the pre-NAC specimens (Table 3.20).
Expression of IDO and PDL1 showed no association with NAC-responses
In the case of IDO and PDL1 expressions, there were no significant differences
between the NAC-response groups in either the pre-NAC and post-NAC analyses
(Table 3.20).
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Table 3.18 Analyses of IL-1, IL-2, and IFN-γ Expression in the Breast Cancer Pre-NAC and Post-NAC(1)
(1) NAC: Neoadjuvant chemotherapy
Low/Negative
Expression (n)
High
Expression (n)
Pearson Chi-Square Value
(GPR versus PPR, PCR
versus Non PCR)
P Value Low/Negative
Expression (n)
High
Expression (n)
Pearson Chi-Square Value
(GPR versus PPR, PCR
versus Non PCR)
P Value
Good Pathological Response
(GPR, n=9)
2 7 4 5
Poor Pathological Response
(PPR, n=7)
3 4 2 5
Pathological Complete Response
(PCR, n=6)
1 5 3 3
Non Pathological Complete Response
(Non PCR, n=10)
4 6 3 7
Good Pathological Response
(GPR, n=9)
3 6 5 4
Poor Pathological Response
(PPR, n=7)
2 5 6 1
Pathological Complete Response
(PCR, n=6)
2 4 3 3
Non Pathological Complete Response
(Non PCR, n=10)
3 7 8 2
Good Pathological Response
(GPR, n=9)
0 9 4 5
Poor Pathological Response
(PPR, n=7)
2 5 2 5
Pathological Complete Response
(PCR, n=6)
0 6 2 4
Non Pathological Complete Response
(Non PCR, n=10)
2 8 4 6
Cytokines
(n=16)
Groups
Pre-NAC Post-NAC
0.950 0.330 0.640 0.424
IL-2
0.042 0.838 1.667 0.197
0.019
IL-1
0.780 0.377 0.423 0.515
0.889 1.571 0.210
IFN-γ
2.939 0.086 0.423 0.515
1.371 0.242 0.71 0.790
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Figure 3.17 IL-1 (A, B), IL-2 (C, D) and IFN-γ (E, F) expression in the sections of LLABCs, using
IHC staining, at 400x magnification. Briefly, heat-mediated antigen retrieval was performed using
citrate buffer, pH 6 (20 mins). The sections were then incubated with MAbs to IL-1 (Abcam, ab8320) at
a 1:150 dilution for overnight at 4˚C, MAbs to IL-2 (Abcam, ab92381) at a 1:500 dilution for 30 mins 
at RT and Polyclonal Abs to IFN-γ (Abcam, ab9657) at a concentration of 4 µg/ml for 30 mins at RT, 
respectively. Polymeric HRP-linker antibody conjugate was used as secondary antibody. DAB
chromogen was used to visualize the staining. The sections were counterstained with haematoxylin. A,
C, E: low level of expression; B, D, F: high level of expression. The H score [% of positive cells
(brown membrane/cytoplasmic-stained tumour and immune cells) x intensity of staining (1 to 3)] was
used to assess the level of expression; low was ≤ 100 and high was > 100. Scoring performed on a 
whole tissue section (7-10 HPFs); Tu: tumour and Ly: lymphocyte.
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Table 3.19 Analyses of IL-4, IL-10 and TGF-β Expression in the Breast Cancer Pre-NAC and Post-NAC(1)
(1) NAC: Neoadjuvant chemotherapy; (2) TGF-β was scored as negative and positive; * Statistically significant 
Low/Negative
Expression (n)
High
Expression (n)
Pearson Chi-Square Value
(GPR versus PPR, PCR
versus Non PCR)
P Value Low/Negative
Expression (n)
High
Expression (n)
Pearson Chi-Square Value
(GPR versus PPR, PCR
versus Non PCR)
P Value
Good Pathological Response
(GPR, n=9) 1 8 6 3
Poor Pathological Response
(PPR, n=7)
1 6 3 4
Pathological Complete Response
(PCR, n=6)
1 5 4 2
Non Pathological Complete Response
(Non PCR, n=10)
1 9 5 5
Good Pathological Response
(GPR, n=9)
3 6 8 1
Poor Pathological Response
(PPR, n=7)
3 4 0 7
Pathological Complete Response
(PCR, n=6)
2 4 5 1
Non Pathological Complete Response
(Non PCR, n=10)
4 6 3 7
Good Pathological Response
(GPR, n=9)
6 3 5 4
Poor Pathological Response
(PPR, n=7)
3 4 1 6
Pathological Complete Response
(PCR, n=6)
4 2 4 2
Non Pathological Complete Response
(Non PCR, n=10)
5 5 2 8
Cytokines
(n=16)
Groups
Pre-NAC Post-NAC
0.152 0.696 0.423 0.515
IL-10
0.152 0.696 12.444 <0.001*
0.071
IL-4
0.036 0.849 0.907 0.341
0.790 4.267 0.039*
TGF-β
(2)
0.907 0.341 2.861 0.091
0.423 0.515 3.484 0.062
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Figure 3.18 IL-4 (A, B) and IL-10 (C, D) expression in the sections of LLABCs, using IHC staining, at
400x magnification. Briefly, heat-mediated antigen retrieval was performed using citrate buffer, pH 6
(20 mins). The sections were then incubated with polyclonal Abs to IL-4 (Abcam, ab9622) at a
concentration of 4 µg/ml for 30 mins at RT, polyclonal Abs to IL-10 (Abcam, ab34843) at a 1:400
dilution for 30 mins at RT. Polymeric HRP-linker antibody conjugate was used as secondary antibody.
DAB chromogen was used to visualize the staining. The sections were counterstained with
haematoxylin. A, C: low level of expression; B, D: high level of expression. The H score [% of positive
cells (brown membrane/cytoplasmic-stained tumour and immune cells) x intensity of staining (1 to 3)]
was used to assess the level of expression; low was ≤ 100 and high was > 100. Scoring performed on a 
whole tissue section (7-10 HPFs); Tu: tumour and Ly: lymphocyte.
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Figure 3.19 TGF-β expression in the sections of LLABCs, using IHC staining, at 400x magnification. 
Briefly, heat-mediated antigen retrieval was performed using citrate buffer, pH 6 (20 mins). The
sections were then incubated with MAbs to TGF-β (Abcam, ab64715) at a concentration of 12 µg/ml 
for overnight at 4˚C. Polymeric HRP-linker antibody conjugate was used as secondary antibody. DAB 
chromogen was used to visualize the staining. The sections were counterstained with haematoxylin. A:
Negative/low level of expression; B: Positive/high level of expression. The H score [% of positive cells
(brown membrane/cytoplasmic-stained tumour and immune cells) x intensity of staining (1 to 3)] was
used to assess the level of expression; low was ≤ 100 and high was > 100. Scoring performed on a 
whole tissue section (7-10 HPFs); Tu: tumour and Ly: lymphocyte.
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Table 3.20 Analyses of VEGF, IDO, IL-17 and PDL1 Expression in the Breast Cancer Pre-NAC and Post-NAC(1)
(1) NAC: Neoadjuvant chemotherapy; * Statistically significant
Low/Negative
Expression (n)
High
Expression (n)
Pearson Chi-Square
Value (GPR versus PPR,
PCR versus Non PCR)
P Value
Low/Negative
Expression (n)
High
Expression (n)
Pearson Chi-Square
Value (GPR versus PPR,
PCR versus Non PCR)
P Value
Good Pathological Res pons e
(GPR, n=9)
5 4 7 2
Poor Pa thological Res pons e
(PPR, n=7)
6 1 4 3
Pathologica l Complete Respons e
(PCR, n=6)
2 4 5 1
Non Pa thological Complete Res ponse
(Non PCR, n=10)
9 1 6 4
Good Pathological Res pons e
(GPR, n=9)
6 3 6 3
Poor Pa thological Res pons e
(PPR, n=7)
5 2 4 3
Pathologica l Complete Respons e
(PCR, n=6)
3 3 4 2
Non Pa thological Complete Res ponse
(Non PCR, n=10)
8 2 6 4
Good Pathological Res pons e
(GPR, n=9)
2 7 6 3
Poor Pa thological Res pons e
(PPR, n=7)
3 4 1 6
Pathologica l Complete Respons e
(PCR, n=6)
2 4 5 1
Non Pa thological Complete Res ponse
(Non PCR, n=10)
3 7 2 8
Good Pathological Res pons e
(GPR, n=9)
3 6 7 2
Poor Pa thological Res pons e
(PPR, n=7)
3 4 4 3
Pathologica l Complete Respons e
(PCR, n=6)
3 3 4 2
Non Pa thological Complete Res ponse
(Non PCR, n=10)
3 7 7 3
Cytokines
(n=16)
Groups
Pre-NAC Post-NAC
VEGF
1.667 0.197 0.780 0.377
5.605 0.018* 0.950 0.330
0.071 0.790
IL-17
0.780 0.377 4.390 0.036*
IDO
0.042 0.838 0.152 0.696
PDL1
0.152 0.696 0.780 0.377
0.640 0.424 0.019 0.889
0.019 0.889 6.112 0.013*
1.571 0.210
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Figure 3.20 VEGF expression in the sections of LLABCs, using IHC staining, at 400x magnification.
Briefly, heat-mediated antigen retrieval was performed using citrate buffer, pH 6 (20 mins). The
sections were then incubated with MAbs to VEGF (Dako, M7273) at a 1:50 dilution for 30 mins at RT.
Polymeric HRP-linker antibody conjugate was used as secondary antibody. DAB chromogen was used
to visualize the staining. The sections were counterstained with haematoxylin. A: low level of
expression; B: high level of expression. The H score [% of positive cells (brown
membrane/cytoplasmic-stained tumour and immune cells) x intensity of staining (1 to 3)] was used to
assess the level of expression; low was ≤ 100 and high was > 100. Scoring performed on a whole tissue 
section (7-10 HPFs); Tu: tumour, Ma: macrophage and Ly: lymphocyte.
Figure 3.21 IDO expression in the sections of LLABCs, using IHC staining, at 400x magnification.
Briefly, heat-mediated antigen retrieval was performed using citrate buffer, pH 6 (20 mins). The
sections were then incubated with MAbs to IDO (Abcam, ab55305) at a concentration of 0.75 µg/ml for
15 mins at RT. Polymeric HRP-linker antibody conjugate was used as secondary antibody. DAB
chromogen was used to visualize the staining. The sections were counterstained with haematoxylin. A:
low level of expression; B: high level of expression. The H score [% of positive cells (brown
membrane/cytoplasmic-stained tumour and immune cells) x intensity of staining (1 to 3)] was used to
assess the level of expression; low was ≤ 100 and high was > 100. Scoring performed on a whole tissue 
section (7-10 HPFs); Tu: tumour, Ma: macrophage and Ly: lymphocyte.
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Figure 3.22 IL-17 expression in the sections of LLABCs, using IHC staining, at 400x magnification.
Briefly, heat-mediated antigen retrieval was performed using citrate buffer, pH 6 (20 mins). The
sections were then incubated with polyclonal Abs to IL-17 (Abcam, ab9565) at a 1:100 dilution for 30
mins at RT. Polymeric HRP-linker antibody conjugate was used as secondary antibody. DAB
chromogen was used to visualize the staining. The sections were counterstained with haematoxylin. A:
low level of expression; B: high level of expression. The H score [% of positive cells (brown
membrane/cytoplasmic-stained tumour and immune cells) x intensity of staining (1 to 3)] was used to
assess the level of expression; low was ≤ 100 and high was > 100. Scoring performed on a whole tissue 
section (7-10 HPFs); Tu: tumour and Ly: lymphocyte.
Figure 3.23 PDL1 expression in the sections of LLABCs, using IHC staining, at 400x magnification.
Briefly, heat-mediated antigen retrieval was performed using citrate buffer, pH 6 (20 mins). The
sections were then incubated with polyclonal Abs to PDL1 (Abcam, ab58810) at a concentration of 2.5
µg/ml for 15 mins at RT. Polymeric HRP-linker antibody conjugate was used as secondary antibody.
DAB chromogen was used to visualize the staining. The sections were counterstained with
haematoxylin. A: low level of expression; B: high level of expression. The expression was graded as
negative/low level of expression when there was no detectable or weak staining (brown
membrane/cytoplasmic-stained tumour and immune cells). High level of expression represented
moderate to strong staining according to the majority of staining intensity throughout a whole tissue
section (7-10 HPFs); Tu: tumour and Ly: lymphocyte.
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NAC reduced IL-4 expression in breast tumours (n=16)
Table 3.21 illustrates the effect of NAC on the alteration of the expression of
cytokines, IDO, VEGF and PDL1 in breast cancers. The expression of IL-4 following
NAC was significantly altered (p=0.016). In 43.8% (7 out of 16) of cases, the level of
expression was altered from high (pre-NAC) to low/negative (post-NAC). In none of
the cases (0 out of 16) was the level of expression altered from low/negative (pre-
NAC) to high (post-NAC). Thus, the level of IL-4 expression in breast tumours was
significantly reduced with NAC.
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Table 3.21 Alteration of Expression of Cytokines, Indoleamine 2,3-dioxygenase
(IDO), Programmed Death Ligand 1 (PDL1) and Vascular Endothelial Growth Factor
(VEGF) in LLABCs(1) Undergoing NAC(2)
(1) LLABCs: Large and locally advanced breast cancers; (2) NAC: Neoadjuvant chemotherapy; (3)
Related-Samples McNemar Test; (4) TGF-β was scored as negative and positive; * Statistically 
significant
Low/Negative
Expression (n)
High
Expression (n)
Low/Negative
Expression (n)
3 2
High
Expression (n)
3 8
Low/Negative
Expression (n)
4 1
High
Expression (n)
7 4
Low/Negative
Expression (n)
0 2
High
Expression (n)
6 8
Low/Negative
Expression (n)
2 0
High
Expression (n)
7 7
Low/Negative
Expression (n)
3 3
High
Expression (n)
5 5
Low/Negative
Expression (n)
4 5
High
Expression (n)
2 5
Low/Negative
Expression (n)
8 3
High
Expression (n)
3 2
Low/Negative
Expression (n)
8 3
High
Expression (n)
2 3
Low/Negative
Expression (n)
3 2
High
Expression (n)
4 7
Low/Negative
Expression (n)
5 1
High
Expression (n)
6 4
Groups
Cytokines
(n=16)
IL-1 Pre-NAC 1.000
Pre-NAC 0.727
TGF-β
(4) Pre-NAC 0.453
VEGF Pre-NAC 1.000
IDO Pre-NAC 1.000
PDL1 Pre-NAC 0.125
IL-17 Pre-NAC 0.688
IL-2 Pre-NAC 0.070
IFN-γ Pre-NAC 0.289
IL-4
Post-NAC
Pre-NAC 0.016*
P Value(3)
IL-10
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3.2 Analyses of Metastatic Tumours in ALNs
High level of TILs was associated with a pCR in tumour-involved ALNs (n=20)
The level of TILs present in tumour nests of metastatic deposits in ALNs were
assessed in pre-NAC ALN biopsies (n=20). High level of TIL infiltration (more than
60% of metastatic tumour nests containing lymphocytes) was found in 55.6% (5 out of
9) cases of metastatic ALNs which subsequently had a pCR with NAC, compared with
9.1% (1 out of 11) of cases in which the metastatic tumours persisted within the nodes
after NAC, (p=0.024) (Table 3.22).
High level of CD163+ TIMs was associated with a pCR in tumour-involved ALNs
High level of CD163+ TIMs in metastatic tumours was found to be significantly
associated with a pCR [100% (9 out of 9) versus 36.4% (4 out of 11), p=0.003] (Table
3.22).
High level of CD4+ and CD8+ T cell and CD56+ NK cell infiltration was associated
with a pCR in tumour-involved ALNs
Table 3.23 shows that a high level of CD4+ (p=0.004) and CD8+ T cell (p=0.001) and
CD56+ NK cell (p=0.010) infiltration in metastatic tumours in ALNs was significantly
associated with a pCR in the metastases. These results resembled the findings in
primary tumours in breast and confirmed the relevancy of these subsets in modifying
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the response to NAC in metastases. No association was found between the levels of
Tregs (FOXP3+, CTLA-4+) and ALN pCR (p>0.05).
Table 3.22 Tumour-infiltrating Lymphocytes (TILs) and CD163+ TIMs in Metastatic
Tumours in ALNs(1) Pre-NAC(2) and Association with a PCR in the ALNs Following
NAC
(1) ALNs: Axillary lymph nodes; (2) NAC: Neoadjuvant chemotherapy; * Statistically significant
Low
Infiltration
(n)
High
Infiltration
(n)
Pearson Chi-Square
Value (PCR versus
Non PCR)
P Value
Pathological Complete Response
(PCR, n=9) 4 5
Non Pathological Complete Response
(Non PCR, n=11) 10 1
Pathological Complete Response
(PCR, n=9) 0 9
Non Pathological Complete Response
(Non PCR, n=11) 7 4
TILs
(n=20)
CD163+
Macrophages
(n=20)
8.811 0.003*
Immune Cell
Subsets
Groups
Pre-NAC
5.089 0.024*
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Table 3.23 Intratumoural Tumour-infiltrating Lymphocyte Subsets in Metastatic
Tumours in ALNs(1) Pre-NAC(2) and Association with Subsequent PCR Following
NAC
(1) ALNs: Axillary lymph nodes; (2) NAC: Neoadjuvant chemotherapy; (3) Average cell count per 400x
high-power field; (4) Mann-Whitney U test; * Statistically significant
Pathological Complete Response
(PCR, n=9) 65.0 (19.4-157.4)
Non Pathological Complete Response
(Non PCR, n=11) 13.2 (0.6-100.8)
Pathological Complete Response
(PCR, n=9) 99.2 (33.2-160.8)
Non Pathological Complete Response
(Non PCR, n=11) 11.6 (0.4-93.0)
Pathological Complete Response
(PCR, n=9) 18.0 (5.0-73.6)
Non Pathological Complete Response
(Non PCR, n=11) 6.4 (1.0-20.4)
Pathological Complete Response
(PCR, n=9) 2.6 (0.4-11.6)
Non Pathological Complete Response
(Non PCR, n=11) 0.8 (0.0-2.2)
Pathological Complete Response
(PCR, n=9) 2.2 (1.0-26.8)
Non Pathological Complete Response
(Non PCR, n=11) 1.0 (0.0-2.2)
CD56+ NK cells 0.010*
P Value(4)
(PCR versus Non PCR)
Tumour Infiltration
Median (range)(3)
CD8+ T cells 0.001*
FOXP3+ Tregs 0.152
CTLA-4+ Tregs 0.112
Immune Cell
Subsets (n=20) Groups
CD4+ T cells 0.004*
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Figure 3.24 Summary of the median numbers of tumour-infiltrating lymphocyte subsets in pre-NAC
metastatic tumours in ALNs and subsequent pCR and non pCR following NAC
Higher levels of tumour-infiltrating Tregs (FOXP3+, CTLA-4+) in ALN
metastases than in corresponding primary breast tumours (n=20)
The levels of TILs, TIMs and intratumoural tumour-infiltrating lymphocyte subsets
present in primary breast tumours were compared with their corresponding ipsilateral
ALN metastases (n=20). The levels of TILs, TIMs, CD4+ and CD8+ T cell subsets
remained unchanged in the ALN metastases (p>0.05). There were, however,
significantly higher levels of tumour-infiltrating Tregs (FOXP3+, CTLA-4+) in ALN
metastases. The median number of tumour-infiltrating FOXP3+ Tregs in metastatic
tumours was 7.2 (1.0-73.6) cells/HPF compared with 5.5 (0.4-96.8) cells/HPF in the
corresponding primary tumours (p=0.026). The median number of tumour-infiltrating
CTLA-4+ Tregs in metastatic tumours was 0.8 (0-11.6) cells/HPF compared with 0.4
178
(0-2.2) cells/HPF in the corresponding primary tumours (p=0.036). Higher Treg
infiltrations in ALN metastases may reflect a greater immunosuppression in the
microenvironment of metastatic ALN tumours, compared with the primary tumour
bed. The CD8⁺ T cell: FOXP3⁺ Treg ratio, however, was not significantly different
between the primary and metastatic tumours (p=0.167). The median number of
tumour-infiltrating CD56+ NK cells was also significantly increased in metastatic
tumours, compared with primary tumours [1.5 (0-26.8) versus 0.8 (0-3.2), p=0.006]
(Table 3.24 and 3.25).
Table 3.24 Comparison of Tumour-infiltrating Lymphocytes (TILs) and CD163+
Macrophages Between Primary Breast Tumours and Metastatic Tumours in Women
with LLABCs(1)
(1) LLABCs: Large and locally advanced breast cancers; (2) ALNs: Axillary lymph nodes; (3) Related-
Samples McNemar Test
Low
Infiltration (n)
High
Infiltration (n)
Low
Infiltration (n)
11 2
High
Infiltration (n)
3 4
Low
Infiltration (n)
6 2
High
Infiltration (n)
1 11
Metastatic Tumours in ALNs(2) P Value(3)
(Primary versus
Metastases)
Primary
Tumours
in Breast
1.000
Groups
CD163+
Macrophages
Primary
Tumours
in Breast
1.000
TILs
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Table 3.25 Comparison of Intratumoural Tumour-infiltrating Immune Cell Subsets
Between Primary Breast Tumours and Metastatic Tumours in Women with LLABCs(1)
(1) LLABCs: Large and locally advanced breast cancers; (2) ALNs: Axillary lymph nodes; (3) Average cell
count per 400x high-power field; (4) Wilcoxon signed rank test; * Statistically significant
Figure 3.25 Summary of the median numbers of tumour-infiltrating lymphocyte subsets between
primary and metastatic tumours; ALNs: Axillary lymph nodes
Immune Cell
Subsets (n=20)
Primary Tumours in Breast
Median (Range)(3)
Metastatic Tumours in ALNs(2)
Median (Range)(3)
P Value(4)
(Primary versus
Metastases)
CD4+ T cells 12.8 (0.6-166.2) 26.1 (0.6-157.4) 0.313
CD8+ T cells 27.4 (0.4-112.6) 37.1 (0.4-160.8) 0.117
FOXP3+ Tregs 5.5 (0.4-96.8) 7.2 (1.0-73.6) 0.026*
CTLA-4+ Tregs 0.4 (0.0-2.2) 0.8 (0.0-11.6) 0.036*
CD56+ NK cells 0.8 (0.0-3.2) 1.5 (0.0-26.8) 0.006*
CD8/FOXP3 ratio 3.91 (0.18-45.00) 3.29 (0.40-21.92) 0.167
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CD8+ T cells and CD56+ NK cells showed a positive correlation between primary
and metastatic tumours
Table 3.26 shows the correlations between specific immune cell infiltrates in primary
breast tumours and ALN metastatic tumours. CD8+ T cells and CD56+ NK cells were
documented to have a positive correlation (p=0.020 and <0.001, respectively).
Increased infiltration of CD8+ T cells and CD56+ NK cells in the tumour
microenvironment of primary tumours had a concordant increase of these infiltrates in
ipsilateral ALN metastatic tumours.
Table 3.26 Correlations of Tumour-infiltrating Lymphocyte Subsets Between Primary
Breast Tumours and Metastatic Tumours in Women with LLABCs(1) [Spearman's
Correlation Coefficient (rho)] (n=20)
(1) LLABCs: Large and locally advanced breast cancers; (2) ALNs: Axillary lymph nodes; (3) NA: Not
applicable; * Statistically significant
CD4+ T
cells
CD8+ T
cells
FOXP3+
Tregs
CTLA-4+
Tregs
CD56+ NK
cells
CD4+ T cells
Correlation Coefficient 0.061 NA NA NA NA
P Value (2-tailed) 0.797 NA NA NA NA
CD8+ T cells
Correlation Coefficient NA 0.514 NA NA NA
P Value (2-tailed) NA 0.020* NA NA NA
FOXP3+ Tregs
Correlation Coefficient NA NA 0.390 NA NA
P Value (2-tailed) NA NA 0.089 NA NA
CTLA-4+ Tregs
Correlation Coefficient NA NA NA 0.246 NA
P Value (2-tailed) NA NA NA 0.296 NA
CD56+ NK cells
Correlation Coefficient NA NA NA NA 0.721
P Value (2-tailed) NA NA NA NA <0.001*
Primary
Tumours
in Breast
Groups
Metastatic Tumours in ALNs(2)
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Figure 3.26 FOXP3+ Tregs in the section of metastatic tumour in axillary lymph node, using IHC
staining, at 100x (A), 200x (B) and 400x (C) magnifications. Briefly, heat-mediated antigen retrieval
was performed using citrate buffer, pH 6 (20 mins). The section was then incubated with MAbs to
FOXP3 (Abcam, ab20034) at a concentration of 20 µg/ml for 30 mins at RT. Polymeric HRP-linker
antibody conjugate was used as secondary antibody. DAB chromogen was used to visualize the
staining. The section was counterstained with haematoxylin. The average number of brown nuclear-
stained cells, regardless of intensity, in contact with metastatic tumour cells or within metastatic tumour
cell nests per HPF was counted. MTu: Metastatic tumour; LN: Lymphoid tissue.
Figure 3.27 CD8⁺ T cells (A) and CD56⁺ NK cells (B) in the sections of metastatic tumour in axillary
lymph node, using IHC staining, at 200x magnification. Briefly, heat-mediated antigen retrieval was
performed using citrate buffer, pH 6 (20 mins). The sections were then incubated with MAbs to CD8
(Dako, M7103) at a 1:100 dilution for 30 mins at RT, MAbs to CD56 (Dako, M7304) at a 1:50 dilution
for 30 mins at RT. Polymeric HRP-linker antibody conjugate was used as secondary antibody. DAB
chromogen was used to visualize the staining. The sections were counterstained with haematoxylin. The
average number of brown membrane-stained cells, regardless of intensity, in contact with metastatic
tumour cells or within metastatic tumour cell nests per HPF was counted. MTu: Metastatic tumour; LN:
Lymphoid tissue.
182
3.3 Analyses of ALN Parenchyma
The assessments of various immune cell subsets and expression of cytokines and
biological molecules (IDO, VEGF, PDL1) present in post-NAC tumour-draining
ALNs (lymph node parenchyma), comparing non-metastatic versus metastatic ALNs
(n=33) and metastatic ALNs with pCRs versus metastatic ALNs with non pCRs
(n=24), were carried out.
3.3.1 Immune cell components in ALNs
No differences in immune cell components were found between metastatic and
non-metastatic ALNs
There were no significant differences in the percentage/average number of positively
stained immune cell subsets between metastatic and non-metastatic ALNs. CD4+ and
CD8+ T lymphocytes and FOXP3+ Tregs were prominent immune cells in the para-
cortical area of ALNs. CD68+ and CD163+ macrophages were prominent immune cells
in the medullary area of ALNs. The levels (%) of these subsets present in tumour-free
areas of metastatic and non-metastatic ALNs were similar (p>0.05) (Table 3.27).
CTLA-4+ Tregs, CD56+ NK cells, CD1a+ DCs, PDI+ T cell and CD66b+ PMNs were
much less prominent and found scattered in the para-cortical area of ALNs. The levels
(average cell count/HPF of the highest accumulation) of these minor subsets were also
comparable between metastatic and non-metastatic ALNs (P>0.05) (Table 3.28).
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Table 3.27 Analysis of the Major Immune Cell Subsets in ALNs(1) in Women with
LLABCs(2) Undergoing NAC(3): Comparison of Metastatic and Non-metastatic ALNs
(1) ALNs: Axillary lymph nodes; (2) LLABCs: Large and locally advanced breast cancers; (3) NAC:
Neoadjuvant chemotherapy; (4) Average percentage of positively stained cells out of all the lymphoid
cells in the ALN sections examined; (5) Mann-Whitney U test; (6) Tumour-free areas examined
Figure 3.28 Summary of the median % of major immune cell subsets in metastatic (tumour-free areas)
and non-metastatic ALNs
Immune Cell Subsets Groups
ALN
Median (Range)(4)
P Value(5)
Non-metastatic ALNs (n=9) 63.0 (43.0-74.0)
Metastatic ALNs (n=24)(6) 68.0 (32.0-75.0)
Non-metastatic ALNs (n=9) 26.0 (15.4-34.0)
Metastatic ALNs (n=24) 20.5 (10.4-40.0)
Non-metastatic ALNs (n=9) 4.4 (2.9-8.6)
Metastatic ALNs (n=24) 4.6 (0.2-10.8)
Non-metastatic ALNs (n=9) 25.0 (14.8-34.0)
Metastatic ALNs (n=7) 29.0 (13.8-33.0)
Non-metastatic ALNs (n=9) 21.0 (16.0-29.0)
Metastatic ALNs (n=24) 23.0 (10.0-33.0)
FOXP3+ Tregs (n=33) 0.736
CD4+ T cells (n=33) 0.796
CD8+ T cells (n=33) 0.121
CD68+ Macrophages (n=16) 0.918
CD163+ Macrophages (n=33) 1.000
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Figure 3.29 CD4⁺ T cells in the sections of axillary lymph nodes (ALNs), using IHC staining, at 400x
magnification. Briefly, heat-mediated antigen retrieval was performed using citrate buffer, pH 6 (20
mins). The sections were then incubated with MAbs to CD4 (Dako, M7310) at a 1:80 dilution for 30
mins at RT. Polymeric HRP-linker antibody conjugate was used as secondary antibody. DAB
chromogen was used to visualize the staining. The sections were counterstained with haematoxylin. A:
low percentage of CD4⁺ T cells; B: high percentage of CD4⁺ T cells. The positive brown membrane-
stained cells in tumour-free para-cortical areas of ALNs were quantified as the average % of all cells (5
HPFs).
Figure 3.30 CD8⁺ T cells in the sections of axillary lymph nodes (ALNs), using IHC staining, at 400x
magnification. Briefly, heat-mediated antigen retrieval was performed using citrate buffer, pH 6 (20
mins). The sections were then incubated with MAbs to CD8 (Dako, M7103) at a 1:100 dilution for 30
mins at RT. Polymeric HRP-linker antibody conjugate was used as secondary antibody. DAB
chromogen was used to visualize the staining. The sections were counterstained with haematoxylin. A:
low percentage of CD8⁺ T cells; B: high percentage of CD8⁺ T cells. The positive brown membrane-
stained cells in tumour-free para-cortical areas of ALNs were quantified as the average % of all cells (5
HPFs).
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Figure 3.31 FOXP3⁺ Tregs in the sections of axillary lymph nodes (ALNs), using IHC staining, at 400x
magnification. Briefly, heat-mediated antigen retrieval was performed using citrate buffer, pH 6 (20
mins). The sections were then incubated with MAbs to FOXP3 (Abcam, ab20034) at a concentration of
20 µg/ml for 30 mins at RT. Polymeric HRP-linker antibody conjugate was used as secondary antibody.
DAB chromogen was used to visualize the staining. The sections were counterstained with
haematoxylin. A: low percentage of FOXP3⁺ Tregs; B: high percentage of FOXP3⁺ Tregs. The positive
brown nuclear-stained cells in tumour-free para-cortical areas of ALNs were quantified as the average
% of all cells (5 HPFs).
Figure 3.32 CD68⁺ macrophages in the sections of axillary lymph nodes (ALNs), using IHC staining, at
400x magnification. Briefly, heat-mediated antigen retrieval was performed using citrate, buffer pH 6
(20 mins). The sections were then incubated with MAbs to CD68 (Abcam, ab955) at a 1:300 dilution
for 30 mins at RT. Polymeric HRP-linker antibody conjugate was used as secondary antibody. DAB
chromogen was used to visualize the staining. The sections were counterstained with haematoxylin. A:
low percentage of CD68+ macrophages; B: high percentage of CD68⁺ macrophages. The positive brown
membrane-stained cells in tumour-free medullary areas of ALNs were quantified as the average % of all
cells (5 HPFs).
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Figure 3.33 CD163⁺ macrophages in the sections of axillary lymph nodes (ALNs), using IHC staining,
at 400x magnification. Briefly, heat-mediated antigen retrieval was performed using citrate buffer, pH 6
(20 mins). The sections were then incubated with MAbs to CD163 (Abcam, ab74604) at a pre-diluted
concentration for 30 mins at RT. Polymeric HRP-linker antibody conjugate was used as secondary
antibody. DAB chromogen was used to visualize the staining. The sections were counterstained with
haematoxylin. A: low percentage of CD163⁺ macrophages; B: high percentage of CD163⁺
macrophages. The positive brown membrane-stained cells in tumour-free medullary areas of ALNs
were quantified as the average % of all cells (5 HPFs).
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Table 3.28 Analysis of the Less Prominent Immune Cell Subsets in ALNs(1) in
Women with LLABCs(2) Undergoing NAC(3): Comparison of Metastatic and Non-
metastatic ALNs
(1) ALNs: Axillary lymph nodes; (2) LLABCs: Large and locally advanced breast cancers; (3) NAC:
Neoadjuvant chemotherapy; (4) Average cell count of positively stained cells per 400x High-power field
in the ALN sections examined; (5) Mann-Whitney U test; (6) Tumour-free areas examined; (7) PMNs:
Polymorphonuclear leukocytes
Figure 3.34 Summary of the median numbers (average cell count) of minor immune cell subsets
between metastatic and non-metastatic ALNs
Immune Cell Subsets Groups
ALN
Median (Range)(4)
P Value(5)
Non-metastatic ALNs (n=9) 16.8 (5.2-100.4)
Metastatic ALNs (n=24) (6) 11.0 (0.6-38.6)
Non-metastatic ALNs (n=9) 17.8 (15.8-52.8)
Metastatic ALNs (n=24) 18.3 (2.2-60.4)
Non-metastatic ALNs (n=9) 12.8 (0.8-62.0)
Metastatic ALNs (n=7) 23.8 (6.6-67.0)
Non-metastatic ALNs (n=9) 6.4 (1.4-36.0)
Metastatic ALNs (n=7) 12.6 (2.0-72.6)
Non-metastatic ALNs (n=9) 5.2 (0.6-94.0)
Metastatic ALNs (n=7) 8.4 (1.0-163.0)
CD1a+ DCs (n=16) 0.536
CTLA-4+ Tregs (n=33) 0.193
CD56+ NK cells (n=33) 0.437
PD1+ T cells (n=16) 0.408
CD66b+ PMNs(7) (n=16) 0.837
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Figure 3.35 CTLA-4⁺ Tregs in the sections of axillary lymph nodes (ALNs), using IHC staining, at
400x magnification. Briefly, heat-mediated antigen retrieval was performed using citrate buffer, pH 6
(20 mins). The sections were then incubated with MAbs to CTLA-4 (Santa Cruz Bio, sc-376016) at a
1:200 dilution for 30 mins at RT. Polymeric HRP-linker antibody conjugate was used as secondary
antibody. DAB chromogen was used to visualize the staining. The sections were counterstained with
haematoxylin. A: low number of CTLA-4⁺ Tregs; B: high number of CTLA-4⁺ Tregs. The average
number of cell counts per HPF in tumour-free para-cortical areas of ALNs with the greatest
accumulation of the positive brown membrane-stained cells was quantified.
Figure 3.36 CD56⁺ NK cells in the sections of axillary lymph nodes (ALNs), using IHC staining, at
400x magnification. Briefly, heat-mediated antigen retrieval was performed using citrate buffer, pH 6
(20 mins). The sections were then incubated with MAbs to CD56 (Dako, M7304) at a 1:50 dilution for
30 mins at RT. Polymeric HRP-linker antibody conjugate was used as secondary antibody. DAB
chromogen was used to visualize the staining. The sections were counterstained with haematoxylin. A:
low number of CD56⁺ NK cells; B: high number of CD56⁺ NK cells. The average number of cell counts
per HPF in tumour-free para-cortical areas of ALNs with the greatest accumulation of the positive
brown membrane-stained cells was quantified.
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Figure 3.37 CD1a⁺ DCs in the sections of axillary lymph nodes (ALNs), using IHC staining, at 400x
magnification. Briefly, heat-mediated antigen retrieval was performed using citrate buffer, pH 6 (20
mins). The sections were then incubated with MAbs to CD1a (Dako, M3571) at a 1:200 dilution for 15
mins at RT. Polymeric HRP-linker antibody conjugate was used as secondary antibody. DAB
chromogen was used to visualize the staining. The sections were counterstained with haematoxylin. A:
low number of CD1a⁺ DCs; B: high number of CD1a⁺ DCs. The average number of cell counts per HPF
in tumour-free para-cortical areas of ALNs with the greatest accumulation of the positive brown
membrane-stained cells was quantified.
Figure 3.38 PD1⁺ T cells in the sections of axillary lymph nodes (ALNs), using IHC staining, at 400x
magnification. Briefly, heat-mediated antigen retrieval was performed using citrate buffer, pH 6 (20
mins). The sections were then incubated with MAbs to PD1 (Abcam, ab52587) at a 1:100 dilution for
30 mins at RT. Polymeric HRP-linker antibody conjugate was used as secondary antibody. DAB
chromogen was used to visualize the staining. The sections were counterstained with haematoxylin. A:
low number of PD1⁺ T cells; B: high number of PD1⁺ T cells. The average number of cell counts per
HPF in tumour-free para-cortical areas of ALNs with the greatest accumulation of the positive brown
membrane-stained cells was quantified.
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Figure 3.39 CD66b⁺ PMNs in the sections of axillary lymph nodes (ALNs), using IHC staining, at
400x magnification. Briefly, heat-mediated antigen retrieval was performed using citrate buffer, pH 6
(20 mins). The sections were then incubated with MAbs to CD66b (LS Bio, LS-B7134) at a
concentration of 10 µg/ml for 30 mins at RT. Polymeric HRP-linker antibody conjugate was used as
secondary antibody. DAB chromogen was used to visualize the staining. The sections were
counterstained with haematoxylin. A: low number of CD66b⁺ PMNs; B: high number of CD66b⁺
PMNs. The average number of cell counts per HPF in tumour-free para-cortical areas of ALNs with the
greatest accumulation of the positive brown membrane-stained cells was quantified.
Metastatic ALNs with high CD8+ T cell and low FOXP3+ Treg components were
significantly associated with a pCR (n=24)
The significantly higher % of CD8+ T cells [27% (13.4-40) versus 19.5% (10.4-30),
p=0.048] and significantly lower % of FOXP3+ Tregs [3.1% (0.2-6.9) versus 6.5%
(1.7-10.8), p=0.019] in the para-cortical areas (tumour-free) of ALNs were found to be
significantly associated with a pCR in the metastatic deposits following NAC. No
significant association was found for CD4+ T cells, CTLA-4+ Tregs, CD56+ NK cells
and CD163+ macrophages (p>0.05) (Table 3.29).
191
Table 3.29 Analyses of Immune Cell Subsets in Metastatic ALNs(1) in Women with
LLABCs(2) Undergoing NAC(3): Comparing Metastatic ALNs with PCRs and Non
pCRs
(1) ALNs: Axillary lymph nodes; (2) LLABCs: Large and locally advanced breast cancers; (3) NAC:
Neoadjuvant chemotherapy; (4) Average percentage of positively stained cells out of all the lymphoid
cells in the ALN sections (CD4+ and CD8+ T cells, FOXP3+ Tregs and CD163+ macrophages); (5) Mann-
Whitney U test; (6) Average cell count of positive stained cells per 400x high-power field in the ALN
sections (CTLA-4+ Tregs and CD56+ NK cells); * Statistically significant
Immune Cell Subsets
(n=24)
Groups
ALN
Median (Range)(4)
P Value(5)
Pathological Complete Response
(PCR, n=10) 61.0 (32.0-75.0)
Non Pathological Complete Response
(Non PCR, n=14) 69.0 (36.0-74.0)
Pathological Complete Response
(PCR, n=10) 27.0 (13.4-40.0)
Non Pathological Complete Response
(Non PCR, n=14) 19.5 (10.4-30.0)
Pathological Complete Response
(PCR, n=10) 3.1 (0.2-6.9)
Non Pathological Complete Response
(Non PCR, n=14) 6.5 (1.7-10.8)
Pathological Complete Response
(PCR, n=10) 24.0 (10.0-33.0)
Non Pathological Complete Response
(Non PCR, n=14) 22.5 (14.4-33.0)
Immune Cell Subsets
(n=24)
Groups
ALN
Median (Range)(6)
P Value(5)
Pathological Complete Response
(PCR, n=10) 5.7 (0.6-29.6)
Non Pathological Complete Response
(Non PCR, n=14) 11.2 (3.2-38.6)
Pathological Complete Response
(PCR, n=10) 19.7 (2.2-60.4)
Non Pathological Complete Response
(Non PCR, n=14) 15.9 (6.8-39.0)
FOXP3+ Tregs 0.019*
CD4+ T cells 0.172
CD8+ T cells 0.048*
CTLA-4+ Tregs 0.341
CD163+ Macrophages 0.796
CD56+ NK cells 0.472
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Figure 3.40 Summary of the median % of major immune cell subsets between metastatic axillary lymph
nodes (ALNs) with pCR and non pCR
High % of CD8⁺ T cell: % of FOXP3⁺ Treg ratio in ALN para-cortical areas was
associated with a pCR in tumour-involved ALNs
The ratio of CD8⁺ T cell: FOXP3⁺ Treg infiltrates in primary tumours was
significantly higher in breast cancers subsequently showing a pCR post-NAC
(previously presented in Table 3.6). This ratio in ALN metastatic tumours was also
higher in the pCR group but did not reach statistical significance (5.87 versus 1.93,
p=0.08) (Table 3.30). High % of CD8⁺ T cell: % of FOXP3⁺ Treg ratio in the para-
cortical areas of ALNs was significantly associated with a pCR in tumour deposits in
metastatic ALNs. A median ratio of 7.24 was found in metastatic ALNs with a pCR
compared with 3.19 in metastatic ALNs with a non pCR (p=0.006).
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Table 3.30 The Association between CD8+ T Cell: FOXP3+ Treg Ratio and
Pathological Complete Response (pCR) to Neoadjuvant Chemotherapy
(1) CD8:FOXP3 ratio in primary and metastatic tumours; the ratio was calculated from the level of
tumour-infiltrating CD8⁺ T cells and tumour-infiltrating FOXP3⁺ Tregs (intratumourally). In ALNs, the
ratio was calculated from the % of CD8⁺ T cells and % of FOXP3⁺ Tregs present in ALN (tumour-free
areas) parenchyma; (2) Mann-Whitney U test; (3) ALN: Axillary lymph node; * Statistically significant
3.3.2 Expression of cytokines and biological molecules in ALNs
Th1, Th2 and Th17 cytokines, IDO, PDL1, TGF-β, IL-1 and VEGF were studied in 
post-NAC ALNs and the levels of expression between metastatic and non-metastatic
ALNs were compared (n=16).
ALNs with no metastases expressed high levels of the Th1 cytokines IL-2 and
IFN-γ (n=16) 
Significantly higher levels of IL-2 and IFN-γ expressions were found in post-NAC 
non-metastatic ALNs [88.9% (8 out of 9) versus 14.3% (1 out of 7), p=0.003 and
72.8% (8 out of 11) versus 20% (1 out of 5), p=0.049, respectively], compared with
metastatic ALNs (Table 3.31).
Sites Groups Median (Range)(1) P Value
(2)
(PCR versus Non PCR)
Tumours with PCR 7.40 (0.27-45.00)
Tumours with Non pCR 1.48 (0.18-6.04)
Metastatic tumours with PCR 5.87 (1.35-21.92)
Metastatic tumours with Non pCR 1.93 (0.40-7.20)
ALNs with PCR 7.24 (3.33-75.00)
ALNs with Non pCR 3.19 (1.78-8.00)
0.006*
Primary breast tumours, n=33
(CD8ЀdĐĞůů͗&K yWϯЀdƌĞŐƌĂƟŽͿ
Metastatic tumours, n=20
;ϴЀdĐĞůů͗&K yWϯЀdƌĞŐƌĂƟŽͿ
ALNs (3) with metastases, n=24
(%CD8⁺ T cell : %FOXP3ЀdƌĞŐƌĂƟŽͿ
0.002*
0.080
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ALNs with metastases expressed high levels of the Th2 cytokine IL-10 (n=16)
By contrast, IL-10 showed a significantly higher expression in post-NAC metastatic
ALNs [71.4% (5 out of 7) versus 22.2% (2 out of 9), p=0.049]. There were no
significant differences in the levels of expression of IL-1, IL-17, IDO, TGF-β, PDL1 
and VEGF between metastatic and non-metastatic ALNs following NAC (p>0.05)
(Table 3.31).
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Table 3.31 Expression of Cytokines, Indoleamine 2,3-dioxygenase (IDO),
Programmed Death Ligand 1 (PDL1) and Vascular Endothelial Growth Factor (VEGF)
in ALNs(1) in Women with LLABCs(2) Following NAC(3)
(1) ALNs: Axillary lymph nodes; (2) LLABCs: Large and locally advanced breast cancers; (3) NAC:
Neoadjuvant chemotherapy; (4) IDO and TGF-β were scored as negative and positive; * Statistically 
significant
Cytokines
(n=16) Groups
Low/Negative
Expression (n)
High
Expression (n)
Pearson Chi-
Square Value P Value
Non-metastatic ALN (n=9) 3 6
Metastatic ALN (n=7) 2 5
Non-metastatic ALN (n=9) 1 8
Metastatic ALN (n=7) 6 1
Non-metastatic ALN (n=9) 3 6
Metastatic ALN (n=7) 3 4
Non-metastatic ALN (n=9) 7 2
Metastatic ALN (n=7) 2 5
Non-metastatic ALN (n=9) 1 8
Metastatic ALN (n=7) 3 4
Non-metastatic ALN (n=9) 2 7
Metastatic ALN (n=7) 4 3
Non-metastatic ALN (n=9) 7 2
Metastatic ALN (n=7) 5 2
Non-metastatic ALN (n=9) 1 8
Metastatic ALN (n=7) 4 3
Non-metastatic ALN (n=9) 5 4
Metastatic ALN (n=7) 5 2
Non-metastatic ALN (n=9) 6 3
Metastatic ALN (n=7) 6 1
IL-1 0.042 0.838
IL-2 8.905 0.003*
IL-4 0.152 0.696
IL-10 3.874 0.049*
IL-17 2.116 0.146
IDO(4) 2.049 0.152
PDL1 0.085 0.771
IFN-γ 3.883  0.049*
TGF-β
(4) 0.423 0.515
VEGF 0.762 0.383
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Figure 3.41 IL-1 expression in the sections of axillary lymph nodes (ALNs), using IHC staining, at
400x magnification. Briefly, heat-mediated antigen retrieval was performed using citrate buffer, pH 6
(20 mins). The sections were then incubated with MAbs to IL-1 (Abcam, ab8320) at a 1:150 dilution for
overnight at 4˚C. Polymeric HRP-linker antibody conjugate was used as secondary antibody. DAB 
chromogen was used to visualize the staining. The sections were counterstained with haematoxylin. A:
low level of IL-1 expression; B: high level of IL-1 expression. The H score [% of positive cells (brown
membrane/cytoplasmic-stained cells) x intensity of staining (1 to 3)] was used to assess the level of
expression; low was ≤ 100 and high was > 100. Scoring performed on non-metastatic areas of a whole 
ALN section (7-10 HPFs).
Figure 3.42 IL-2 expression in the sections of axillary lymph nodes (ALNs), using IHC staining, at
400x magnification. Briefly, heat-mediated antigen retrieval was performed using citrate buffer, pH 6
(20 mins). The sections were then incubated with MAbs to IL-2 (Abcam, ab92381) at a 1:500 dilution
for 30 mins at RT. Polymeric HRP-linker antibody conjugate was used as secondary antibody. DAB
chromogen was used to visualize the staining. The sections were counterstained with haematoxylin. A:
low level of IL-2 expression; B: high level of IL-2 expression. The H score [% of positive cells (brown
membrane/cytoplasmic-stained cells) x intensity of staining (1 to 3)] was used to assess the level of
expression; low was ≤ 100 and high was > 100. Scoring performed on non-metastatic areas of a whole 
ALN section (7-10 HPFs).
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Figure 3.43 IL-4 expression in the sections of axillary lymph nodes (ALNs), using IHC staining, at
400x magnification. Briefly, heat-mediated antigen retrieval was performed using citrate buffer, pH 6
(20 mins). The sections were then incubated with polyclonal Abs to IL-4 (Abcam, ab9622) at a
concentration of 4 µg/ml for 30 mins at RT. Polymeric HRP-linker antibody conjugate was used as
secondary antibody. DAB chromogen was used to visualize the staining. The sections were
counterstained with haematoxylin. A: low level of IL-4 expression; B: high level of IL-4 expression.
The H score [% of positive cells (brown membrane/cytoplasmic-stained cells) x intensity of staining (1
to 3)] was used to assess the level of expression; low was ≤ 100 and high was > 100. Scoring performed 
on non-metastatic areas of a whole ALN section (7-10 HPFs).
Figure 3.44 IL-10 expression in the sections of axillary lymph nodes (ALNs), using IHC staining, at
400x magnification. Briefly, heat-mediated antigen retrieval was performed using citrate buffer, pH 6
(20 mins). The sections were then incubated with polyclonal Abs to IL-10 (Abcam, ab34843) at a 1:400
dilution for 30 mins at RT. Polymeric HRP-linker antibody conjugate was used as secondary antibody.
DAB chromogen was used to visualize the staining. The sections were counterstained with
haematoxylin. A: low level of IL-10 expression; B: high level of IL-10 expression. The H score [% of
positive cells (brown membrane/cytoplasmic-stained cells) x intensity of staining (1 to 3)] was used to
assess the level of expression; low was ≤ 100 and high was > 100. Scoring performed on non-metastatic 
areas of a whole ALN section (7-10 HPFs).
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Figure 3.45 IL-17 expression in the sections of axillary lymph nodes (ALNs), using IHC staining, at
400x magnification. Briefly, heat-mediated antigen retrieval was performed using citrate buffer, pH 6
(20 mins). The sections were then incubated with polyclonal Abs to IL-17 (Abcam, ab9565) at a 1:100
dilution for 30 mins at RT. Polymeric HRP-linker antibody conjugate was used as secondary antibody.
DAB chromogen was used to visualize the staining. The sections were counterstained with
haematoxylin. A: low level of IL-17 expression; B: high level of IL-17 expression. The H score [% of
positive cells (brown membrane/cytoplasmic-stained cells) x intensity of staining (1 to 3)] was used to
assess the level of expression; low was ≤ 100 and high was > 100. Scoring performed on non-metastatic 
areas of a whole ALN section (7-10 HPFs).
Figure 3.46 IDO expression in the sections of axillary lymph nodes (ALNs), using IHC staining, at
400x magnification. Briefly, heat-mediated antigen retrieval was performed using citrate buffer, pH 6
(20 mins). The sections were then incubated with MAbs to IDO (Abcam, ab55305) at a concentration of
0.75 µg/ml for 15 mins at RT. Polymeric HRP-linker antibody conjugate was used as secondary
antibody. DAB chromogen was used to visualize the staining. The sections were counterstained with
haematoxylin. A: low level of IDO expression; B: high level of IDO expression. The H score [% of
positive cells (brown membrane/cytoplasmic-stained cells) x intensity of staining (1 to 3)] was used to
assess the level of expression; low was ≤ 100 and high was > 100. Scoring performed on non-metastatic 
areas of a whole ALN section (7-10 HPFs).
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Figure 3.47 PDL1 expression in the sections of axillary lymph nodes (ALNs), using IHC staining, at
400x magnification. Briefly, heat-mediated antigen retrieval was performed using citrate buffer, pH 6
(20 mins). The sections were then incubated with polyclonal Abs to PDL1 (Abcam, ab58810) at a
concentration of 2.5 µg/ml for 15 mins at RT. Polymeric HRP-linker antibody conjugate was used as
secondary antibody. DAB chromogen was used to visualize the staining. The sections were
counterstained with haematoxylin. A: low level of PDL1 expression; B: high level of PDL1 expression.
PDL1 expression was scored as negative/low (no detectable or weak brown membrane/cytoplasmic
staining) and high (moderate to strong staining). The staining grade was defined according to the
majority of the staining intensity in non-metastatic areas throughout an ALN section (7-10 HPFs).
Figure 3.48 IFN-γ expression in the sections of axillary lymph nodes (ALNs), using IHC staining, at 
400x magnification. Briefly, heat-mediated antigen retrieval was performed using citrate buffer, pH 6
(20 mins). The sections were then incubated with polyclonal Abs to IFN-γ (Abcam, ab9657) at a 
concentration of 4 µg/ml for 30 mins at RT. Polymeric HRP-linker antibody conjugate was used as
secondary antibody. DAB chromogen was used to visualize the staining. The sections were
counterstained with haematoxylin. A: low level of IFN-γ expression; B: high level of IFN-γ expression. 
The H score [% of positive cells (brown membrane/cytoplasmic-stained cells) x intensity of staining (1
to 3)] was used to assess the level of expression; low was ≤ 100 and high was > 100. Scoring performed 
on non-metastatic areas of a whole ALN section (7-10 HPFs).
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Figure 3.49 TGF-β expression in the sections of axillary lymph nodes (ALNs), using IHC staining, at 
400x magnification. Briefly, heat-mediated antigen retrieval was performed using citrate buffer, pH 6
(20 mins). The sections were then incubated with MAbs to TGF-β (Abcam, ab64715) at a concentration 
of 12 µg/ml for overnight at 4˚C. Polymeric HRP-linker antibody conjugate was used as secondary 
antibody. DAB chromogen was used to visualize the staining. The sections were counterstained with
haematoxylin. A: low level of TGF-β expression; B: high level of TGF-β expression. The H score [% of 
positive cells (brown membrane/cytoplasmic-stained cells) x intensity of staining (1 to 3)] was used to
assess the level of expression; low was ≤ 100 and high was > 100. Scoring performed on non-metastatic 
areas of a whole ALN section (7-10 HPFs).
Figure 3.50 VEGF expression in the sections of axillary lymph nodes (ALNs), using IHC staining at
400x magnification. Briefly, heat-mediated antigen retrieval was performed using citrate buffer, pH 6
(20 mins). The sections were then incubated with MAbs to VEGF (Dako, M7273) at a 1:50 dilution for
30 mins at RT. Polymeric HRP-linker antibody conjugate was used as secondary antibody. DAB
chromogen was used to visualize the staining. The sections were counterstained with haematoxylin. A:
low level of VEGF expression; B: high level of VEGF expression. The H score [% of positive cells
(brown membrane/cytoplasmic-stained cells) x intensity of staining (1 to 3)] was used to assess the level
of expression; low was ≤ 100 and high was > 100. Scoring performed on non-metastatic areas of a 
whole ALN section (7-10 HPFs).
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3.4 Circulating and Tumour-infiltrating Tregs: Comparisons and Correlations
The levels of blood and tumour-infiltrating FOXP3⁺ and CTLA-4⁺ Tregs, pre- and
post-NAC (n=16), were analysed for the association with pathological response to
NAC, the effects of NAC on levels of infiltration and any correlations between the
blood and tumour microenvironment.
Pre-NAC blood and tumour Tregs did not modify pathological response to NAC
Similar to pre-NAC tumour-infiltrating Tregs (FOXP3⁺ and CTLA-4⁺), the levels of
pre-NAC circulating Tregs [absolute numbers (AbNs) and %] were not significantly
different in any of the different NAC response groups (GPR versus PPR and pCR
versus non pCR, p>0.05) (Table 3.32).
Higher post-NAC blood (%) and intratumoural FOXP3⁺ Tregs were associated
with a poor response to NAC
Post-NAC, there was a significantly higher % of circulating FOXP3⁺ Tregs and
significantly higher levels of intratumoural FOXP3⁺ Tregs in the PPR group (p=0.001
and p=0.016, respectively) and in the patients whose tumours had no pCR (p=0.007
and p<0.001, respectively) (Table 3.33). Another significant difference was also
observed in the AbNs of circulating CTLA-4⁺ Tregs. A higher blood AbN of
circulating CTLA-4⁺ Tregs was significantly associated with the PPR group (p=0.008)
(Table 3.33).
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Table 3.32 Analyses of Pre-NAC Circulating and Tumour-infiltrating FOXP3+ and CTLA-4+ Tregs in Patients with LLABCs(1)
(1) LLABCs: Large and locally advanced breast cancers; (2) Average count per 400x high-power field; (3) Mann-Whitney U test; (4) AbN: Absolute number (cells/mm3);
(5) GPR: Good pathological response; (6) PPR: Poor pathological response; (7) PCR: Pathological complete response
Tregs Groups
Intratumoural
Median (Range)(2)
P Value(3)
Peritumoural
Median (Range)(2)
P Value(3)
% Circulating
Median (Range) P Value
(3) AbN Circulating
Median (Range)(4)
P Value(3)
GPR (n=9)(5) 12.8 (2.4-96.8) 13.8 (2.2-110.6) 1.50(0.62-3.40) 235 (107-427)
PPR (n=7)(6) 16.8 (4.2-45.6) 17.4 (6.6-44.8) 2.17 (1.18-3.24) 165 (155-180)
PCR (n=6)(7) 36.6 (2.4-96.8) 18.0 (5.2-110.6) 1.55 (1.10-3.24) 266 (107-427)
Non PCR (n=10) 14.1 (4.2-45.6) 15.9 (2.2-44.8) 1.85 (0.62-3.40) 168 (155-235)
GPR (n=9) 0.4 (0.0-4.0) 0.6 (0.2-10.0) 1.10 (0.05-3.24) 13 (5-19)
PPR (n=7) 0.4 (0.0-2.2) 0.6 (0.2-1.6) 1.35 (0.76-1.71) 17 (8.5-19)
PCR (n=6) 1.1 (0.2-4.0) 1.4 (0.2-10.0) 1.05 (0.05-3.24) 15 (6-19)
Non PCR (n=10) 0.3 (0.0-2.2) 0.4 (0.2-1.6) 1.46 (0.23-1.80) 14.5 (5-19)
0.470 0.606 0.837 0.174
0.606 0.606 0.536 0.071
0.492 0.562 0.958 0.181
FOXP3+
CTLA-4+
0.147 0.093 0.635 0.875
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Table 3.33 Analyses of Post-NAC Circulating and Tumour-infiltrating FOXP3+ and CTLA-4+ Tregs in Patients with LLABCs(1)
(1) LLABCs: Large and locally advanced breast cancers; (2) Average count per 400x high-power field; (3) Mann-Whitney U test; (4) AbN: Absolute number (cells/mm3);
(5) GPR: Good pathological response; (6) PPR: Poor pathological response; (7) PCR: Pathological complete response; * Statistically significant
Tregs Groups
Intratumoural
Median (Range)(2)
P Value(3)
Peritumoural
Median (Range)(2)
P Value(3)
% Circulating
Median (Range) P Value
(3) AbN Circulating
Median (Range)(4)
P Value(3)
GPR (n=9)(5) 0.0 (0.0-2.4) 0.8 (0.4-7.4) 0.53 (0.25-0.90) 166 (35-230)
PPR (n=7)(6) 2.2 (0.6-22.2) 1.4 (1.0-28.4) 1.18 (0.80-1.85) 157 (118-168)
PCR (n=6)(7) 0.0 (0.0-0.0) 1.3 (0.4-7.4) 0.35 (0.25-0.90) 173 (49-230)
Non PCR (n=10) 1.8 (0.6-22.2) 1.4 (0.4-28.4) 1.15 (0.53-1.85) 158 (35-177)
GPR (n=9) 0.0 (0.0-1.2) 0.0 (0.0-1.2) 0.58 (0.10-1.71) 5 (2-7)
PPR (n=7) 0.4 (0.0-1.2) 0.4 (0.0-5.2) 0.89 (0.37-1.69) 7 (6-15)
PCR (n=6) 0.0 (0.0-1.0) 0.0 (0.0-0.2) 0.55 (0.10-1.25) 5.5 (2-7)
Non PCR (n=10) 0.3 (0.0-1.2) 0.3 (0.0-5.2) 0.77 (0.37-1.71) 6.5 (4-15)
0.114 0.299 0.299 0.008*
0.118 0.181 0.220 0.181
FOXP3+
CTLA-4+
0.313
0.016* 0.252 0.001* 0.470
<0.001* 0.635 0.007*
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Concurrent reduction of blood and tumour-infiltrating Tregs as a result of NAC
Table 3.34 shows the very important effects of NAC on FOXP3⁺ and CTLA-4⁺ Tregs.
There were significant reductions in the peripheral circulating (% and AbNs) and
tumour-infiltrating (intratumoural and peritumoural) Tregs after NAC. These findings
emphasise the positive influences of NAC on anticancer immune defences by
significantly abolishing both systemic and local immune regulatory cells.
Table 3.34 Analyses of Circulating and Tumour-infiltrating FOXP3+ and CTLA-4+
Tregs in Patients with LLABCs(1) Undergoing NAC(2) (n=16)
(1) LLABCs: Large and locally advanced breast cancers; (2) NAC: Neoadjuvant chemotherapy; (3)
Wilcoxon signed rank test; (4) Average count per 400x high-power field; (5) AbN: Absolute number
(cells/mm3); * Statistically significant
A positive correlation between blood (%) and tumour-infiltrating FOXP3⁺ Tregs
post-NAC
Prior to NAC, the level of circulating Tregs was not found to be significantly
correlated with the level of Tregs in the tumour microenvironment. However, this
correlation became significant after NAC. There was a positive correlation between
Tregs Groups Pre-NAC Post-NAC P Value(3)
Intratumoural Infiltrating: Median (Range) (4) 14.8 (2.4-96.8) 0.7 (0-22.2) 0.001*
Peritumoural Infiltrating: Median (Range) (4) 15.9 (2.2-110.6) 1.4 (0.4-28.4) 0.001*
% Circulating: Median (Range) 1.54 (0.62-3.40) 0.81 (0.25-1.85) 0.001*
AbN Circulating: Median (Range) (5) 170 (107-427) 159 (35-230) < 0.001*
Intratumoural Infiltrating: Median (Range) 0.4 (0.0-4.0) 0.1 (0.0-1.2) 0.060
Peritumoural Infiltrating: Median (Range) 0.6 (0.2-10.0) 0.1 (0.0-5.2) 0.029*
% Circulating: Median (Range) 1.31 (0.05-3.24) 0.72 (0.10-1.71) 0.017*
AbN Circulating: Median (Range) 15 (5-19) 6 (2-15) <0.001*
FOXP3+
CTLA-4+
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post-NAC % of peripheral circulating FOXP3⁺ Tregs and post-NAC intratumoural
FOXP3⁺ Tregs [Correlation Coefficient (rho) 0.687, p=0.003] (Table 3.35). Patients
with a higher % of peripheral circulating FOXP3⁺ Tregs after NAC had high FOXP3⁺
Tregs in the residual tumours. This was significantly associated with a poor response
to NAC. There was no significant correlation observed between circulating and
tumour-infiltrating CTLA-4⁺ Tregs (Tables 3.36).
Table 3.35 Correlation Between Circulating and Tumour-infiltrating FOXP3+ Tregs
[Spearman's Correlation Coefficient (rho)] in Patients with LLABCs(1) Undergoing
NAC(2) (n=16)
(1) LLABCs: Large and locally advanced breast cancers; (2) NAC: Neoadjuvant chemotherapy; NA: Not
applicable; * Statistically significant
Intratumoural
infiltrating
Peritumoural
infiltrating
Intratumoural
infiltrating
Peritumoural
infiltrating
%Circulating
Correlation Coefficient -0.116 -0.208
P Value (2-tailed) 0.668 0.440
AbN Circulating
Correlation Coefficient -0.191 -0.263
P Value (2-tailed) 0.478 0.325
%Circulating
Correlation Coefficient 0.687 0.347
P Value (2-tailed) 0.003* 0.188
AbN Circulating
Correlation Coefficient -0.342 0.016
P Value (2-tailed) 0.195 0.952
Post-NAC
NA NA
NA NA
NA NA
NA NA
Groups
Pre-NAC Breast Post-NAC Breast
Pre-NAC
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Table 3.36 Correlation Between Circulating and Tumour-infiltrating CTLA-4+ Tregs
[Spearman's Correlation Coefficient (rho)] in Patients with LLABCs(1) Undergoing
NAC(2) (n=16)
(1) LLABCs: Large and locally advanced breast cancers; (2) NAC: Neoadjuvant chemotherapy; NA: Not
applicable
The significant findings from the study are summarised in Table 3.37. The results
document those findings from our study which are in agreement with previously
published data (referenced). Table 3.37 also documents new/original findings which,
to the best of our knowledge, have not been previously published.
Intratumoural
infiltrating
Peritumoural
infiltrating
Intratumoural
infiltrating
Peritumoural
infiltrating
%Circulating
Correlation Coefficient -0.425 -0.220
P Value (2-tailed) 0.101 0.412
AbN Circulating
Correlation Coefficient 0.055 0.242
P Value (2-tailed) 0.839 0.367
%Circulating
Correlation Coefficient 0.145 0.305
P Value (2-tailed) 0.592 0.250
AbN Circulating
Correlation Coefficient 0.270 0.034
P Value (2-tailed) 0.312 0.899
Post-NAC
NA NA
NA NA
NA NA
NA NA
Groups
Pre-NAC Breast Post-NAC Breast
Pre-NAC
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Table 3.37 Summary of the Key and Significant Findings from the Study
New/Original Findings
Primary tumours
1. Pre-NAC CD56+ NK cells were associated with a pCR
2. Pre-NAC CD163+ TIMs were associated with a pCR
3. Pre-NAC CTLA-4+ Tregs (peritumoural) were associated with a pCR
4. NAC reduced CTLA-4+ Tregs, PD1+ T cells, CD56+ NK cells (intratumoural) and CD1a+ DCs
(intratumoural)
5. NAC reduced both the blood and tumour FOXP3+ and CTLA-4+ Tregs concurrently
6. There was a positive correlation between blood (%) and tumour (intratumoural) FOXP3+ Tregs (post-NAC)
7. High FOXP3+ Tregs (post-NAC) in blood (%) and tumour (intratumoural) were associated with a poor
pathological response
8. Pre-NAC high VEGF expression was associated with a pCR
9. Post-NAC high IL-10 and IL-17 expressions were associated with a non pCR
10. NAC reduced IL-4 expression
Metastatic tumours
1. High levels of TILs, CD4+ and CD8+ T cells, CD56+ NK cells and CD163+ TIMs were associated with
ALN pCRs
2. Higher levels of FOXP3+ and CTLA-4+ Tregs and CD56+ NK cells were present in metastatic tumours than
in the corresponding primary tumours
3. CD8+ T cells and CD56+ NK cells showed a positive correlation between metastatic and primary tumours
ALNs
1. High % of CD8+ T cells and low % of FOXP3+ Tregs in para-cortical (tumour-free) areas of metastatic
ALNs were associated with ALN pCRs
2. High CD8:FOXP3 ratio in para-cortical (tumour-free) areas of metastatic ALNs was associated with an
ALN pCR
3. Th2 polarisation was present in ALNs with metastases (high IL-10, low IL-2 and IFN-γ in ALNs with 
metastases)
Confirmed Previously Published Findings
Primary tumours
1. Pre-NAC TILs (ITu-Ly, Str-Ly and LPBC) were associated with pCRs [Denkert et al. (2010), West et al.
(2011), Yamaguchi et al. (2012), Ono et al. (2012), Lee et al. (2013), Issa-Nummer et al. (2013)]
2. Pre-NAC CD4+ and CD8+ T cells were associated with pCRs [Oda et al. (2012), Seo et al. (2013), Lee et al.
(2013), Garcia-Martinez et al. (2014)]
3. Pre-NAC high CD8:FOXP3 ratio was associated with a pCR [Ladoire et al. (2011)]
4. NAC reduced FOXP3+ Tregs [Aruga et al. (2009), Liu et al. (2012), Demir et al. (2013)] and CD4+ (but not
CD8+) T cells [Garcia-Martinez et al. (2014)]
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CHAPTER 4: DISCUSSION
4.1 Introduction and Overview
Variable levels of the tumour-infiltrating immune cells and the expression of a range
of cytokines and different biological molecules in the tumour microenvironment of
paraffin-embedded breast cancer and ALN specimens were well demonstrated with the
IHC techniques used. The parameters studied represented the in situ immunity in the
tumour microenvironment and the tumour-draining ALNs which, as well as the
systemic immune system, play a key role in the responses elicited in breast cancers
with NAC. The broad range of immune cell subsets and biologically active molecules
studied in this thesis provides a better understanding of the possible anticancer role of
the local immune milieu and its contribution to immune-mediated tumour cell death
associated with NAC.
The NAC combination (AC followed by T ± X) used in our trial is known to have
immunomodulatory effects. Doxorubicin has been shown to enhance the generation of
antigen-specific CD8+ T cells and promote tumour infiltration by activated IFN-γ 
producing CD8+ T cells [172, 173]. In vitro, doxorubicin increased antigen-specific
CD4+ Th1 responses by inducing expression of CD40L and 4-1BB on CD4+ T cells
[31]. Cyclophosphamide inhibits the generation and function of FOXP3+ Tregs in
humans with various cancers [32, 169]. Taxanes have been shown to have immune
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stimulatory effects against tumours [95, 103]. In patients with advanced breast cancer,
docetaxel therapy was associated with an increase in serum IFN-γ, IL-2 and IL-6 
levels and enhancement of circulating NK cell activity [29, 30]. Capecitabine is
enzymatically converted to 5-FU on ingestion. 5-FU is known to increase the
expression of TAAs on tumour cells and to enhance ADCC [177].
Our study encompassed the crucial immune subsets which play a major role in
anticancer immune defences (innate: NK cells, DCs and macrophages; adaptive: T
effector lymphocytes), as well as the major inhibitory mechanisms enabling immune
escape and inducing tumour tolerance (Tregs, PD1⁺ T cells, M2-polarised TIMs and
PMNs). The complex biological interactions between the immune cell subsets, as well
as between immune cells and tumour cells (either by direct contact or secreting
cytokines/ biological molecules) in situ in the tumour environment and their
relationship to circulating subsets (documented in a previous study [15]) were
investigated. We confirmed previously published findings and made a number of new
(not previously reported) and significant observations, in LLABCs and ALNs pre- and
post-NAC.
Tumour destruction by NAC is a complex process and involves various interactions
between the cancer and the host immune cells. Cytotoxic chemotherapy non-
specifically destroys tumour cells as well as normal rapidly proliferating cells. Innate
and adaptive anticancer immunity, systemically and in situ, which are enhanced by
NAC (e.g. by releasing TAAs, activating DCs and reducing immune inhibitory
mechanisms), make an important contribution to tumour cell death. Immune-mediated
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tumour cell death, in turn, enhances the response of NAC on tumour cell destruction
and clearance. Our findings that putative anticancer immune subsets (tumour-
infiltrating CD4⁺ and CD8⁺ T cells, and CD56⁺ NK cells) appeared to make an
important contribution to a pCR and that NAC significantly reduced the level of
immune inhibitory/regulatory subsets (tumour-infiltrating Tregs, PD1⁺ T cells)
confirmed the hypothesis postulated in the thesis. However, inadequate or suboptimal
anticancer immune responses (low/moderately activated), which are unable to kill and
delete all tumour cells, may result in a state of dormancy (no or very low tumour cell
proliferative rate) [161]. As most chemotherapeutic agents act during cell division, a
dormant state may induce tumour cells to become less sensitive or even resistant to
NAC. In contrast, some inhibitory immune subsets which are able to promote tumour
growth (increasing proliferative rate) may make such tumours more sensitive to NAC.
These reasons may be responsible for some of our findings showing that certain
inhibitory immune subsets (high levels of CD163⁺ TIMs and peritumoural CTLA-4⁺
Tregs) were also associated with a pCR. The thesis characterised the different subsets
present in the tumour microenvironment which were associated with a good
pathological response to NAC and a pCR, and identified high levels of TILs and
CD56+ NK cells as independent predictors of a pCR (multivariate analysis).
The NAC used in our study differentially preserved the tumour-infiltrating CD8+ T
cells but significantly reduced both the circulating and tumour-infiltrating FOXP3+
and CTLA-4+ (peritumoural) Tregs, as well as immune checkpoint PD1+ T cells,
thereby preventing the secretion of inhibitory cytokines (IL-4, IL-10, TGF-β), and 
disrupting the PD1/PDL1 pathway. The restoration of immune anticancer effector
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mechanisms is likely to lead to an enhancement of immune-mediated tumour cell
death. Moreover, the significant correlation of high CD8+ T cells and CD8+ T cell:
FOXP3+ Treg ratio with pCR (and hence DFS and OS) suggests a close association
between high levels of CD8+ T cells/CTLs and the concomitant depletion of Tregs.
The close interrelationship between a pCR in LLABCs and the concomitant immune
changes induced by NAC suggests that immune-mediated tumour cell death may be a
crucial component of NAC-associated tumour cell destruction and removal.
The clinical benefits of NAC are compromised by its toxic morbidity, as well as the
costs involved. Not all of the patients with LLABCs respond well to NAC [105]. Non-
responsiveness or progressive disease during NAC cycles results in patient
disappointment and medical staff frustration, and the risk of a reduced likelihood of a
cure. The immunological parameters characterised in the breast (and ALNs) may be
used in conjunction with other clinical and pathological parameters to specifically
identify patients with LLABCs who are more likely to achieve a pCR with NAC, and
thus best suited to receive NAC.
4.2 Tumour-infiltrating Immune Cells and Pathological Responses to NAC
4.2.1 TILs and pCR
In pre-NAC specimens, we investigated the putative anticancer defences, as
characterised by TILs, and their possible role in the responses elicited with NAC. A
high level of TILs denoted a prominent immune inflammatory response in the tumour
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microenvironment in women with LLABCs. This was significantly associated with a
good pathological response and pCR in the breast. These findings are similar to the
results from a much larger (1000 samples) study of TILs and NAC responses in breast
cancer [19]. Although the high level of TILs was significantly associated with high
grade and ER-ve tumours, which may have contributed to a higher pCR rate, the
multivariate analysis established the independent predictive value of TILs as a
predictor of a pCR after adjusting for tumour grade and ER status. Our findings of a
high level of TILs as an independent predictive factor for a pCR with NAC is in
agreement with the few previously published articles [17-19, 384, 389, 394]. This
important finding has confirmed the strong association between the in situ immune
profile in the breast tumour microenvironment and the pathological responses elicited
with NAC.
The level of TILs has been evaluated in stroma and in tumour nests (intratumoural)
separately. We documented that both stromal and intratumoural TILs, as well as
LPBCs, were associated with a pCR and there was a positive correlation between the
levels of stromal and intratumoural TILs. TILs, however, are able to move within the
living tissue microenvironment. The distinction may be somewhat artificial and related
to the static situation in histological sections [422]. Both compartments, therefore,
represent TILs. Some studies have found stromal TILs to be a superior and more
reproducible parameter than intratumoural TILs in the prediction of clinical outcomes
[385, 386] and a pCR with NAC [384]. Nevertheless, both stromal and intratumoural
TILs are predictive of pathological response to NAC in most studies.
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The evidence of TILs in prediction of a pCR in breast cancer with NAC has
accumulated during the time while our study was on-going. Recently, a systematic
review and meta-analysis validated the predictive role of TILs in response to NAC in
breast cancer [432] and the ‘International TILs Working Group’ has been established
[422]. Despite the results from this meta-analysis, it is still unclear as to the predictive
role of different subsets of TILs in response to NAC.
4.2.2 CD4+, CD8+ T lymphocytes, FOXP3+ Tregs and pCR
The major component of TILs is T lymphocytes, which are predominantly CD4⁺ and
CD8⁺ T cells. CD4⁺ and CD8⁺ T cells are the major effectors of the adaptive cell-
mediated immune response (T-helper cells and CTLs). The significantly higher levels
of CD4⁺ and CD8⁺ T cells (intratumoural and peritumoural) in LLABCs with pCRs
support the postulate that adaptive anticancer immunity plays an important role in
modulating responses of the breast cancer to NAC. These findings are consistent with
results from previous studies [393, 394, 396]. A recently published study, however,
documented a significantly higher pCR rate in breast tumours with a high level of
CD4⁺ T cell but low level of CD8⁺ T cell infiltrates. This study attributed the high
level of CD4⁺ T cell infiltration as the main factor responsible for the occurrence of a
pCR [224]. The results in this study were obtained using the TMA technique. TMAs
focus on a much smaller area in studied specimens with the risk of bias due to the
potential heterogeneity of distribution of TILs, thus accounting for some of the
variance with the findings published by a number of other authors [393, 394, 396]. In
our study, full tissue sections were used to document TIL subsets. The difference in
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intrinsic subtypes of breast cancer studied as well as the variation in NAC regimens
used among the studies may also be responsible for some of the contradictive findings.
The median number of intratumoural CD4⁺ T cells [Median: 36.8 (Interquartile range,
IQR: 19.7 – 293.9) cells/mm2] was higher than the median number of infiltrating
CD4⁺ T cells present in normal breast lobules [Median: 27.3 (IQR: 0 - 101.2)
cells/mm2] [433], whereas the median number of intratumoural CD8⁺ T cells
[Median: 79.4 (IQR: 23.4 – 257.9) cells/mm2] was lower than the median number of
infiltrating CD8⁺ T cells present in normal lobules [Median: 216.3 (IQR: 145.8 –
303.3) cells/mm2] [433]. Our data, which was presented as the median number of cells
per HPF (0.239 mm2) with a minimum to maximum range was converted to cells per 1
mm2 with interquartile ranges (1st quartile to 3rd quartile) to enable direct comparisons
to be made. The comparison between normal breast tissue and LLABCs showed an
inverted ratio of CD4+ and CD8+ components of T lymphocytes present in the local
milieu. However, the differences in CD4⁺ and CD8⁺ T cell levels between normal
breast tissue and LLABC are less pronounced than the levels in the FOXP3⁺ Treg subset between normal and malignant breast tissues. The median number of
intratumoural FOXP3⁺ Tregs present in LLABCs [Median: 23.4 (IQR: 9.6 – 61.9)
cells/mm2] was substantially increased when compared with normal breast lobules
[Median: 0.5 (IQR: 0 – 4) cells/mm2]. The data on FOXP3⁺ Tregs present in normal
breast tissue was documented from specimens obtained from women undergoing a
reduction mammoplasty [229]. There was more than a 45 fold higher median number
of FOXP3⁺ Tregs present in LLABCs, compared with normal breast tissue indicating
the very prominent immunosuppression in the tumour microenvironment of LLABCs.
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Similar to TIL compartments, both peritumoural and intratumoural infiltrates represent
the extent and distribution of the infiltration of these immune cell subsets. There is a
postulate that lymphocytes directly interacting with cancer cells (intratumoural) might
be more relevant and, therefore, more useful for prognostic/predictive evaluation. The
intratumoural infiltrates, however, are usually present in lower numbers and detected
in fewer cases. They are also more heterogeneous than peritumoural infiltrates. Some
authors suggest that the peritumoural/stromal infiltration is a superior and more
reproducible parameter than intratumoural infiltration in documenting the level of
immune infiltrates in the tumour microenvironment [422]. Since the peritumoural
infiltration is measured in the areas/spaces between tumour nests, the growth pattern
of tumour nests will not affect the measurement (cell count). Moreover, measurement
of intratumoural infiltration may not add anything further to the information provided
by peritumoural infiltration. Despite the methodological reasoning mentioned above,
both peritumoural and intratumoral CD4⁺ and CD8⁺ T cells are predictive of a pCR
with NAC in our study. A positive correlation with the grade of pathological response
(1-5) to NAC was also shown in the study.
The level of tumour-infiltrating FOXP3⁺ Tregs in our study, however, failed to
demonstrate any predictive role for a pCR. The previous studies of pre-NAC tumour-
infiltrating FOXP3⁺ Tregs and the pCR rate following NAC in breast cancers had
shown inconsistent findings. Oda et al. (2012) documented that the presence of pre-
NAC tumour-infiltrating FOXP3⁺ Tregs in breast cancers was significantly associated
with high pCR rates [396]. Seo et al. (2013) and Lee et al. (2013) also documented
that the high levels of tumour-infiltrating FOXP3⁺ Tregs were associated with a pCR
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[393, 394]. On the other hand, other studies have shown that absence or low levels of
pre-NAC tumour-infiltrating FOXP3⁺ Tregs in breast cancers was associated with a
better prognosis (DFS and OS) and a high pCR [229, 234, 390]. The variability of
breast cancer subtypes (ER and HER2 status, tumour grade, etc.) enrolled in each
study and also the subtypes of FOXP3⁺ Tregs (iTregs and nTregs) present in the
tumours, as well as the presence of FOXP3 on activated T lymphocytes may be
responsible for these different findings. To address the relevance of pre-NAC tumour-
infiltrating FOXP3⁺ Tregs, the specific subtypes of breast cancer and Tregs need to be
identified and compared.
Nevertheless, the relevance of tumour-infiltrating FOXP3⁺ Treg levels was shown
when combined with the CD8+ T cell levels. The association of high levels of tumour-
infiltrating CD4+ and CD8+ T cells (which are major components of TILs) and a pCR
with NAC (mentioned above) may be an effect of the high level of TILs in the
specimens but the CD8⁺ T cell: FOXP3⁺ Treg ratio is not. The CD8⁺ T cell: FOXP3⁺
Treg ratio is likely to be a good biological marker representing the status of adaptive
anticancer immunity in the local milieu of LLABCs. CD8+ CTLs are able to destroy
tumour cells after appropriate activation while FOXP3+ Tregs inhibit and dampen
down the generation of CTLs, secrete immunosuppressive IL-10 and TGF-β, as well 
as mediate IL2 deprivation in the local milieu [8, 227]. A high ratio (intratumoural or
peritumoural) in the tumour microenvironment in our study was associated with a pCR
and also had a positive correlation with the pathological grade of response to NAC.
These results highlight the requirement for activated CTLs and concomitant depletion
of immunosuppressive Tregs. Dysfunctional CD8⁺ T cell responses as a result of
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excessive and prolonged stimulation and continuous inappropriate signal activation
results in T cell exhaustion and loss of effector and memory function. This persists
even after removal of Tregs [434]. The results of our study confirm the findings
previously documented by Ladoire et al. (2011) [391]. Increased number of CD8+ T
cells and decreased number of FOXP3+ Tregs in the tumour microenvironment are
likely to be associated with a better response to NAC.
Although identifying specific subsets of TILs with the IHC technique may not be more
reliable than the level of TILs in terms of predicting a pCR with NAC, it provides a
better understanding of the immune complexity in the tumour microenvironment and
the possible contribution of specific immune cell subsets to immune-mediated tumour
cell death associated with a better pathological response to NAC.
4.2.3 CD56⁺ NK cells and pCR
High levels of CD56⁺ NK cell infiltration, either intratumoural or peritumoural, were
associated with good pathological responses and pCRs. Furthermore, the level of ≥3 
cells/5HPFs was an independent predictive factor for a pCR. CD56 has been used to
document the subset of TILs in breast cancer by Hornychova et al. (2008). They
demonstrated an increased number of CD56+ NK cell counts after NAC [388]. CD56⁺
NK cells have been shown to play an important role in tumour immune surveillance,
in the prevention of progressive tumour growth and in the defence against metastatic
dissemination. An important mechanism of the CD56⁺ NK cell anticancer effect, apart
from tumour cell lysis, occurs via the secretion of IFN-γ, activation of T lymphocytes 
and the selective generation of immunogenic DCs [435, 436]. Although most
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established tumours in animal models have very low levels of NK cells, adoptively
transferred ex vivo activated NK cells readily infiltrate tumours and induce tumour cell
death [437]. However, in situ production of IL-2 and IL-15 is necessary to continually
reactivate infiltrating NK cells to prevent NK cell exhaustion and inhibition by
suppressor/inhibitory cells and humoral factors, such as TGF-β in the tumour milieu 
[438, 439]. Most human solid tumours have very low levels of CD56⁺ NK cell
infiltration. However, where there was more prominent infiltration by CD56⁺ NK cells
in certain cancers (colorectal carcinoma, oesophageal squamous cell carcinoma,
gastric carcinoma, squamous cell lung cancer), this was shown to be associated with
an improved prognosis and reduction in tumour recurrence [256-259].
There is a dearth of published evidence regarding tumour-infiltrating CD56⁺ NK cells
in LLABCs. To the best of our knowledge, this is the first time that this significant
association between tumour-infiltrating CD56⁺ NK cells and pathological responses to
NAC in LLABCs has been described. This finding emphasises the important role of
innate immunity in modifying the response to NAC.
However, reduced NK cell cytotoxicity and altered NK cell phenotypic profiles have
been demonstrated in patients with breast cancer. There was also an increased
proportion of more immature or non-cytotoxic NK cells [440, 441]. The IHC
technique used in the study was unable to define specific NK cell subsets
(CD16+CD56dim and CD16-CD56bright) with their different NK cell functions
(cytotoxicity, cytokine secretion). In addition, we did not demonstrate any association
between in situ tumour levels of IL-2, INF-γ or TGF-β and the pathological response 
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elicited in the breast tumour by NAC. The levels of tumour-infiltrating CD56⁺ NK
cells documented in our study may not be representative of their functional activity
(cytotoxicity and/or cytokine secretion).
4.2.4 CD1a⁺ DCs
The level of tumour-infiltrating CD1a⁺ DCs, which has been documented to show a
significantly better clinical outcome and OS in many solid cancers [284-287], has not
been found to be significantly associated with a better OS in breast cancer [281].
There has been no previously published study regarding tumour-infiltrating CD1a⁺
DCs in LLABCs and their relationship to pathological responses with NAC. Our
findings showed no significant association between the levels of tumour-infiltrating
CD1a⁺ DCs and pathological responses to NAC. DCs are potent APCs and are
necessary to initiate and direct adaptive anticancer immunity. Our findings may
indicate that the higher levels of DCs in the microenvironment of LLABCs did not
exhibit better anticancer functions and support the previous studies that DCs in breast
cancers are poorly activated/switched-off [279, 280]. The number/density of tumour-
infiltrating CD1a⁺ DCs alone cannot predict the outcome of treatment. Additionally,
the different subtypes and level of maturation of DCs affect their functions and
expressions. Identification of tumour-infiltrating DCs with different cellular
(activating) markers, apart from CD1a, may be more relevant.
The immunological functions of tumour-infiltrating DCs in LLABCs remain poorly
defined. These cells were documented to be immature/poorly activated or switched-
off, therefore, unable to induce an efficient anticancer immune response. Inhibition of
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DC maturation and function appears to be one of the mechanisms that tumours exploit
to evade anticancer immunity [442]. It has been shown that cancer cells were able to
induce the differentiation of mature DCs to TGF-β secreting DCs in vitro. These DCs
were poor at eliciting the activation of naïve T cells and sustaining the differentiation
into Th1 cells. TGF-β secreting DCs directly expand FOXP3+ Tregs (through TGF-β) 
and also recruit FOXP3+ Tregs through chemokine production such as CCL22 [443].
Several therapeutic strategies have been proposed in attempting to restore the ability of
DCs to mediate an efficient anticancer immune response.
4.2.5 PD1⁺ T cells and CTLA-4⁺ Tregs as immune co-inhibitory subsets
Even through PD1⁺ T cells were frequently found in the microenvironment of
LLABCs, as well as the expression of PDL1, their levels were not shown to have any
association with pathological responses to NAC. Targeting the co-inhibitory
checkpoint pathway of PD1 is a new and effective treatment modality/option for
advanced metastatic melanoma and NSCLC [189, 190]. Its relevance in LLABCs
requires further investigation. Similar to PD1, another co-inhibitory checkpoint
molecule is CTLA-4. Contrary to our postulate, a high level of peritumoural CTLA-4⁺
Tregs (provides inhibitory effect to anticancer immune response) in LLABCs showed
a significant association with a pCR. High levels of tumour-infiltrating PD1⁺ T cells
and CTLA-4⁺ Tregs, as well as PDL1 expression, have been shown to be associated
with poor survival and positively correlated with high tumour grade and in TNBCs
[190, 242, 297, 298]. The association between high levels of CTLA-4⁺ Tregs and high
tumour grade with a pCR may be responsible for this contradictory finding in our
study.
221
The negative contributions of these immune inhibitory subsets to pathological
responses to NAC may be difficult to establish because their levels are likely to be
prominent in tumour subtypes with high pCR rates. In our study, 55% of the LLABCs
(18 out of 33 specimens) were high tumour grade and 9% of the LLABCs (3 out of 33
specimens) were TNBCs. In the analysis of clinical and pathological parameters, high
tumour grade was significant associated with a pCR. The analysis within a particular
subtype of breast cancer may provide a better understanding for the possible
contribution of these inhibitory subsets to pathological response to NAC.
4.2.6 CD66b⁺ PMNs (TANs)
High levels of tumour-infiltrating CD66b⁺ PMNs have been demonstrated to be
significantly associated with poor clinical outcomes (DFS, OS) in various solid
cancers [306-308]. In our study they were not significantly associated with
pathological responses to NAC in LLABCs. Mildly/or moderately activated PMNs
(recently described as N2 tumour-associated neutrophils) release small/moderate
amounts of oxygen radicals and proteinases when they enter the tumour
microenvironment [303, 304]. The small/moderate levels of these toxic substances are
unable to destroy tumours but promote tumour growth and invasiveness. However,
they were present in small numbers in the microenvironment of LLABCs. The
differences of responses to NAC may be difficult to identify with a small cohort of
only 16 patients. However, this is the first time that a relationship between tumour-
infiltrating CD66b⁺ PMNs and pathological responses to NAC in LLABCs has been
described (no published data, to date).
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4.2.7 CD163+ TIMs and pCR
TIMs derived from circulating monocytes are recruited to the tumour
microenvironment by a number of chemokines and factors released from necrotic
cells, and in response to hypoxia. Once localised, monocytes respond to the tumour
microenvironment and mature into TIMs expressing CD163 (a haemoglobin scavenger
receptor), as an alternatively activated M2 phenotype [265]. These macrophages
develop properties favouring tumour growth and metastatic spread [262, 266, 267].
The data from a meta-analysis (solid tumours including breast cancer) showed that
high levels of tumour-infiltrating M2 macrophages were associated with poor
prognosis (DFS and OS) [268]. Contrary to our postulate (high levels of the M2 TIMs
negatively influenced anticancer immune defences and pathological responses to
NAC), high levels of tumour-infiltrating CD163⁺ macrophages (M2 phenotype),
which support tumour progression and immune escape, were significantly associated
with a good pathological response and pCR in our study. Since a pCR is a surrogate
marker for a good OS [107-109], our findings demonstrated the reverse results.
Heys et al. (2012) documented TIMs in breast cancer using CD68, suppressor of
cytokine signalling (SOCS) 1 and SOCS3. SOCS1 (representing M2 macrophages)
inhibits pro-inflammatory signalling pathways downstream of IFN-γ and TLR4, whilst 
SOCS3 (representing classically activated M1 macrophages) inhibits signal transducer
and activator of transcription 3 (STAT3) signalling. High levels of SOCS3+ TIMs in
breast tumours were associated with a pCR with NAC. There was no association
between SOCS1+ TIMs and pathological response to NAC [274]. These findings are
different from our results. The use of different cellular markers in documenting the
alternative activated M2 macrophages yielded variable results. To differentiate M2
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and M1 macrophages in the tumour microenvironment may need more specific
markers. However, there is a lack of published data on CD163⁺ TIMs and their
relationship with pathological responses to NAC in breast cancer. Our findings suggest
that high levels of CD163⁺ TIMs may be a predictor for a good pathological response/
pCR to NAC, but not necessarily to DFS and OS, as discussed above for CTLA-4+
Tregs. Similar findings published with other parameters, indicate that certain types of
cancers (e.g. TNBCs) are associated with a high pCR but have a poor long-term
outcome [110]. The high level of the M2 CD163⁺ TIMs in the microenvironment, as
well as their production of certain biological molecules (VEGF, EGF and MMPs) may
make the local environment a privileged site for tumour cell proliferation and invasion
[264]. Highly proliferative and more aggressive breast tumours have better responses
to chemotherapy [19, 51]. The significantly high level of VEGF in the specimens with
pCR from our study also supports this concept.
Macrophages are heterogeneous with different subsets having different functions. The
present study suggests that the level of CD68+ TIMs (general macrophage marker) in
the microenvironment of breast tumours is not associated with a pCR and thus not
related to prognosis [273]. Thus, it is unsurprising that our study also showed no
association of CD68+ TIMs with pathological response to NAC. Identifying TIMs with
cellular markers related to their functions/activations, as for CD163 or SOCS, is
necessary to document the potential contribution of TIMs to tumour cell growth and
response to NAC.
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4.3 CD44⁺, CD24-/low CSCs and PCR
In solid tumours, it has been demonstrated that only a small proportion of the cancer
cells are able to form colonies in an in vitro clonogenic assay [444]. A phenotypically
distinct subset of cancer cells has the capacity to proliferate and form new tumours.
Some biological markers can be used to identify these clonogenic cells in the tumours
distinguishing the tumourigenic (tumour initiating CSCs) cells from other non-
tumorigenic cells. The putative stem cell markers CD44⁺ and CD24-/low are frequently
used to identify CSCs present in breast cancer (strongly express the adhesion molecule
CD44 and very low levels of the adhesion molecule CD24) [377, 378]. Poor
response/resistance to NAC in LLABCs may be related to the presence of CSCs,
which are inherently resistant to chemotherapy and radiotherapy [374-376]. Our study,
however, failed to demonstrate any significant association between the different
pathological responses with NAC in breast tumours with the presence of CSCs. The
expression of CD44⁺ CD24-/low was not predictive of a pCR. In the study, the
expression of CD44 and CD24 were documented by a single IHC-staining of two
sections from each specimen. This method may not be appropriate to document the
CSCs in breast tumours. Abraham et al. (2005) in an IHC study evaluating breast
CSCs (identified these markers by double-staining IHC technique) showed no
association with clinical outcome and OS [378].
In LLABCs with no pCR following NAC, the expression of these adhesion molecules
in residual tumours compared with the corresponding pre-NAC tumours was not
significantly altered. NAC had no significant effect on the level of expression of these
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markers in LLABCs. These findings partly support the postulate that CD44⁺ CD24-/low
breast cancer cells (putative CSCs) are resistant to NAC but the expression of CD44⁺
CD24-/low is unable to predict the response of a pCR to NAC.
4.4 Metastatic Tumours: Local Immune Milieu and PCR in Metastatic ALNs
Data from our NAC study, which was recently published, showed a greater clinical
benefit when there was a pCR in both the primary breast tumour and metastatic
tumour in the ALNs, compared with a pCR in the breast tumour alone [110].
Therefore, identifying the immune predictors of a pCR in metastatic ipsilateral ALNs
is even more important than pCR responses in primary tumours.
Our findings showed that the levels and types of cellular immune infiltrates present in
ALN metastatic tumours were significantly associated with the subsequent
pathological responses to NAC. The immune parameters (TILs, CD163+ TIMs, CD4+
and CD8+ T cells, and CD56+ NK cells) which were significantly associated with a
pCR in the primary tumours were also found to be significant associated with a pCR in
the ipsilateral tumour-draining metastatic ALNs. These findings may indicate that the
relevance of the local immune milieu in predicting pathological response to NAC
remains during metastatic spread to ALNs. To the best of our knowledge, this is the
first time to date that the association of specific immune infiltrates and a pCR with
NAC have been documented in metastatic tumours in ALNs. There is a dearth of
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publications regarding the biological markers predicting a pCR with NAC in
metastatic tumours in ALNs in breast cancer.
The comparison of the levels of immune infiltrates between primary tumours and ALN
metastases indicated some specific alteration of the intrinsic immune milieu when the
primary tumours had spread. The metastatic process involves diverse interactions
between tumour cells and their microenvironment. Primary tumours consist of
heterogeneous populations of tumour cells with genetic alterations that allow them to
overcome physical boundaries, disseminate, and deposit in a distant site. This complex
process requires intrinsic cellular alterations such as surface adhesion molecules,
membrane receptors, matrix metalloproteinases and abilities to escape from anticancer
immune surveillance. Only 0.01% or fewer of the tumour cells entering the lymphatic
or blood circulation develop into metastases. A successful colonisation of escaping
tumour cells is also depends on the microenvironment of metastatic sites [149, 445].
There was no significant change in the level of TILs and CD163+ TIMs between
primary tumours and corresponding ALN metastatic tumours. The CD4+ and CD8+ T
cell subsets also remained comparable. Contrary to the findings documented by
Cimino-Mathews et al. (2013), the level of TILs (CD4+ and CD8+ T cell subsets) was
significantly lower in metastases [398]. This finding, however, came from the study of
distant metastatic tumours (compared with primary tumours). The immune
microenvironment present in loco-regional lymph node metastases may be different
from distant metastases. The distant metastases indicate the final stage of malignant
disease in which anticancer immunity is overwhelming evaded.
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The significantly higher levels of Tregs (FOXP3+, CTLA-4+) in ALN metastatic
tumours indicate a more immunosuppressed tumour microenvironment. This may be
one of the major mechanisms that enables/promotes metastatic spread. Tregs
(FOXP3+, CTLA-4+), therefore, are probably one of the major immune subsets playing
a key role in metastatic spread to and progressive growth in ALNs. However,
significantly higher levels of CD56+ NK cells in metastatic tumours were also
observed. Due to the dearth of data on levels of immune cell infiltration of ALN
metastatic tumours, in comparison with the primary tumours in the breast, this thesis is
the first to document these interesting observations.
4.5 Expression of Cytokines and Pathological Response to NAC
In solid tumours, malignant cells and host immune infiltrating cells express and
secrete a range of Th1, Th2 and Th17 cytokines (IL-1, IL-2, IL-4, IL-10, IL-17, IFN-γ) 
and TGF-β. These cytokines modulate and suppress the in situ anticancer immune
responses, enhancing tumour cell growth and progression, and propensity to
metastasise [318, 321, 322, 325, 326, 332, 342]. In our study, the semi-quantitative
method used did not discriminate between the tumour-infiltrating immune cells and
the malignant cells, nor quantify precisely the contribution of the various host immune
cells to the cytokine levels in the tumour microenvironment.
Regardless of the presence of a significantly high level of TILs or CD4+ subset in
LLABCs with subsequent pCR with NAC, the expression of Th1, Th2 and Th17
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cytokine profiles present in pre-NAC breast cancer specimens did not show any
association or prediction of the subsequent pathological response to NAC. The study,
however, documented a wide range of cytokine expressions in situ, including IFN-γ 
and TGF-β, in both breast cancer cells and infiltrating immune cells. Since the tumour 
cells were able to express a wide range of cytokines [144, 317], the expression of
cytokines present in the tumour microenvironment assessed by the IHC technique in
the study may not accurately represent the functional activity of the immune cell
infiltrates.
In post-NAC, there was a significantly high level of expression of IL-10 and a non-
significantly (p=0.062) high level of expression of TGF-β in breast cancer specimens 
showing no pCR or a poor response to NAC. These findings suggest that Th2
polarisation in the tumour microenvironment may be one of the mechanisms enabling
the tumour cells to be resistant to NAC. Data from our previous study showed that in
vitro cytokine production by T lymphocytes from the blood of patients with LLABCs
also showed Th2 polarisation [15]. In addition, a significantly high level of expression
of IL-17 was observed in breast cancer specimens with no pCR or a poor response to
NAC (post-NAC). This is the first time, to the best of our knowledge, that the
relationship between the expression of cytokines in the tumour microenvironment and
the pathological responses to NAC in LLABCs has been demonstrated.
In the tumour microenvironment Th1, Th2 and Th17 cytokines, as well as TGF-β, play 
an important role in modulating in situ innate and adaptive immune mechanisms
[446]. The Th1 cytokines IL-2 and IFN-γ enhance CTL- and NK cell-mediated 
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regression of cancer cells. IFN-γ can either promote or suppress Treg activity 
depending on the cytokine environment. IL-2 also has a key role in controlling Treg
function in the periphery [447]. The Th2 cytokines IL-4 and IL-10 suppress the
generation of CTLs and Th1 cells and recruit tumour entry of Tregs [8, 150].
Moreover, IL-4 has been shown to both increase and inhibit Treg function. It can
enhance FOXP3 expression and suppressor activity of Tregs and conversely, can
inhibit TGF-β induced Treg development [448, 449]. Th1 and Th2 cytokine 
expression in tumours has a variable effect on patient outcomes in a range of human
cancers, including breast cancer [209]. The role of IL-17 is not well defined. Some
animal studies suggest it promotes tumour growth and angiogenesis [328, 329].
Yamazaki et al. (2008) have shown that IL-17 promotes the recruitment of Tregs to
sites of IL-17 mediated inflammation [450]. Others have suggested an increased
generation of CTLs and an enhanced tumour rejection [330, 451]. Contradictory
results have been demonstrated in a range of human tumours, including breast cancer
[209]. In one study in breast cancer, the level of Th17 cells was shown to be increased
and associated with an improved prognosis [332]. TGF-β expression is usually up-
regulated in human cancers. It induces production of FOXP3+ Tregs and has strong
immunosuppressive effects, inhibiting the generation and activity of innate (DCs, NK
cells) and adaptive (CD4+ and CD8+ T cells) immunity [8, 446]. TGF-β can promote 
an epithelial to mesenchymal transition, resulting in enhanced tumour cell mobility,
local invasion and formation of metastases [157]. An inflammatory environment, not
infrequent in tumours, can induce the transformation of FOXP3+ Tregs into FOXP3-
effector cells producing IFN-γ [452]. This is further evidence of the plasticity of the 
different CD4+ T cell effector-regulator subsets. The interplay between the different T
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cell profiles in human cancers is complex, the outcomes variable and in need of further
careful study.
4.6 NAC Modulates Anticancer Immune Defences in Tumour Microenvironment
The differences in the levels of immune cell infiltrations and expression of various
cytokines and biological molecules between pre- and post-NAC tumours demonstrated
the effects of NAC on these immune parameters. We documented the significant
reduction of the major inhibitory immune cell subsets (FOXP3⁺ and CTLA-4⁺ Tregs
and PD1⁺ T cells) in the tumour microenvironment post-NAC whilst the TILs and
CD8⁺ T cell subset showed no significant changes. Notably, the significant reduction
of the levels of tumour-infiltrating FOXP3⁺ Tregs following NAC is concordant with
previous studies [13, 395, 397]. Reducing the levels of infiltrating Tregs may be an
effect of cyclophosphamide. Anthracyclines enhance the generation of antigen-specific
CD8+ T cells and promote tumour infiltration by activated IFN-γ producing CD8+ T
cells [172, 173]. Capecitabine (via 5-FU) increases the expression of TAAs on tumour
cells and production of IFN-γ by tumour-infiltrating CD8+ T cells [177]. The
enhancing of the generation and function of CD8+ T cells by NAC combinations used
in the study supports our findings that infiltrating CD8+ T cells were relatively
resistant to NAC. The NAC differentially preserved the tumour-infiltrating CD8+ T
cell subset but significantly reduced inhibitory subsets leading to the restoration of
immune anticancer effector mechanisms. These findings emphasise the beneficial
effects of NAC in enhancing anticancer immunity. In our previous study, the NAC
regimen with anthracyclines, cyclophosphamide, taxanes and capecitabine modulated
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and enhanced anticancer immune defences systemically through the reduction of
circulating Tregs and MDSCs [15]. Part of this cohort was used to characterise the in
situ tumour microenvironment in this thesis.
Significant effects of NAC were also found in reducing intratumoural CD56⁺ NK cells
and CD1a⁺ DCs which may result in the inhibition of anticancer innate immunity.
These findings are contrary to the previous findings documented by Hornychova et al.
(2008) that the number of CD56⁺ NK cells and CD1a⁺ DCs was increased after NAC
in breast tumours with no pCR [388]. In our previous study of NK cells [453], there
was a significant reduction of blood NK cell activity in women with LLABCs and this
reduction was more pronounced in patients with poor responses to NAC. As a result,
the NK cells present in the tumour microenvironment after NAC may or may not be
functional.
In addition, tumour-infiltrating CD4⁺ T cells were also significantly reduced.
However, the effect of tumour-infiltrating CD4⁺ T cells on anticancer immunity
depends on Th1/Th2 polarisation in the local milieu. The reduction of tumour-
infiltrating CD4⁺ T cells may help to regularise the Th1/Th2 polarity. This significant
reduction may be a result of the reduction of Tregs as a substantial number of the
Tregs are CD4+ FOXP3+ T cells. The significant reduction of infiltrating CD4+ T cells
(but preserved infiltrating CD8+ T cells) following NAC is concordant with previously
published findings [224].
232
Furthermore, we documented no significant changes in the level of CD163⁺ and
CD68⁺ TIMs and tumour-infiltrating CD66b⁺ PMNs following NAC. An unchanged
level of CD163⁺ TIMs following NAC suggests that the NAC was unable to re-
polarise the M2 macrophages to the M1 phenotype. The macrophages and PMNs play
a crucial role in innate immunity and their alternative activated phenotypes may
negatively influence the anticancer immunity [10, 303]. It was interesting to note that
tumour-infiltrating CD66b⁺ PMNs appeared to be resistant to chemotherapy, in
contrast to their sensitivity whist in the circulation. These findings, including the
significant reduction in the level of intratumoural CD56⁺ NK cells and CD1a⁺ DCs
following NAC, suggest that the beneficial effect of NAC on enhancing anticancer
immunity in the local milieu was more convincingly demonstrated for the adaptive
rather than the innate immune pathways.
Effect of NAC on the expression of cytokines was documented by the alteration of the
levels of expression between pre- and post-NAC breast cancer specimens. Following
NAC, the expression of IL-4 was significantly reduced whilst the other cytokines
remained unaltered. IL-4 is a key immunosuppressive Th2 cytokine. This significant
reduction in the level of IL-4 expression suggests a positive effect of NAC on
anticancer immune defences. This finding, documented for the first time, showed the
effects of NAC on altering the polarisation towards a Th1 cytokine profile in the
tumour microenvironment in the patients with LLABCs. Nevertheless, NAC did not
significantly alter the expression of other important biological molecules (VEGF, IDO,
PDL1 and IL-17).
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4.7 Regulatory T Cells: Systemic and Local Milieu
It has been documented that the circulating levels of Tregs are significantly increased
in patients with solid cancers, as well as in patients with LLABCs [15, 454]. The
increased levels detected in the blood may not always reflect the situation in the
tumour microenvironment [38]. To document the relationship between the systemic
and local tumour microenvironment, the circulating FOXP3⁺ and CTLA-4⁺ Tregs
were analysed for correlations with tumour-infiltrating FOXP3⁺ and CTLA-4⁺ Tregs
in the same cohort of patients. We documented no significant correlation in pre-NAC
data. Nevertheless, the NAC was able to modulate anticancer immunity both
systemically and locally. This was demonstrated by the significant concurrent
reductions of circulating FOXP3⁺ and CTLA-4⁺ Tregs (both % and AbNs) and
tumour-infiltrating FOXP3⁺ and CTLA-4⁺ Tregs (both peritumoural and intratumoural
infiltrations) following NAC. There was also a significant positive correlation between
the % of circulating FOXP3⁺ Tregs and intratumoural FOXP3⁺ Tregs in post-NAC
specimens.
4.8 ALNs and the Immune Microenvironment
In the study of ALN specimens, the levels/proportions of various immune subsets
present in tumour-draining ALNs were not significantly altered by the presence of
metastatic disease. Because the study was carried out in non-metastatic areas of ALNs,
it is possible that the alteration of the immune microenvironment of metastatic tumour
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deposits in ALNs may be present only within or around the metastatic tumours. The
metastatic tumours, however, were unable to alter phenotypically the immune
microenvironment of ALNs in general. Our findings are partly consistent with three
studies by Mansfield et al. [282, 431, 455]. These three studies were carried out in
sentinel lymph nodes (SLNs: the first group of ALNs directly receiving lymphatic
drainage from breast tumours) with and without SLN metastases. Non-metastatic areas
of the SLNs were studied. Similar to our findings, there were no significant
differences in the percentages of CD8⁺ T cells and CD1a⁺ DCs and expression of IDO
between metastatic and non-metastatic SLNs [282, 455]. However, these studies
showed a significantly higher % of FOXP3⁺ Tregs (20% versus 14%, p=0.02) [455]
and significantly lower % of CD163⁺ macrophages (10.5% versus 13.8%, p=0.002)
[431] in metastatic SLNs, in contrast to our results which failed to demonstrate such
changes. These different findings may be a result of a different immune
microenvironment between SLNs, the first group of tumour-draining lymph nodes and
thus exposed for longer periods to afferent tumour cell dissemination and suppressor
molecules than more centrally sited ALNs.
It is also possible that these different findings amongst studies may be an effect of
NAC. The results of previous studies mentioned above were from non-NAC pre-
treated SLNs whilst our results were from post-NAC surgical specimens of ALNs.
There is a dearth of published studies documenting the immune microenvironment in
tumour-draining ALNs, particularly regarding metastatic spread.
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The significantly high expression of IL-2 and IFN-γ in non-metastatic ALNs and the 
significantly high expression of IL-10 in metastatic ALNs support the postulate of a
Th1 polarisation in the local immune milieu in non-metastatic ALNs and the Th2
polarisation in the local immune milieu in metastatic ALNs, respectively. The
cytokine polarisation towards a Th2 profile in the microenvironment of ALNs may
suppress the generation of specific immune effector cells and allow the metastatic foci
to embed and grow. It is possible that the metastatic deposits themselves induce the
polarisation of the cytokine profiles in the microenvironment by the secretion of IL-10
and TGF-β [144, 317]. Matsuura et al. (2006) demonstrated in SLNs that in the 
absence of metastases, DC maturation and Th1 responses were low. In the presence of
SLN metastatic disease, however, DC maturation and Th2 polarisation occurred [456].
In contrast to ALNs with metastases, the levels of cytokines present in the
microenvironment of ALNs with no metastases are probably derived exclusively from
ALN immune cells. Our study confirmed the immunosuppressive microenvironment
in metastatic ALNs. Our study is the first to document (to the best of our knowledge)
the significance of cytokine expression in tumour-draining ALNs in women with
LLABCs undergoing NAC.
4.9 Metastatic ALNs and ALN PCR
The levels/proportions of various immune subsets present in the tumour-free
parenchyma in tumour-draining ALNs, which had not shown any relationship with
metastases, were significantly associated with a pCR in the metastatic tumours in the
ALNs following NAC. The in situ immune milieu in metastatic ALNs was also
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demonstrated to be significantly associated with a pathological response to NAC.
Significantly higher levels of the CD8+ T cell subset and significantly lower levels of
the FOXP3+ Tregs (tumour-free para-cortex) were demonstrated in metastatic ALNs to
be associated with a pCR (metastatic ALNs with pCR versus non pCR). Moreover, the
CD8⁺ T cell: FOXP3⁺ Treg ratio (good marker of the status of adaptive anticancer
immunity) in the tumour-free para-cortex was also associated with a pCR in metastatic
ALNs. These findings suggest a positive anticancer effect of the in situ immune milieu
in ALNs on the pathological response of ALN metastases following NAC. There is a
dearth of publications regarding a pCR in metastatic ALNs in breast cancer and no
study to date which has demonstrated the contribution of the in situ immune milieu in
the tumour-draining ALNs to a pCR following NAC.
4.10 Study Challenges, Unresolved Issues and Limitations of the Thesis
The interactions of host immune defences and tumour cells in the tumour
microenvironment are complex and not well defined. The density/distribution of
immune cell infiltrates in LLABCs identified by H&E staining and IHC of paraffin-
embedded specimens is a snapshot taken when the tumour was removed and formalin-
fixed. It may not fully or reliably represent a more dynamic and changing immune
status in the microenvironment in vivo. These cellular infiltrates may be high in
number but dysfunctional or severely immunosuppressed. Some of the phenotypic
cellular markers used in this study to specifically document the immune cell subsets
may encompass more than one subset [e.g. FOXP3⁺ Tregs, CTLA-4⁺ Tregs and PD1⁺
T cells also express CD4, some CD56⁺ NK cells can express CD8 and some CD8⁺ T
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cells can express CD56 (NKT cells)] [457]. The expressions of some cellular markers
may be plastic (e.g. FOXP3 expressed on activated T cells) [235]. For these reasons,
more specific cellular markers related to the function of the particular cell subset may
need to be used to document these immune infiltrates. Moreover, the expression of
cytokines and biological molecules present in specimens is the sum of molecules
produced by various immune cell subsets and/or tumour cells. These expressions may
not reliably represent a particular immune function of a specific immune cell subset.
The changes in the level of immune cell infiltrations and alterations in the level of
cytokine/biological molecule expression following NAC were assessed by snapshots
of a dynamic process taken between the time points of prior to and after 8 cycles of
NAC and thus were the summation of numerous factors and processes which may alter
during the course of the NAC. Some of these changes/alterations may be a result of
several confounding factors affecting the immune status of patients. The patients’
general well-being, nutritional status and medication used are examples. Therefore, the
significant changes/alterations in the immune microenvironment present in the study
may not be exclusively from an effect of NAC.
MDSC is another major immune inhibitory subset which plays an important role in the
tumour microenvironment. The level/density of MDSC infiltrates may affect the
response to NAC. A number of cellular markers are needed to specifically identify the
phenotypic characteristics of this subset. Moreover, a great number of MDSC
phenotypes with different functions have been described in various solid cancers and
diseases [260]. These factors make the study of tumour-infiltrating MDSCs with the
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IHC technique limited and difficult. Fresh tissue specimens processed into single cell
suspensions and flow cytometry with fluorescence activated cell sorting (FACS) are
recommended for use in analyses of tissue-infiltrating MDSCs [458]. For these
reasons, the characterisation of MDSCs in the microenvironment of LLABCs was not
carried out.
An important limitation of our study is the sample number. The sample size of this
study was based on a cohort of patients from a previous study in which circulating
Tregs were documented pre- and post-NAC [15]. A sample size of at least 7 in each
group having an 80% power to detect a difference between two groups with p values
of ≤0.05 (two-sided) was calculated by assuming the common standard deviation of 
circulating blood Tregs as 0.5. As our findings are derived from several assays of
different parameters, the sample size of at least 7 in each group may not be appropriate
for some of the tests. In addition, the issue of multiple hypothesis testing may lower
the significance of our findings. In characterising the Th1/Th2 cytokine polarisation
and expression of biological molecules (a total of 10 variables), as well as
documenting 10 various immune cell subsets, our hypothesis testing consisted of
multiple assessments. When a Bonferroni correction for multiple comparisons was
undertaken, p values ≤ 0.0025 were considered statistically significant while p values 
≤ 0.05 were identified as trends. A high level of significance of p≤0.0025 is likely to 
be difficult to obtain from a small sample size. A larger cohort, therefore, may need to
be studied to resolve these limitations. Moreover, the study was retrospective and non-
randomised. The significant findings from the study are relevant but need to be
confirmed before implementing these findings into the clinical setting.
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CHAPTER 5: CONCLUSIONS
The findings from our study have further established that the immune
microenvironment is a key contributing factor to achieving a better outcome from
NAC in both primary tumours and metastatic tumours in tumour-draining ALNs. The
level of TILs and various immune cell infiltrations (CD4⁺ and CD8⁺ T cells, CD56⁺
NK cells and CD163⁺ macrophages) in LLABCs, which were well demonstrated with
the IHC techniques used, could be clinically useful to further define women with
LLABCs who may benefit from NAC. Moreover, a high level of TILs and
peritumoural CD56+ NK cell infiltration ≥3 cells/5HPFs can be used as independent 
predictive factors for a pCR. These biological markers can be readily determined from
histopathological examination of breast tumour biopsies (using H&E and IHC) before
commencing therapy. They may supplement other clinical parameters in establishing
optimal treatment, as well as prognostic prediction, for individual women with
LLABCs suitable for NAC.
The thesis has confirmed previously published findings, namely the significant
association between TILs and subsets (CD4⁺ and CD8⁺) including the CD8⁺ T cell:
FOXP3⁺ Treg ratio and a pCR, as well as the significant reduction of tumour-
infiltrating Tregs following NAC. The work described in the thesis has also
documented new and not previously reported findings. To the best of our knowledge,
this is the first time that the following significant associations in women with LLABCs
undergoing NAC have been reported: (1) a high level of tumour-infiltrating CD56⁺
NK cells and CD163⁺ TIMs with a pCR; (2) a high level of expression of IL-10 and
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IL-17 in breast tumours post-NAC with a poor response to NAC; (3) Th2 cytokine
polarisation in tumour-draining ALNs with ALN metastases; (4) the significant
concomitant reduction of circulating and tumour-infiltrating Tregs with NAC; and (5)
the reduction in the level of PD1⁺ T cell infiltrates and IL-4 expression in LLABCs
after NAC. See Table 3.37 which summarises the key and significant findings of the
study, and classifies them into new/original and confirmatory (previously published)
findings.
Findings in the thesis also suggest that the beneficial effects of NAC may be
significantly mediated via modulation of anticancer immunity, in particularly the
adaptive immune pathway and the reduction of its associated T regulatory pathways.
The NAC combination used in our study differentially preserved the tumour-
infiltrating CD8+ T cell population but significantly reduced both the circulating and
tumour-infiltrating Tregs (FOXP3+, CTLA-4+) and immune checkpoint PD1+ T cells,
thereby preventing the secretion of immunosuppressive cytokines (IL-4, IL-10, TGF-
β), and disrupting the PD1/PDL1 pathway. This restoration of immune anticancer 
effector mechanisms leads to immune-mediated tumour cell death. Moreover, the
significant correlation of a high level of CD8+ T cell infiltrates and CD8+ T cell:
FOXP3+ Treg ratio and a pCR (and hence DFS and OS) in breast cancers (breast, ALN
metastases) highlights the requirement for activated CTLs and concomitant depletion
of Tregs. The close interrelationship between a pCR in LLABCs and the concomitant
immune changes induced by NAC suggests that immune-mediated tumour cell death
is a crucial component of NAC-associated tumour cell destruction and removal. A
better understanding of this relationship, in particular, the factors preventing optimal
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delivery of immune-mediated tumour cell death is essential for devising more
effective chemotherapeutic strategies in the management of breast cancer.
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CHAPTER 6: FURTHER STUDIES
LLABC is a heterogeneous malignancy and consists of different subtypes. The
relevance of the tumour local immune milieu in predicting and contributing to the
pathological responses with NAC may be influenced by the different biological
subtypes within the cancer. Patients with ER-ve and HER2+ve breast cancers, as well
as tumours with high histological grade, respond well to NAC. These patients are
likely to derive optimal benefit from NAC. On the other hand, LLABCs with ER+ve,
HER2-ve or low grade tumours have low pCR rates. NAC is expensive, costly,
associated with a significant morbidity and the pCR rate is variable. Thus the decision
to treat with NAC as a primary systemic treatment in patients with LLABCs needs
more careful consideration and assessment to evaluate these detrimental consequences
against the likely benefits, especially in elderly patients and those with severe co-
morbidities. Immunological parameters such as TILs and other immune cell infiltrates,
which are associated with good responses to NAC, may be helpful in predicting the
likely response to NAC and decision to its use. In order to confirm the significance of
the findings found in the thesis with these tumour subtypes and differential immune
cell infiltrates, a larger, prospective, randomised cohort will need to be further studied.
Documenting the level/density of MDSCs in the microenvironment of LLABCs and
their contribution to NAC responses, as well as the effects of NAC on MDSC
infiltrates will require different methodology from IHC. This is an interesting area for
further exploration. Targeted therapy with MAb (trastuzumab), as well as NAC, has
been increasingly used in primary systemic treatment for HER2+ve LLABCs. TILs
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and other immune infiltrates may provide important and additional biomarkers
reflecting the anticancer immune responses in the tumour microenvironment, and
should be further investigated for their predictive and prognostic roles in response to
this targeted approach.
Further and better understanding of the mechanisms underlying the density and
distribution of immune cell infiltrates and cytokine expression in the tumour milieu, as
well as their changes/alterations after primary treatment may contribute to the
development of new immune-targeted therapies for breast cancer. Functional assays
will be crucial and may require the removal of cells from fresh specimens (as
suggested for MDSCs) and use in vitro assays. Alternatively, IHC needs to be used to
characterise biomarkers of molecular and transcriptional pathways in cells in tumour
specimens in the breast and tumour-draining ALNs.
244
Appendix 1
Table A. Patient and Tumour Characteristics, Responses to Neoadjuvant Chemotherapy and 4 Years Follow-up (n=33)
Patient
No.
Age
BMI(1)
(kg/m2)
Menopausal
Status(2)
Nodal Status
(Clinical
Assessment)
Tumour
Size (mm)
Tumour
Type
Histological
Grade(3)
ER
Status(4)
HER-2
Status(5)
NAC
Regimen(6)
Clinical
Response(7)
Pathological
Response
(Breast)(8)
Pathological
Response (Axilla:
Nodal Metastasis)(9)
Recurrence(10) Death(10)
5 40 21.90 pre +ve 40x50 ductal 3 +ve -ve 4AC-4TX responder grade 5 grade 3 no no
7 61 33.29 post -ve 70x60 ductal 3 -ve +ve 4AC-4T responder grade 5 NA no no
9 51 21.87 pre -ve 34x32 ductal 3 -ve -ve 4AC-4TX responder grade 5 NA no no
11 35 28.32 pre +ve 100x82 ductal 2 +ve -ve 4AC-4T responder grade 4 grade 3 yes yes
12 57 24.44 post +ve 47x42 ductal 3 +ve -ve 4AC-4T responder grade 4 grade 2 yes yes
13 43 31.56 pre -ve 35x35 ductal 3 +ve +ve 4AC-4T responder grade 3 NA yes no
15 35 25.85 pre +ve 50x40 ductal 2 +ve -ve 2AC-6TX non-responder grade 3 grade 2 no no
17 61 23.81 post -ve 36x21 ductal 2 +ve +ve 4AC-4T responder grade 5 NA no no
20 57 26.29 post -ve 38x35 ductal 2 +ve -ve 2AC-6T non-responder grade 3 NA no no
21 48 30.25 pre +ve 22x15 ductal 1 +ve -ve 4AC-4T responder grade 3 grade 1 yes no
22 47 23.52 pre +ve 40x40 ductal 3 +ve -ve 2AC-6TX non-responder grade 5 grade 3 no no
29 54 25.49 post +ve 34x27 lobular 2 +ve -ve 4AC-4TX responder grade 3 grade 2 yes no
37 52 24.70 post -ve 40x39 ductal 1 +ve -ve 4AC-4TX responder grade 3 NA no no
38 63 31.35 post -ve 44x44 ductal 3 +ve -ve 4AC-4T responder grade 4 NA yes yes
40 50 26.49 post -ve 36x32 metaplastic 3 -ve -ve 4AC-4T responder grade 5 NA no no
41 51 32.03 pre -ve 30x30 ductal 3 +ve -ve 4AC-4TX responder grade 5 NA no no
46 38 33.19 pre +ve 39x38 ductal 3 -ve +ve 4AC-4TX responder grade 5 grade 3 no no
63 37 20.93 pre +ve 35x30 ductal 2 -ve +ve 4AC-4T responder grade 4 grade 2 yes no
73 47 30.01 pre +ve 33x33 ductal 3 -ve +ve 4AC-4TX responder grade 5 grade 3 no no
77 65 27.63 post +ve 20x20 ductal 3 -ve +ve 2AC-6T non-responder grade 1 grade 2 yes yes
80 45 29.30 pre +ve 36x31 ductal 2 +ve -ve 2AC-6T non-responder grade 2 grade 1 yes no
82 67 28.65 post +ve 30x30 lobular 2 +ve -ve 4AC-4TX responder grade 5 grade 2 no no
83 50 22.37 pre +ve 40x40 ductal 3 -ve +ve 2AC-6TX non-responder grade 3 grade 2 no no
84 47 26.29 post +ve 45x30 ductal 2 +ve -ve 4AC-4T responder grade 3 grade 2 yes yes
86 64 32.37 post -ve 40x40 ductal 2 +ve -ve 2AC-6T non-responder grade 2 grade 2 no no
88 58 32.97 post +ve 25x15 ductal 2 +ve -ve 2AC-6TX non-responder grade 4 grade 1 no no
89 49 39.65 pre +ve 25x25 ductal 2 +ve -ve 2AC-6TX non-responder grade 2 grade 2 no no
90 56 26.01 post +ve 30x27 ductal 3 +ve -ve 4AC-4TX responder grade 5 grade 3 no no
96 51 25.28 post +ve 45x45 ductal 3 -ve -ve 2AC-6T non-responder grade 5 grade 2 yes yes
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(1) BMI: Body mass index (≤30: Non-obese, >30: Obese) 
(2) Menopausal status: Pre-menopausal, age < 55 years with normal menstrual cycles; Post-menopausal, age > 50 years with no spontaneous menses for at least one year/
or age ≤ 50 years with no spontaneous menses within the past 2 years/or women who had bilateral oophorectomy prior to the diagnosis of breast cancer 
(3) Histological grade: Grade 1 (well differentiated), grade 2 (moderately differentiated), grade 3 (poorly differentiated)
(4) ER (oestrogen receptor): Allred scoring system was used for measuring expression of ER (score ≥ 3 for positive, < 3 for negative) 
(5) HER2 (human epidermal growth factor receptor 2): Determined by FISH (fluorescence in-situ hybridisation)
(6) A: Adriamycin (doxorubicin), C: Cyclophosphamide, T: Taxotere (docetaxel) and X: Xeloda® (capecitabine)
(7) Clinical response was assessed by MRI (magnetic resonance imaging) of breast after 2 cycles of AC using the RECIST criteria
(8) Pathological response in breast was graded as grade 1: No change or some alteration to individual malignant cells but no reduction in overall cellularity; grade 2: A
minor loss of tumour cells but overall cellularity still high, up to 30 % loss; grade 3: Between an estimated 30% and 90% reduction in tumour cells; grade 4: A marked
disappearance of tumour cells such that only small clusters or widely dispersed individual cells remain, more than 90% loss of tumour cells; grade 5: No malignant cells
identifiable from the site of the tumour (pCR)
(9) Pathological response in axilla was graded as grade 1: Metastasis with no fibrosis; grade 2: Metastasis with variable replacement by fibrous tissue; grade 3: No
malignant cells identifiable but replacement by fibrous tissue (pCR); NA (not applicable): No nodal metastasis
(10) Recurrent disease and death from a median follow-up of 51 months
108 56 24.92 post +ve 47x40 ductal 3 -ve +ve 4AC-4TX responder grade 5 grade 3 no no
112 49 37.41 pre +ve 50x40 ductal 2 +ve -ve 4AC-4TX responder grade 5 grade 3 no no
114 38 31.21 pre +ve 42x36 ductal 3 -ve +ve 4AC-4T responder grade 5 grade 3 no no
115 65 32.22 post +ve 14x12 ductal 3 +ve -ve 4AC-4T responder grade 5 grade 3 no no
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Appendix 2
IHC Staining Procedure
1. Place slides on the 60°C hotplate for 10 minutes
2. Allow to cool and place in Leica autostainer slide rack
3. Load the rack into an autostainer and run 'Program 1' for dewaxing/ rehydrating
sections (xylene 5 minutes x 2 times; IMS 2minutes x 3 times; water 5 minutes)
4. When the program has finished, the autostainer machine sounds an alarm; follow the
instructions for removing rack and place it in a water bath.
5. Perform antigen retrieval; for microwave HIER, use the Leica autostainer pots without
metal handles and with cut-away lids.
6. Working in a large bath of tap water, load slides onto the Sequenza plates, then place
in Sequenza trays.
7. Fill the Sequenza reservoir half full with TBS (Tris Buffered Saline) to rinse the slides,
and watch it flow through to ensure there are no air bubbles (as this will impair staining).
If the TBS runs through a sequenza plate either very quickly or very slowly, this indicates
an air bubble, in which case the slide must be re-loaded into the Sequenza plate.
8. Apply Peroxidase Block (Novolink Kit) for 5 minutes
9. Wash with TBS for 5 minutes x 2 times
10. Apply Protein Block (Novolink Kit) for 5 minutes
11. Wash with TBS for 5 minutes x 2 times
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12. Apply 100 µl of primary antibody (optimally diluted in Leica antibody diluent) and
incubate for the required time
13. Wash with TBS for 5 minutes x 2 times
14. Apply 100 µl Post Primary Block (Novolink Kit) for 30 minutes
15. Wash with TBS for 5 minutes x 2 times
16. Apply 100 µl Novolink Polymer for 30 minutes
17. Make up DAB working solution; 1:20 DAB chromogen in DAB substrate buffer
(Novolink kit) DAB working solution should be kept in the dark and used within 6 hours.
18. Wash sections with TBS for 5 minutes x 2 times
19. Apply 100 µl DAB working solution for 5 minutes
20. Wash with TBS for 5 minutes x 2 times
21. Apply 1O0 µl Novolink haematoxylin for 6 minutes
22. Remove slides from Sequenza plates and place in a Leica autostainer rack, under
water
23. Dehydrate and clear using Leica Autostainer; program 2 (IMS for 2 minutes x 3
times; xylene for 5 minutes x 2 times)
24. Remove the final xylene pot to a fume-cupboard and replace with another xylene pot
in the machine
25. Mount sections in DPX.
Note: Do not allow the sections to dry at any stage of this procedure
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Appendix 3
Solutions and Reagents
1. Sodium Citrate Buffer pH 6.0, 1 litre
• Tri-sodium citrate (di-hydrate) 2.9 g
• Distilled water 1000 ml
• Mix to dissolve sodium citrate and adjust pH to 6.0 with 1M HCl.
Add 0.5 ml Tween20. Store at room temperature or at 4˚C if storing for longer than 3 
months.
Final concentrations: Sodium citrate 0.01M, Tween20 0.05%
2. TBST (Tris-Buffered Saline, 0.05% Tween20), 1 litre
• 10X TBS (Tris-Buffered Saline) 100 ml
• Distilled water 900 ml
• Tween20 0.5 ml
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Appendix 4
TNM Classification of Breast Cancer (AJCC/UICC 7th Edition, 2010)
Primary tumour (T)
TX Primary tumour cannot be assessed
T0 No evidence of primary tumour
Tis Carcinoma in situ
Tis (DCIS) Ductal carcinoma in situ
Tis (LCIS) Lobular carcinoma in situ
Tis (Paget)
Paget disease of the nipple NOT associated with invasive carcinoma and/or
carcinoma in situ (DCIS and/or LCIS) in the underlying breast parenchyma.
Carcinomas in the breast parenchyma associated with Paget disease are
categorized based on the size and characteristics of the parenchymal disease,
although the presence of Paget disease should still be noted
T1 Tumour ≤ 20 mm in greatest dimension 
T1mi Tumour ≤ 1 mm in greatest dimension 
T1a Tumour > 1 mm but ≤ 5 mm in greatest dimension 
T1b Tumour > 5 mm but ≤ 10 mm in greatest dimension 
T1c Tumour > 10 mm but ≤ 20 mm in greatest dimension 
T2 Tumour > 20 mm but ≤ 50 mm in greatest dimension 
T3 Tumour > 50 mm in greatest dimension
T4
Tumour of any size with direct extension to the chest wall and/or to the skin
(ulceration or skin nodules)
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T4a
Extension to chest wall, not including only pectoralis muscle
adherence/invasion
T4b
Ulceration and/or ipsilateral satellite nodules and/or edema (including peau
d’orange) of the skin, which do not meet the criteria for inflammatory
carcinoma
T4c Both T4a and T4b
T4d Inflammatory carcinoma
Regional lymph nodes (N)
Clinical (N)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis to movable ipsilateral level I, II axillary lymph node(s)
N2
Metastases in ipsilateral level I, II axillary lymph nodes that are clinically
fixed or matted or in clinically detected ipsilateral internal mammary nodes
in the absence of clinically evident axillary lymph node metastasis
N2a
Metastases in ipsilateral level I, II axillary lymph nodes fixed to one another
(matted) or to other structures
N2b
Metastases only in clinically detected ipsilateral internal mammary nodes
and in the absence of clinically evident level I, II axillary lymph node
metastases
N3 Metastases in ipsilateral infraclavicular (level III axillary) lymph node(s),
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with or without level I, II axillary node involvement, or in clinically detected
ipsilateral internal mammary lymph node(s) and in the presence of clinically
evident level I, II axillary lymph node metastasis; or metastasis in ipsilateral
supraclavicular lymph node(s), with or without axillary or internal mammary
lymph node involvement
N3a Metastasis in ipsilateral infraclavicular lymph node(s)
N3b
Metastasis in ipsilateral internal mammary lymph node(s) and axillary
lymph node(s)
N3c Metastasis in ipsilateral supraclavicular lymph node(s)
Pathological (pN)
pNX Regional lymph nodes cannot be assessed
pN0
No regional lymph node metastasis identified histologically. Note: Isolated
Tumour cell clusters (ITCs) are defined as small clusters of cells ≤ 0.2 mm, 
or single tumour cells, or a cluster of < 200 cells in a single histologic cross-
section; ITCs may be detected by routine histology or by
immunohistochemical (IHC) methods; nodes containing only ITCs are
excluded from the total positive node count for purposes of N classification
but should be included in the total number of nodes evaluated
pN0(i-) No regional lymph node metastases histologically, negative IHC
pN0(i+)
Malignant cells in regional lymph node(s) ≤ 0.2 mm (detected by 
hematoxylin-eosin [H&E] stain or IHC, including ITC)
pN0(mol-) No regional lymph node metastases histologically, negative molecular
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findings (reverse transcriptase polymerase chain reaction [RT-PCR])
pN0(mol+)
Positive molecular findings (RT-PCR) but no regional lymph node
metastases detected by histology or IHC
pN1
Micrometastases; or metastases in 1-3 axillary lymph nodes and/or in
internal mammary nodes, with metastases detected by sentinel lymph node
biopsy but not clinically detected
pN1mi Micrometastases (> 0.2 mm and/or > 200 cells, but none > 2.0 mm)
pN1a Metastases in 1-3 axillary lymph nodes (at least 1 metastasis > 2.0 mm)
pN1b
Metastases in internal mammary nodes, with micrometastases or
macrometastases detected by sentinel lymph node biopsy but not clinically
detected
pN1c
Metastases in 1-3 axillary lymph nodes and in internal mammary lymph
nodes, with micrometastases or macrometastases detected by sentinel lymph
node biopsy but not clinically detected
pN2
Metastases in 4-9 axillary lymph nodes or in clinically detected‡ internal
mammary lymph nodes in the absence of axillary lymph node metastases
pN2a Metastases in 4-9 axillary lymph nodes (at least 1 Tumour deposit > 2.0 mm)
pN2b
Metastases in clinically detected internal mammary lymph nodes in the
absence of axillary lymph node metastases
pN3
Metastases in ≥ 10 axillary lymph nodes; or in infraclavicular (level III 
axillary) lymph nodes; or in clinically detected‡ ipsilateral internal
mammary lymph nodes in the presence of ≥ 1 positive level I, II axillary 
lymph nodes; or in > 3 axillary lymph nodes and in internal mammary
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lymph nodes, with micrometastases or macrometastases detected by sentinel
lymph node biopsy but not clinically detected; or in ipsilateral
supraclavicular lymph nodes
pN3a
Metastases in ≥ 10 axillary lymph nodes (at least 1 Tumour deposit > 2.0 
mm); or metastases to the infraclavicular (level III axillary lymph) nodes
pN3b
Metastases in clinically detected ipsilateral internal mammary lymph nodes
in the presence of ≥ 1 positive axillary lymph nodes; or in > 3 axillary lymph
nodes and in internal mammary lymph nodes, with micrometastases or
macrometastases detected by sentinel lymph node biopsy but not clinically
detected
pN3c Metastases in ipsilateral supraclavicular lymph nodes
Distant metastasis (M)
M0 No clinical or radiographic evidence of distant metastasis
cM0(i+)
No clinical or radiographic evidence of distant metastases, but deposits of
molecularly or microscopically detected Tumour cells in circulating blood,
bone marrow, or other non-regional nodal tissue that are no larger than 0.2
mm in a patient without symptoms or signs of metastases
M1
Distant detectable metastases as determined by classic clinical and
radiographic means and/or histologically proven > 0.2 mm
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TNM Staging
Stage T N M
0 Tis N0 M0
IA T1 N0 M0
IB T0 N1mi M0
T1 N1mi M0
IIA T0 N1 M0
T1 N1 M0
T2 N0 M0
IIB T2 N1 M0
T3 N0 M0
IIIA T0 N2 M0
T1 N2 M0
T2 N2 M0
T3 N1 M0
T3 N2 M0
IIIB T4 N0 M0
T4 N1 M0
T4 N2 M0
IIIC Any T N3 M0
IV Any T Any N M1
Data from National Comprehensive Cancer Network (NCCN) Clinical Practice
Guidelines in Oncology, 2013 [82]
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